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Abstract
The Concise Guide to PHARMACOLOGY 2015/16 provides concise overviews of the key properties of over 1750 human drug targets with their pharmacology, plus links to an open access knowledgebase
of drug targets and their ligands (www.guidetopharmacology.org), which provides more detailed views of target and ligand properties. The full contents can be found at http://onlinelibrary.wiley.com/doi/
10.1111/bph.13348/full. G protein-coupled receptors are one of the eight major pharmacological targets into which the Guide is divided, with the others being: ligand-gated ion channels, voltage-gated
ion channels, other ion channels, nuclear hormone receptors, catalytic receptors, enzymes and transporters. These are presented with nomenclature guidance and summary information on the best
available pharmacological tools, alongside key references and suggestions for further reading. The Concise Guide is published in landscape format in order to facilitate comparison of related targets.
It is a condensed version of material contemporary to late 2015, which is presented in greater detail and constantly updated on the website www.guidetopharmacology.org, superseding data presented
in the previous Guides to Receptors & Channels and the Concise Guide to PHARMACOLOGY 2013/14. It is produced in conjunction with NC-IUPHAR and provides the official IUPHAR classification
and nomenclature for human drug targets, where appropriate. It consolidates information previously curated and displayed separately in IUPHAR-DB and GRAC and provides a permanent, citable,
point-in-time record that will survive database updates.
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Overview: G protein-coupled receptors (GPCRs) are the largest
class of membrane proteins in the human genome. The term
"7TM receptor" is commonly used interchangeably with "GPCR",
although there are some receptors with seven transmembrane
domains that do not signal through G proteins. GPCRs share
a common architecture, each consisting of a single polypeptide
with an extracellular N-terminus, an intracellular C-terminus and
seven hydrophobic transmembrane domains (TM1-TM7) linked
by three extracellular loops (ECL1-ECL3) and three intracellular
loops (ICL1-ICL3). About 800 GPCRs have been identified in
man, of which about half have sensory functions, mediating ol-
faction ( 400), taste (33), light perception (10) and pheromone
signalling (5) [1309]. The remaining 350 non-sensory GPCRs
mediate intersignalling by ligands that range in size from small
molecules to peptide to large proteins; they are the targets for
the majority of drugs in clinical usage [1451, 1560], although
only a minority of these receptors are exploited therapeutically.
The first classification scheme to be proposed for GPCRs [984] di-
vided them, on the basic of sequence homology, into six classes.
These classes and their prototypemembers were as follows: Class
A (rhodopsin-like), Class B (secretin receptor family), Class C
(metabotropic glutamate), Class D (fungal mating pheromone
receptors), Class E (cyclic AMP receptors) and Class F (friz-
zled/smoothened). Of these, classes D and E are not found in
vertebrates. An alternative classification scheme "GRAFS" [1666]
divides vertebrate GPCRs into five classes, overlapping with the
A-F nomenclature, viz:
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Glutamate family (class C), which includes metabotropic glutamate receptors, a calcium-sensing receptor and GABAB receptors, as well as three taste type 1 receptors [class C list] and a family of
pheromone receptors (V2 receptors) that are abundant in rodents but absent in man [1309].
Rhodopsin family (class A), which includes receptors for a wide variety of small molecules, neurotransmitters, peptides and hormones, together with olfactory receptors, visual pigments, taste type 2
receptors and five pheromone receptors (V1 receptors). [Class A list]
Adhesion family GPCRs are phylogenetically related to class B receptors, from which they differ by possessing large extracellular N-termini that are autoproteolytically cleaved from their 7TM domains
at a conserved "GPCR proteolysis site" (GPS) which lies within a much larger ( 320 residue) "GPCR autoproteolysis-inducing" (GAIN) domain, an evolutionary ancient mofif also found in polycystic kidney
disease 1 (PKD1)-like proteins, which has been suggested to be both required and sufficient for autoproteolysis [1538]. [Adhesion family list].
Frizzled family (class F) consists of 10 Frizzled proteins (FZD(1-10)) and Smoothened (SMO). [Frizzled family list]. The FZDs are activated by secreted lipoglycoproteins of the WNT family, whereas
SMO is indirectly activated by the Hedgehog (HH) family of proteins acting on the transmembrane protein Patched (PTCH).
Secretin family (class B), encoded by 15 genes in humans. The ligands for receptors in this family are polypeptide hormones of 27-141 amino-acid residues; nine of the mammalian receptors respond
to ligands that are structurally related to one another (glucagon, glucagon-like peptides (GLP-1, GLP-2), glucose-dependent insulinotropic polypeptide (GIP), secretin, vasoactive intestinal peptide (VIP),
pituitary adenylate cyclase-activating polypeptide (PACAP) and growth-hormone-releasing hormone (GHRH) [703].
GPCR families
Family Class A Class B (Secretin) Class C (Glutamate) Adhesion Frizzled
Receptors with known ligands 197a 15 12 0 11
Orphans 87 (54)a - 8 (1)a 26 (6)a 0
Sensory (olfaction) 390b,c - - - -
Sensory (vision) 10d opsins - - - -
Sensory (taste) 30c taste 2 - 3c taste 1 - -
Sensory (pheromone) 5c vomeronasal 1 - - - -
Total 719 15 22 33 11
aNumbers in brackets refer to orphan receptors for which an endogenous ligand has been proposed in at least one publication, see [396]; b[1443]; c[1309]; d[1866].
Much of our current understanding of the structure and function of GPCRs is the result of pioneering work on the visual pigment rhodopsin and on the β2 adrenoceptor, the latter culminating in the
award of the 2012 Nobel Prize in chemistry to Robert Lefkowitz and Brian Kobilka [975, 1073].
Family structure
5746 Orphan and other 7TM receptors
5746 Class A Orphans
5756 Class C Orphans
5756 Taste 1 receptors
5757 Taste 2 receptors
5758 Other 7TM proteins
5759 5-Hydroxytryptamine receptors
5764 Acetylcholine receptors (muscarinic)
5766 Adenosine receptors
5768 Adhesion Class GPCRs
5770 Adrenoceptors
5774 Angiotensin receptors
5775 Apelin receptor
5777 Bile acid receptor
5778 Bombesin receptors
5780 Bradykinin receptors
5781 Calcitonin receptors
5783 Calcium-sensing receptors
5784 Cannabinoid receptors
5785 Chemerin receptor
5785 Chemokine receptors
5791 Cholecystokinin receptors
5792 Class Frizzled GPCRs
5793 Complement peptide receptors
5795 Corticotropin-releasing factor receptors
5796 Dopamine receptors
5798 Endothelin receptors
5799 G protein-coupled estrogen receptor
5800 Formylpeptide receptors
5801 Free fatty acid receptors
5803 GABAB receptors
5805 Galanin receptors
5806 Ghrelin receptor
5807 Glucagon receptor family
5809 Glycoprotein hormone receptors
5810 Gonadotrophin-releasing hormone receptors
5811 GPR18, GPR55 and GPR119
5812 Histamine receptors
5814 Hydroxycarboxylic acid receptors
5815 Kisspeptin receptor
5816 Leukotriene receptors
5818 Lysophospholipid (LPA) receptors
5819 Lysophospholipid (S1P) receptors
5820 Melanin-concentrating hormone receptors
5821 Melanocortin receptors
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5822 Melatonin receptors
5823 Metabotropic glutamate receptors
5826 Motilin receptor
5827 Neuromedin U receptors
5828 Neuropeptide FF/neuropeptide AF receptors
5829 Neuropeptide S receptor
5829 Neuropeptide W/neuropeptide B receptors
5830 Neuropeptide Y receptors
5832 Neurotensin receptors
5833 Opioid receptors
5835 Orexin receptors
5836 Oxoglutarate receptor
5836 P2Y receptors
5838 Parathyroid hormone receptors
5839 Platelet-activating factor receptor
5840 Prokineticin receptors
5841 Prolactin-releasing peptide receptor
5842 Prostanoid receptors
5844 Proteinase-activated receptors
5846 QRFP receptor
5846 Relaxin family peptide receptors
5848 Somatostatin receptors
5850 Succinate receptor
5850 Tachykinin receptors
5852 Thyrotropin-releasing hormone receptors
5852 Trace amine receptor
5854 Urotensin receptor
5854 Vasopressin and oxytocin receptors
5856 VIP and PACAP receptors
Orphan and other 7TM receptors
G protein-coupled receptors! Orphan and other 7TM receptors
Class A Orphans
G protein-coupled receptors! Orphan and other 7TM receptors! Class A Orphans
Overview: Table 1 lists a number of putative GPCRs identified by NC-IUPHAR [530], for which preliminary evidence for an endogenous ligand has been published, or for which there exists a potential
link to a disease, or disorder. These GPCRs have recently been reviewed in detail [396]. The GPCRs in Table 1 are all Class A, rhodopsin-like GPCRs. Class A orphan GPCRs not listed in Table 1 are putative
GPCRs with as-yet unidentified endogenous ligands.
Table 1: Class A orphan GPCRs with putative endogenous ligands
GPR1 GPR3 GPR4 GPR6 GPR12 GPR15 GPR17 GPR20
GPR22 GPR26 GPR31 GPR34 GPR35 GPR37 GPR39 GPR50
GPR63 GRP65 GPR68 GPR75 GPR84 GPR87 GPR88 GPR132
GPR149 GPR161 GPR183 LGR4 LGR5 LGR6 MAS1 MRGPRD
MRGPRX1 MRGPRX2 P2RY10 TAAR2
In addition the orphan receptors GPR18, GPR55 and GPR119 which are reported to respond to endogenous agents analogous to the endogenous cannabinoid ligands have been grouped together
(GPR18, GPR55 and GPR119).
Nomenclature GPR1 GPR3 GPR4 GPR6
HGNC, UniProt GPR1, P46091 GPR3, P46089 GPR4, P46093 GPR6, P46095
Endogenous ligand – – Protons –
Endogenous agonists chemerin (RARRES2, Q99969)
(pKd 8.3) [95]
– – –
Agonists – diphenyleneiodonium chloride
(pEC50 6) [2091]
– –
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(continued)
Nomenclature GPR1 GPR3 GPR4 GPR6
Comments Reported to act as a co-receptor
for HIV [1724]. See review [396]
for discussion of pairing with
chemerin.
sphingosine 1-phosphate was
reported to be an endogenous agonist
[1921], but this finding was not
replicated in subsequent studies
[2093]. Reported to activate adenylyl
cyclase constitutively through Gs
[466]. Gene disruption results in
premature ovarian ageing [1063],
reduced β-amyloid deposition [1868]
and hypersensitivity to thermal pain
[1615] in mice. First small molecule
inverse agonist [860] and agonists
identified [2091].
An initial report suggesting activation
by lysophosphatidylcholine and
sphingosylphosphorylcholine [2131]
has been retracted [2148]. GPR4,
GPR65, GPR68 and GPR132 are now
thought to function as proton-sensing
receptors detecting acidic pH [396,
1704]. Gene disruption is associated
with increased perinatal mortality and
impaired vascular proliferation [2085].
Negative allosteric modulators of
GPR4 have been reported [1889].
An initial report that
sphingosine 1-phosphate (S1P) was a
high-affinity ligand (EC50 value of
39nM) [815, 1921] was not repeated
by arrestin PathHunter[TM] assays
[1785, 2093]. Reported to activate
adenylyl cyclase constitutively through
Gs and to be located intracellularly
[1453]. GPR6-deficient mice showed
reduced striatal cyclic AMP production
in vitro and selected alterations in
instrumental conditioning in vivo.
[1134].
Nomenclature GPR12 GPR15 GPR17 GPR19
HGNC, UniProt GPR12, P47775 GPR15, P49685 GPR17, Q13304 GPR19, Q15760
Endogenous
agonists
– – UDP-glucose (pEC50 5.9–9.5)
[130, 344], LTC4 (pEC50 7.8–9.5)
[344], UDP-galactose (pEC50
6–8.9) [130, 344],
uridine diphosphate (pEC50
6–8.8) [130, 344], LTD4 (pEC50
8.1–8.4) [344]
–
Comments Reports that
sphingosine 1-phosphate is a
ligand of GPR12 [814, 1921] have
not been replicated in
arrestin-based assays [1785,
2093]. Gene disruption results in
dyslipidemia and obesity [154].
Reported to act as a co-receptor
for HIV [462]. In an
infection-induced colitis model,
Gpr15 knockout mice were more
prone to tissue damage and
inflammatory cytokine expression
[945].
Reported to be a dual leukotriene
and uridine diphosphate receptor
[344]. Another group instead
proposed that GPR17 functions as
a negative regulator of the CysLT1
receptor response to leukotriene
D4 (LTD4). For further discussion,
see [396]. Reported to antagonize
CysLT1 receptor signalling in vivo
and in vitro [1175]. See reviews
[250] and [396].
–
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Nomenclature GPR20 GPR21 GPR22 GPR25 GPR26
HGNC, UniProt GPR20, Q99678 GPR21, Q99679 GPR22, Q99680 GPR25, O00155 GPR26, Q8NDV2
Comments Reported to inhibit adenylyl
cyclase constitutively through
Gi/o [708]. GPR20 deficient mice
exhibit hyperactivity characterised
by increased total distance
travelled in an open field test
[207].
Gpr21 knockout mice were
resistant to diet-induced obesity,
exhibiting an increase in glucose
tolerance and insulin sensitivity, as
well as a modest lean phenotype
[1448].
Gene disruption results in
increased severity of functional
decompensation following aortic
banding [10]. Identified as a
susceptibility locus for
osteoarthritis [494, 929, 1935].
– Has been reported to activate
adenylyl cyclase constitutively
through Gs [880]. Gpr26
knockout mice show increased
levels of anxiety and
depression-like behaviours [2117].
Nomenclature GPR27 GPR31 GPR32 GPR33 GPR34
HGNC, UniProt GPR27, Q9NS67 GPR31, O00270 GPR32, O75388 GPR33, Q49SQ1 GPR34, Q9UPC5
Rank order of
potency
– – resolvin D1 > LXA4 – –
Endogenous
agonists
– 12S-HETE (Selective) (pEC50 9.6)
[665] – Mouse
resolvin D1 (pEC50 11.1) [1006],
LXA4 (pEC50 9.7) [1006]
– lysophosphatidylserine
(Selective) (pEC50 6.6–6.9) [960,
1817]
Labelled ligands – – [3H]resolvin D1 (Agonist) (pKd
9.7) [1006]
– –
Comments Knockdown of Gpr27 reduces
endogenous mouse insulin
promotor activity and
glucose-stimulated insulin
secretion [1012].
See [396] for discussion of
pairing.
resolvin D1 has been
demonstrated to activate GPR32
in two publications [316, 1006].
The pairing was not replicated in
a recent study based on arrestin
recruitment [1785]. GPR32 is a
pseudogene in mice and rats.
See reviews [250] and [396].
GPR33 is a pseudogene in most
individuals, containing a
premature stop codon within the
coding sequence of the second
intracellular loop [1621].
Lysophosphatidylserine has been
reported to be a ligand of GPR34
in several publications, but the
pairing was not replicated in a
recent study based on arrestin
recruitment [1785]. Fails to
respond to a variety of
lipid-derived agents [2093].
Gene disruption results in an
enhanced immune response
[1102]. Characterization of
agonists at this receptor is
discussed in [819] and [396].
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Nomenclature GPR35 GPR37 GPR37L1 GPR39 GPR42
HGNC, UniProt GPR35, Q9HC97 GPR37, O15354 GPR37L1, O60883 GPR39, O43194 GPR42, O15529
Endogenous agonists 2-oleoyl-LPA (pEC50 7.3–7.5)
[1436], kynurenic acid (pEC50
3.9–4.4) [1785, 1980]
– – Zn2+ [775] –
Agonists – neuropeptide head activator
(pEC50 8–8.5) [1578]
– compound 1 [PMID: 24900608]
(pEC50 4.9–7.2) [166]
–
Comments Several studies have shown that
kynurenic acid is an agonist of
GPR35 but it remains
controversial whether the
proposed endogenous ligand
reaches sufficient tissue
concentrations to activate the
receptor [1015]. 2-oleoyl-LPA has
also been proposed as an
endogenous ligand [1436] but
these results were not replicated
in an arrestin assay [1785]. The
phosphodiesterase inhibitor
zaprinast [1863] has become
widely used as a surrogate agonist
to investigate GPR35
pharmacology and signalling
[1863]. GPR35 is also activated by
the pharmaceutical adjunct
pamoic acid [2124]. See reviews
[396] and [429].
Reported to associate and
regulate the dopamine
transporter [1207] and to be a
substrate for parkin [1205]. Gene
disruption results in altered striatal
signalling [1206]. The peptides
prosaptide and prosaposin are
proposed as endogenous ligands
for GPR37 and GPR37L1 [1264].
The peptides prosaptide and
prosaposin are proposed as
endogenous ligands for GPR37
and GPR37L1 [1264].
Zn2+ has been reported to be a
potent and efficacious agonist of
human, mouse and rat GPR39
[2089]. obestatin (GHRL,
Q9UBU3), a fragment from the
ghrelin precursor, was reported
initially as an endogenous ligand,
but subsequent studies failed to
reproduce these findings. GPR39
has been reported to be
down-regulated in adipose tissue
in obesity-related diabetes [273].
Gene disruption results in obesity
and altered adipocyte metabolism
[1497]. Reviewed in [396].
–
Nomenclature GPR45 GPR50 GPR52 GPR61
HGNC, UniProt GPR45, Q9Y5Y3 GPR50, Q13585 GPR52, Q9Y2T5 GPR61, Q9BZJ8
Comments – GPR50 is structurally related to MT1
and MT2 melatonin receptors, with
which it heterodimerises
constitutively and specifically
[1089]. Gpr50 knockout mice
display abnormal thermoregulation
and are much more likely than
wild-type mice to enter
fasting-induced torpor [111].
First small molecule
agonist reported [1703].
GPR61 deficient mice exhibit obesity
associated with hyperphagia [1363].
Although no endogenous ligands
have been identified,
5-(nonyloxy)tryptamine has been
reported to be a low affinity inverse
agonist [1852].
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Nomenclature GPR62 GPR63 GPR65 GPR68 GPR75
HGNC, UniProt GPR62, Q9BZJ7 GPR63, Q9BZJ6 GPR65, Q8IYL9 GPR68, Q15743 GPR75, O95800
Endogenous
ligand
– – Protons Protons –
Comments – sphingosine 1-phosphate and
dioleoylphosphatidic acid have been
reported to be low affinity agonists
for GPR63 [1394] but this finding
was not replicated in an
arrestin-based assay [2093].
GPR4, GPR65, GPR68 and GPR132
are now thought to function as
proton-sensing receptors detecting
acidic pH [396, 1704]. Reported to
activate adenylyl cyclase; gene
disruption leads to reduced
eosinophilia in models of allergic
airway disease [1000].
GPR68 was previously identified as a
receptor for
sphingosylphosphorylcholine (SPC)
[2068], but the original publication
has been retracted [2067]. GPR4,
GPR65, GPR68 and GPR132 are now
thought to function as
proton-sensing receptors detecting
acidic pH [396, 1704]. A family of
3,5-disubstituted isoxazoles were
identified as agonists of GPR68
[1617].
CCL5 (CCL5, P13501) was reported
to be an agonist of GPR75 [816],
but the pairing could not be
repeated in an arrestin assay [1785].
Nomenclature GPR78 GPR79 GPR82 GPR83 GPR84
HGNC, UniProt GPR78, Q96P69 GPR79, – GPR82, Q96P67 GPR83, Q9NYM4 GPR84, Q9NQS5
Agonists – – – Zn2+ (pEC50 5) [1351] – Mouse decanoic acid (pEC50 5–5.4)
[1785, 1981], undecanoic acid
(pEC50 5.1) [1981], lauric acid
(pEC50 5) [1981]
Comments GPR78 has been reported to be
constitutively active, coupled to
elevated cAMP production [880].
– Mice with Gpr82 knockout have a
lower body weight and body fat
content associated with reduced
food intake, decreased serum
triglyceride levels, as well as higher
insulin sensitivity and glucose
tolerance [479].
One isoform has been implicated
in the induction of CD4(+)
CD25(+) regulatory T cells (Tregs)
during inflammatory immune
responses [696]. The extracellular
N-terminal domain is reported as
an intramolecular inverse agonist
[1352].
Medium chain free fatty acids with
carbon chain lengths of 9-14
activate GPR84 [1828, 1981]. A
surrogate ligand for GPR84,
6-n-octylaminouracil has also been
proposed [1828]. See review [396]
for discussion of classification.
Mutational analysis and molecular
modelling of GPR84 has been
reported [1397].
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Nomenclature GPR85 GPR87 GPR88 GPR101
HGNC, UniProt GPR85, P60893 GPR87, Q9BY21 GPR88, Q9GZN0 GPR101, Q96P66
Endogenous
agonists
– LPA (pEC50 7.4) [1344,
1836]
– –
Agonists – – compound 2 [PMID: 24793972]
(pEC50 6.2) [868]
–
Comments Proposed to regulate
hippocampal neurogenesis in
the adult, as well as
neurogenesis-dependent
learning and memory [303].
– Gene disruption results in altered
striatal signalling [1137]. Small
molecule agonists have been
reported [147].
Mutations in GPR101 have
been linked to gigantism and
acromegaly [1906].
Nomenclature GPR132 GPR135 GPR139 GPR141 GPR142
HGNC, UniProt GPR132, Q9UNW8 GPR135, Q8IZ08 GPR139, Q6DWJ6 GPR141, Q7Z602 GPR142, Q7Z601
Endogenous
ligand
Protons – – – –
Agonists – – compound 1a [PMID: 24900311]
(pEC50 7.4) [1721]
– –
Comments GPR4, GPR65, GPR68 and
GPR132 are now thought to
function as proton-sensing
receptors detecting acidic pH
[396, 1704]. Reported to respond
to lysophosphatidylcholine [891],
but later retracted [2038].
– Peptide agonists have been
reported [828].
– Small molecule agonists have
been reported [1890, 2106].
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Nomenclature GPR146 GPR148 GPR149 GPR150 GPR151
HGNC, UniProt GPR146, Q96CH1 GPR148, Q8TDV2 GPR149, Q86SP6 GPR150, Q8NGU9 GPR151, Q8TDV0
Comments Yosten et al. demonstrated
inhibition of proinsulin C-peptide
(INS, P01308)-induced
stimulation of cFos expression
folllowing knockdown of GPR146
in KATO III cells, suggesting
proinsulin C-peptide as an
endogenous ligand of the
receptor [2103].
– Gpr149 knockout mice displayed
increased fertility and enhanced
ovulation, with increased levels of
FSH receptor and cyclin D2 mRNA
levels [463].
– GPR151 responded to galanin
with an EC50 value of 2 M,
suggesting that the endogenous
ligand shares structural features
with galanin (GAL, P22466) [813].
Nomenclature GPR152 GPR153 GPR160 GPR161 GPR162
HGNC, UniProt GPR152, Q8TDT2 GPR153, Q6NV75 GPR160, Q9UJ42 GPR161, Q8N6U8 GPR162, Q16538
Comments – – – A C-terminal truncation (deletion) mutation in Gpr161 causes
congenital cataracts and neural tube defects in the vacuolated lens
(vl) mouse mutant [1226]. The mutated receptor is associated with
cataract, spina bifida and white belly spot phenotypes in mice [994].
Gene disruption is associated with a failure of asymmetric embryonic
development in zebrafish [1085].
–
Nomenclature GPR171 GPR173 GPR174 GPR176 GPR182
HGNC, UniProt GPR171, O14626 GPR173, Q9NS66 GPR174, Q9BXC1 GPR176, Q14439 GPR182, O15218
Endogenous
agonists
– – lysophosphatidylserine (pEC50
7.1) [825]
– –
Comments GPR171 has been shown to be
activated by the endogenous
peptide BigLEN {Mouse}. This
receptor-peptide interaction is
believed to be involved in
regulating feeding and
metabolism responses [621].
– See [819] which discusses
characterization of agonists at this
receptor.
– Rat GPR182 was first proposed as
the adrenomedullin receptor
[904]. However, it was later
reported that rat and human
GPR182 did not respond to
adrenomedullin [927] and
GPR182 is not currently
considered to be a genuine
adrenomedullin receptor [722].
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Nomenclature GPR183 LGR4 LGR5 LGR6 MAS1
HGNC, UniProt GPR183, P32249 LGR4, Q9BXB1 LGR5, O75473 LGR6, Q9HBX8 MAS1, P04201
Endogenous
agonists
7α,25-dihydroxycholesterol
(Selective) (pEC50 8.1–9.8)
[694, 1125],
7α,27-dihydroxycholesterol
(Selective) (pEC50 8.9) [1125],
7β, 25-dihydroxycholesterol
(Selective) (pEC50 8.7) [1125],
7β, 27-dihydroxycholesterol
(Selective) (pEC50 7.3) [1125]
R-spondin-2 (RSPO2, Q6UXX9)
(pEC50 12.5) [266], R-spondin-1
(RSPO1, Q2MKA7) (pEC50 10.7)
[266], R-spondin-3 (RSPO3,
Q9BXY4) (pEC50 10.7) [266],
R-spondin-4 (RSPO4, Q2I0M5)
(pEC50 10.1) [266]
R-spondin-2 (RSPO2, Q6UXX9)
(pEC50 12) [266], R-spondin-1
(RSPO1, Q2MKA7) (pEC50 11.1)
[266], R-spondin-3 (RSPO3,
Q9BXY4) (pEC50 11) [266],
R-spondin-4 (RSPO4, Q2I0M5)
(pEC50 9.4) [266]
R-spondin-1 (RSPO1,
Q2MKA7) [266, 2140],
R-spondin-2 (RSPO2,
Q6UXX9) [266, 2140],
R-spondin-3 (RSPO3,
Q9BXY4) [266, 2140],
R-spondin-4 (RSPO4,
Q2I0M5) [266, 2140]
–
Agonists – – – – angiotensin-(1-7) (AGT,
P01019) (pKi 7.3) [612]
– Mouse
Comments Two independent publications
have shown that
7α,25-dihydroxycholesterol is
an agonist of GPR183 and have
demonstrated by mass
spectrometry that this oxysterol
is present endogenously in
tissues [694, 1125].
Gpr183-deficient mice show a
reduction in the early antibody
response to a T-dependent
antigen. GPR183-deficient B
cells fail to migrate to the outer
follicle and instead stay in the
follicle centre [923, 1488].
LGR4 does not couple to
heterotrimeric G proteins or
recruit arrestins when
stimulated by the R-spondins,
indicating a unique mechanism
of action. R-spondins bind to
LGR4, which specifically
associates with Frizzled and LDL
receptor-related proteins (LRPs)
that are activated by the
extracellular Wnt molecules and
then trigger canonical Wnt
signalling to increase gene
expression [266, 1612, 2140].
Gene disruption leads to
multiple developmental
disorders [869, 1154, 1781,
2005].
The four R-spondins can bind to
LGR4, LGR5, and LGR6, which
specifically associate with
Frizzled and LDL
receptor-related proteins (LRPs),
proteins that are activated by
extracellular Wnt molecules and
which then trigger canonical
Wnt signalling to increase gene
expression [266, 2140].
– –
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Nomenclature MAS1L MRGPRD MRGPRE MRGPRF MRGPRG
HGNC, UniProt MAS1L, P35410 MRGPRD, Q8TDS7 MRGPRE, Q86SM8 MRGPRF, Q96AM1 MRGPRG, Q86SM5
Endogenous
agonists
– β-alanine (pEC50 4.8) [1729, 1785] – – –
Comments – An endogenous peptide with a high degree of
sequence similarity to angiotensin-(1-7) (AGT,
P01019), alamandine (AGT), was shown to
promote NO release in MRGPRD-transfected
cells. The binding of alamandine to MRGPRD
to was shown to be blocked by
D-Pro7-angiotensin-(1-7), β-alanine and
PD123319 [1045]. Genetic ablation of
MRGPRD+ neurons of adult mice decreased
behavioural sensitivity to mechanical stimuli
but not to thermal stimuli [278]. See reviews
[396] and [1779].
See reviews [396] and
[1779].
MRGPRF has been reported to
respond to stimulation by
angiotensin metabolites [589].
See reviews [396] and [1779].
See reviews [396] and
[1779].
Nomenclature MRGPRX1 MRGPRX2 MRGPRX3 MRGPRX4
HGNC, UniProt MRGPRX1, Q96LB2 MRGPRX2, Q96LB1 MRGPRX3, Q96LB0 MRGPRX4, Q96LA9
Endogenous
agonists
bovine adrenal medulla peptide 8-22 (PENK,
P01210) (Selective) (pEC50 5.3–7.8) [299, 1080,
1785]
PAMP-20 (ADM, P35318) (Selective) [899] – –
Agonists – cortistatin-14 {Mouse, Rat} (pEC50 6.9–7.6) [899,
1594, 1785]
– –
Selective agonists – PAMP-12 (human) (pEC50 7.2–7.7) [899] – –
Comments Reported to mediate the sensation of itch [1131,
1739]. Reports that
bovine adrenal medulla peptide 8-22 (PENK,
P01210) was the most potent of a series of
proenkephalin A-derived peptides as an agonist of
MRGPRX1 in assays of calcium mobilisation and
radioligand binding [1080] were replicated in an
independent study using an arrestin recruitment
assay [1785]. See reviews [396] and [1779].
A diverse range of substances has been reported to
be agonists of MRGPRX2, with cortistatin 14 the
highest potency agonist in assays of calcium
mobilisation [1594], also confirmed in an
independent study using an arrestin recruitment
assay [1785]. See reviews [396] and [1779].
– See reviews [396] and
[1779].
Searchable database: http://www.guidetopharmacology.org/index.jsp Class A Orphans 5754
Full Contents of ConciseGuide: http://onlinelibrary.wiley.com/doi/10.1111/bph.13348/full
S.P.H. Alexander et al. The Concise Guide to PHARMACOLOGY 2015/16: G protein-coupled receptors. British Journal of Pharmacology (2015) 172, 5744–5869
Nomenclature OPN3 OPN4 OPN5 P2RY8
HGNC, UniProt OPN3, Q9H1Y3 OPN4, Q9UHM6 OPN5, Q6U736 P2RY8, Q86VZ1
Comments – – Evidence indicates OPN5 triggers a UV-sensitive Gi-mediated
signalling pathway in mammalian tissues [982].
–
Nomenclature P2RY10 TAAR2 TAAR3 TAAR4P
HGNC, UniProt P2RY10, O00398 TAAR2, Q9P1P5 TAAR3, Q9P1P4 TAAR4P, –
Rank order of
potency
– β-phenylethylamine> tryptamine
[185]
– –
Endogenous
agonists
sphingosine 1-phosphate (Selective)
(pEC50 7.3) [1344], LPA (Selective)
(pEC50 6.9) [1344]
– – –
Comments – Probable pseudogene in 10-15% of
Asians due to a polymorphism
(rs8192646) producing a premature
stop codon at amino acid 168 [396].
TAAR3 is thought to be a pseudogene
in man though functional in rodents
[396].
Pseudogene in man but functional in
rodents [396].
Nomenclature TAAR5 TAAR6 TAAR8 TAAR9
HGNC, UniProt TAAR5, O14804 TAAR6, Q96RI8 TAAR8, Q969N4 TAAR9, Q96RI9
Comments Trimethylamine is reported as an agonist [1974]
and 3-iodothyronamine an inverse agonist [426].
– – TAAR9 appears to be functional in most individuals
but has a polymorphic premature stop codon at
amino acid 61 (rs2842899) with an allele frequency
of 10-30% in different populations [1944].
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Class C Orphans
G protein-coupled receptors! Orphan and other 7TM receptors! Class C Orphans
Nomenclature GPR156 GPR158 GPR179 GPRC5A GPRC5B GPRC5C GPRC5D
HGNC, UniProt GPR156, Q8NFN8 GPR158, Q5T848 GPR179, Q6PRD1 GPRC5A, Q8NFJ5 GPRC5B, Q9NZH0 GPRC5C, Q9NQ84 GPRC5D, Q9NZD1
Taste 1 receptors
G protein-coupled receptors! Orphan and other 7TM receptors! Taste 1 receptors
Overview: Whilst the taste of acid and salty foods appear to be
sensed by regulation of ion channel activity, bitter, sweet and umami
tastes are sensed by specialised GPCR. Two classes of taste GPCR
have been identified, T1R and T2R, which are similar in sequence
and structure to Class C and Class A GPCR, respectively. Activation
of taste receptors appears to involve gustducin- (Gαt3) and Gα14-
mediated signalling, although the precise mechanisms remain ob-
scure. Gene disruption studies suggest the involvement of PLCβ2
[2122], TRPM5 [2122] and IP3 [764] receptors in post-receptor sig-
nalling of taste receptors. Although predominantly associated with
the oral cavity, taste receptors are also located elsewhere, includ-
ing further down the gastrointestinal system, in the lungs and in the
brain.
Sweet/Umami
T1R3 acts as an obligate partner in T1R1/T1R3 and T1R2/T1R3 heterodimers, which sense umami or sweet, respectively. T1R1/T1R3 heterodimers respond to L-glutamic acid and may be positively allosterically
modulated by 5’-nucleoside monophosphates, such as 5’-GMP [1096]. T1R2/T1R3 heterodimers respond to sugars, such as sucrose, and artificial sweeteners, such as saccharin [1376].
Nomenclature TAS1R1 TAS1R2 TAS1R3
HGNC, UniProt TAS1R1, Q7RTX1 TAS1R2, Q8TE23 TAS1R3, Q7RTX0
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Taste 2 receptors
G protein-coupled receptors! Orphan and other 7TM receptors! Taste 2 receptors
Bitter
The composition and stoichiometry of bitter taste receptors is not yet established. Bitter receptors appear to separate into two groups, with very restricted ligand specificity or much broader responsiveness. For
example, T2R5 responded to cycloheximide, but not 10 other bitter compounds [287], while T2R14 responded to at least eight different bitter tastants, including (-)-α-thujone and picrotoxinin [119].
Specialist database BitterDB contains additional information on bitter compounds and receptors [2023].
Nomenclature TAS2R1 TAS2R3 TAS2R4 TAS2R5 TAS2R7 TAS2R8
HGNC, UniProt TAS2R1, Q9NYW7 TAS2R3, Q9NYW6 TAS2R4, Q9NYW5 TAS2R5, Q9NYW4 TAS2R7, Q9NYW3 TAS2R8, Q9NYW2
Nomenclature TAS2R9 TAS2R10 TAS2R13 TAS2R14 TAS2R16 TAS2R19
HGNC, UniProt TAS2R9, Q9NYW1 TAS2R10, Q9NYW0 TAS2R13, Q9NYV9 TAS2R14, Q9NYV8 TAS2R16, Q9NYV7 TAS2R19, P59542
Nomenclature TAS2R20 TAS2R30 TAS2R31 TAS2R38 TAS2R39 TAS2R40
HGNC, UniProt TAS2R20, P59543 TAS2R30, P59541 TAS2R31, P59538 TAS2R38, P59533 TAS2R39, P59534 TAS2R40, P59535
Nomenclature TAS2R41 TAS2R42 TAS2R43 TAS2R45 TAS2R46 TAS2R50 TAS2R60
HGNC, UniProt TAS2R41, P59536 TAS2R42, Q7RTR8 TAS2R43, P59537 TAS2R45, P59539 TAS2R46, P59540 TAS2R50, P59544 TAS2R60, P59551
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Other 7TM proteins
G protein-coupled receptors! Orphan and other 7TM receptors! Other 7TM proteins
Nomenclature GPR107 GPR137 OR51E1 TPRA1 GPR143 GPR157
HGNC, UniProt GPR107, Q5VW38 GPR137, Q96N19 OR51E1, Q8TCB6 TPRA1, Q86W33 GPR143, P51810 GPR157, Q5UAW9
Endogenous
agonists
– – – – levodopa [1141] –
Comments GPR107 is a member of
the LUSTR family of
proteins found in both
plants and animals,
having similar topology
to Gprotein-coupled
receptors [461]
– OR51E1 is a putative
olfactory receptor.
TPRA1 shows no
homology to known G
protein-coupled
receptors.
Loss-of-function
mutations underlie ocular
albinism type 1 [103].
GPR157 has ambiguous
sequence similarities to
several different GPCR
families (class A, class B
and the slime mould
cyclic AMP receptor).
Because of its distant
relationship to other
GPCRs, it cannot be
readily classified.
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5-Hydroxytryptamine receptors
G protein-coupled receptors! 5-Hydroxytryptamine receptors
Overview: 5-HT receptors (nomenclature as agreed by the
NC-IUPHAR Subcommittee on 5-HT receptors [789] and
subsequently revised [707]) are, with the exception of the
ionotropic 5-HT3 class, GPCR receptors where the endogenous ag-
onist is 5-hydroxytryptamine. The diversity of metabotropic 5-HT
receptors is increased by alternative splicing that produces isoforms
of the 5-HT2A (non-functional), 5-HT2C (non-functional), 5-HT4,
5-HT6 (non-functional) and 5-HT7 receptors. Unique amongst the
GPCRs, RNA editing produces 5-HT2C receptor isoforms that differ
in function, such as efficiency and specificity of coupling to Gq/11
and also pharmacology [164, 2011]. Most 5-HT receptors (except
5-ht 1e and 5-ht 5a/5b) play specific roles mediating functional re-
sponses in different tissues (reviewed by [1554, 1957].
Nomenclature 5-HT1A receptor 5-HT1B receptor 5-HT1D receptor 5-ht1e receptor 5-HT1F receptor
HGNC, UniProt HTR1A, P08908 HTR1B, P28222 HTR1D, P28221 HTR1E, P28566 HTR1F, P30939
Agonists U92016A (pKi 9.7) [1240],
vilazodone (Partial agonist)
(pKi 9.7) [402], vortioxetine
(Partial agonist) (pKi 7.8) [90]
L-694,247 (pKi 9.2) [637],
naratriptan (Partial agonist)
(pKi 8.1) [1365], eletriptan
(pKi 8) [1365], frovatriptan
(pKi 8) [2069], zolmitriptan
(Partial agonist) (pKi 7.7)
[1365], vortioxetine (Partial
agonist) (pKi 7.5) [90],
rizatriptan (Partial agonist) (pKi
6.9) [1365]
dihydroergotamine (pKi
9.2–9.9) [684, 1084, 1091],
ergotamine (pKi 9.1) [616],
L-694,247 (pKi 9) [2052],
naratriptan (pKi 8.4–9) [432,
1365, 1577], zolmitriptan (pKi
8.9) [1365], frovatriptan (pKi
8.4) [2069], rizatriptan (pKi
7.9) [1365]
BRL-54443 (pKi 8.7) [227] BRL-54443 (pKi 8.9) [227],
eletriptan (pKi 8) [1365],
sumatriptan (pKi 7.2–7.9) [11,
12, 1365, 1968]
Selective
agonists
8-OH-DPAT (pKi 8.4–9.4) [406,
685, 896, 1079, 1280, 1386,
1388, 1389], NLX-101 (pKi
8.6) [1387]
CP94253 (pKi 8.7) [976] PNU109291 (pKi 9.1) [483] –
Gorilla, eletriptan (pKi 8.9)
[1365]
– lasmiditan (pKi 8.7) [1375],
LY334370 (pKi 8.7) [1968],
5-BODMT (pKi 8.4) [966],
LY344864 (pKi 8.2) [1502]
Antagonists (S)-UH 301 (pKi 7.9) [1386] – – – –
Selective
antagonists
WAY-100635 (pKi 7.9–9.2)
[1386, 1388], robalzotan (pKi
9.2) [872]
SB 224289 (Inverse agonist)
(pKi 8.2–8.6) [583, 1384,
1696], SB236057 (Inverse
agonist) (pKi 8.2) [1272],
GR-55562 (pKB 7.4) [791]
SB 714786 (pKi 9.1) [1987] – –
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(continued)
Nomenclature 5-HT1A receptor 5-HT1B receptor 5-HT1D receptor 5-ht1e receptor 5-HT1F receptor
Labelled ligands [3H]robalzotan (Antagonist)
(pKd 9.8) [861],
[3H]WAY100635 (Antagonist)
(pKd 9.5) [933],
[3H]8-OH-DPAT (Agonist) (pKd
6–9.4) [156, 896, 1385, 1388],
[3H]NLX-112 (Agonist) (pKd
8.9) [748], [11C]WAY100635
(Antagonist) [1915],
p-[18F]MPPF (Antagonist)
[368]
[3H]N-methyl-AZ10419369
(Agonist, Partial agonist) (pKd
9.4) [1182], [3H]GR 125,743
(Selective Antagonist) (pKd
8.6–9.2) [637, 2061],
[3H]alniditan (Agonist) (pKd
8.6–9) [1084], [125I]GTI
(Agonist) (pKd 8.9) [193, 232]
– Rat, [3H]eletriptan (Agonist,
Partial agonist) (pKd 8.5)
[1365], [3H]sumatriptan
(Agonist, Partial agonist) (pKd
8) [1365], [11C]AZ10419369
(Agonist, Partial agonist)
[1950]
[3H]eletriptan (Agonist) (pKd
9.1) [1365], [3H]alniditan
(Agonist) (pKd 8.8–8.9)
[1084], [125I]GTI (Selective
Agonist) (pKd 8.9) [193, 232] –
Rat, [3H]GR 125,743 (Selective
Antagonist) (pKd 8.6) [2061],
[3H]sumatriptan (Agonist)
(pKd 8.2) [1365]
[3H]5-HT (Agonist) (pKd
8.1–8.2) [1237, 1463]
[3H]LY334370 (Agonist) (pKd
9.4) [1968], [125I]LSD
(Agonist) (pKd 9) [44] – Mouse
Comments – Wang et al. (2013) report X-ray
structures which reveal the
binding modality of
ergotamine and
dihydroergotamine to the
5-HT1B receptor in comparison
with the structure of the
5-HT2B receptor [1978].
– – –
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Nomenclature 5-HT2A receptor 5-HT2B receptor 5-HT2C receptor 5-HT4 receptor
HGNC, UniProt HTR2A, P28223 HTR2B, P41595 HTR2C, P28335 HTR4, Q13639
Agonists DOI (pKi 7.4–9.2) [204, 1374, 1755] methysergide (Partial agonist) (pKi
8–9.4) [970, 1605, 1969], DOI (pKi
7.6–7.7) [1025, 1374, 1659]
DOI (pKi 7.2–8.6) [465, 1374, 1659],
Ro 60-0175 (pKi 7.7–8.2) [953, 970]
cisapride (Partial agonist) (pKi
6.4–7.4) [77, 128, 597, 1266, 1267,
1941]
Selective agonists – BW723C86 (pKi 7.3–8.6) [108, 970,
1659], Ro 60-0175 (pKi 8.3) [970]
WAY-163909 (pKi 6.7–8) [454],
lorcaserin (pKi 7.8) [1878]
TD-8954 (pKi 9.4) [1250], ML 10302
(Partial agonist) (pKi 7.9–9) [136,
160, 1266, 1267, 1268], RS67506
(pEC50 8.8) [731] – Rat, relenopride
(Partial agonist) (pKi 8.3) [607],
velusetrag (pKi 7.7) [1139, 1763],
BIMU 8 (pKi 7.3) [347]
Antagonists risperidone (Inverse agonist) (pKi
9.3–10) [986, 1008, 1675], mianserin
(pKi 7.7–9.6) [970, 1001, 1280],
ziprasidone (pKi 8.8–9.5) [986, 1008,
1675, 1711], volinanserin (pIC50
6.5–9.3) [970, 1142, 1568],
blonanserin (pKi 9.1) [1421],
clozapine (Inverse agonist) (pKi
7.6–9) [970, 1008, 1277, 1675,
1943], olanzapine (pKi 8.6–8.9) [986,
1008, 1675, 1711], nefazodone (pKi
8.2) [1698], chlorpromazine (Inverse
agonist) (pKi 8.1) [1008], loxapine
(Inverse agonist) (pKi 8.1) [1008],
trifluoperazine (pKi 7.9) [1008],
pimozide (pKi 7.1–7.7) [986, 1008],
trazodone (pKi 7.4) [970], haloperidol
(pKi 6.7–7.3) [1008, 1277, 1675,
1711, 1943], mesoridazine (pKi 7.3)
[326], mirtazapine (pKi 7.2) [513],
mirtazapine (pKi 7.2) [513],
quetiapine (pKi 6.4–7) [986, 1008],
molindone (pKi 6.5) [1008]
mianserin (pKi 7.9–8.8) [180, 970,
1969]
mianserin (Inverse agonist) (pKi
8.3–9.2) [524, 970, 1280],
methysergide (pKi 8.6–9.1) [465,
970], ziprasidone (Inverse agonist)
(pKi 7.9–9) [743, 1008, 1711],
olanzapine (Inverse agonist) (pKi
8.1–8.4) [743, 1008, 1711], loxapine
(Inverse agonist) (pKi 7.8–8) [743,
1008], mirtazapine (pKi 7.4) [513],
mirtazapine (pKi 7.4) [513],
trazodone (pKi 6.6) [970],
trifluoperazine (pKi 6.4) [1008],
agomelatine (pKi 6.2) [1276]
–
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(continued)
Nomenclature 5-HT2A receptor 5-HT2B receptor 5-HT2C receptor 5-HT4 receptor
Selective
antagonists
ketanserin (pKi 8.1–9.7) [234, 970,
1559], pimavanserin (Inverse agonist)
(pKi 9.3) [572, 1943]
BF-1 (pKi 10.1) [1671], RS-127445
(pKi 9–9.5) [180, 970], EGIS-7625
(pKi 9) [1001]
FR260010 (pKi 9) [700], SB 242084
(pKi 8.2–9) [928, 970], RS-102221
(pKi 8.3–8.4) [181, 970]
RS 100235 (pKi 8.7–12.2) [347,
1589], SB 204070 (pKi 9.8–10.4)
[128, 1266, 1267, 1941], GR 113808
(pKi 9.3–10.3) [77, 128, 160, 347,
1267, 1589, 1941]
Labelled ligands [3H]fananserin (Antagonist) (pKd 9.9)
[1188] – Rat, [3H]ketanserin
(Antagonist) (pKd 8.6–9.7) [970,
1559], [11C]volinanserin (Antagonist)
[676], [18F]altanserin (Antagonist)
[1601]
[3H]LSD (Agonist) (pKd 8.7) [1559],
[3H]5-HT (Agonist) (pKd 8.1) [1967]
– Rat, [3H]mesulergine (Antagonist,
Inverse agonist) (pKd 7.9) [970],
[125I]DOI (Agonist) (pKd 7.7–7.6)
[125I]DOI (Agonist) (pKd 8.7–9)
[524], [3H]mesulergine (Antagonist,
Inverse agonist) (pKd 9.3–8.7) [524,
1559], [3H]LSD (Agonist)
[123I]SB 207710 (Antagonist) (pKd
10.1) [228] – Pig, [3H]GR 113808
(Antagonist) (pKd 10.3–9.7) [77, 128,
1268, 1941], [3H]RS 57639 (Selective
Antagonist) (pKd 9.7) [179] – Guinea
pig, [11C]SB207145 (Antagonist)
(pKd 8.6) [1169]
Comments – LSD (lysergic acid) and ergotamine
show a strong preference for arrestin
recruitment over G protein coupling
at the 5-HT2B receptor, with no such
preference evident at 5-HT1B
receptors, and they also antagonise
5-HT7A receptors [1963]. DHE
(dihydroergocryptine), pergolide and
cabergoline also show significant
preference for arrestin recruitment
over G protein coupling at 5-HT2B
receptors [1963].
The serotonin antagonist mesulergine
was key to the discovery of the
5-HT2C receptor [1479].
–
Nomenclature 5-ht5a receptor 5-ht5b receptor 5-HT6 receptor 5-HT7 receptor
HGNC, UniProt HTR5A, P47898 HTR5BP, – HTR6, P50406 HTR7, P34969
Selective agonists – – WAY-181187 (pKi 8.7) [1663], E6801 (Partial agonist)
(pKi 8.7) [769], WAY-208466 (pKi 8.3) [135],
EMD-386088 (pIC50 8.1) [1228]
LP-12 (pKi 9.9) [1082], LP-44 (pKi 9.7) [1082], LP-211
(pKi 9.2) [1083] – Rat, AS-19 (pKi 9.2) [947], E55888
(pKi 8.6) [206]
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(continued)
Nomenclature 5-ht5a receptor 5-ht5b receptor 5-HT6 receptor 5-HT7 receptor
Antagonists – – – lurasidone (pKi 9.3) [829], pimozide (pKi
9.3) [1604] – Rat, vortioxetine (pKi 6.3)
[90]
Selective
antagonists
SB 699551 (pKi 8.2) [366] – SB399885 (pKi 9) [763], SB 271046 (pKi
8.9) [224], cerlapirdine (pKi 8.9) [358],
SB357134 (pKi 8.5) [225], Ro 63-0563
(pKi 7.9–8.4) [168, 1754]
SB269970 (pKi 8.6–8.9) [1874],
SB656104 (pKi 8.7) [531], DR-4004 (pKi
8.7) [615, 938], JNJ-18038683 (pKi 8.2)
[177], SB 258719 (Inverse agonist) (pKi
7.5) [1875]
Labelled ligands [125I]LSD (Agonist) (pKd 9.7) [636],
[3H]5-CT (Agonist) (pKd 8.6) [636]
[125I]LSD (Agonist) (pKd 9.3) [1227]
– Mouse, [3H]5-CT (Agonist) [1965] –
Mouse
[11C]GSK215083 (Antagonist) (pKi 9.8)
[1462], [125I]SB258585 (Selective
Antagonist) (pKd 9) [763], [
3H]LSD
(Agonist) (pKd 8.7) [167],
[3H]Ro 63-0563 (Antagonist) (pKd 8.3)
[168], [3H]5-CT (Agonist)
[3H]5-CT (Agonist) (pKd 9.4) [1874],
[3H]5-HT (Agonist) (pKd 8.1–9) [93,
1793], [3H]SB269970 (Selective
Antagonist) (pKd 8.9) [1874], [
3H]LSD
(Agonist) (pKd 8.5–8.6) [1793]
Comments: Tabulated pKi and KD values refer to binding to hu-
man 5-HT receptors unless indicated otherwise. The nomenclature
of 5-HT1B/5-HT1D receptors has been revised [707]. Only the non-
rodent form of the receptor was previously called 5-HT1D: the hu-
man 5-HT1B receptor (tabulated) displays a different pharmacology
to the rodent forms of the receptor due to Thr335 of the human
sequence being replaced by Asn in rodent receptors. NAS181 is a
selective antagonist of the rodent 5-HT1B receptor. Fananserin and
ketanserin bind with high affinity to dopamine D4 and histamine H1
receptors respectively, and ketanserin is a potent α1 adrenoceptor
antagonist, in addition to blocking 5-HT2A receptors. The human 5-
ht5A receptor has been claimed to couple to several signal transduc-
tion pathways when stably expressed in C6 glioma cells [1404]. The
human orthologue of the mouse 5-ht5b receptor is non-functional
due to interruption of the gene by stop codons. The 5-ht1e receptor
appears not to have been cloned from mouse, or rat, impeding def-
inition of its function. In addition to the receptors listed in the table,
an ’orphan’ receptor, unofficially termed5-HT1P, has been described
[600].
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Acetylcholine receptors (muscarinic)
G protein-coupled receptors! Acetylcholine receptors (muscarinic)
Overview: Muscarinic acetylcholine receptors (nomenclature
as agreed by the NC-IUPHAR Subcommittee on Mus-
carinic Acetylcholine Receptors [275]) are GPCRs of the
Class A, rhodopsin-like family where the endogenous agonist is
acetylcholine. In addition to the agents listed in the table,
AC-42, its structural analogues AC-260584 and 77-LH-28-1,
N-desmethylclozapine, TBPB and LuAE51090 have been described as
functionally selective agonists of the M1 receptor subtype via bind-
ing in a mode distinct from that utilized by non-selective agonists
[71, 878, 1040, 1041, 1232, 1635, 1786, 1787, 1825]. There are
two pharmacologically characterised allosteric sites on muscarinic re-
ceptors, one defined by it binding gallamine, strychnine and brucine,
and the other defined by the binding of KT 5720, WIN 62,577,
WIN 51,708 and staurosporine [1052, 1053].
Nomenclature M1 receptor M2 receptor
HGNC, UniProt CHRM1, P11229 CHRM2, P08172
Agonists carbachol (pKi 3.2–5.3) [334, 846, 2040], pilocarpine (Partial agonist) (pKi 5.1) [846],
bethanechol (pKi 4) [846]
bethanechol (pKi 4) [846]
Antagonists glycopyrrolate (pIC50 9.9) [1801], umeclidinium (pKi 9.8) [1035, 1632], AE9C90CB (pKi
9.7) [1749], propantheline (pKi 9.7) [797], atropine (pKi 8.5–9.6) [334, 552, 759, 797,
1486, 1762], tiotropium (pKi 9.6) [428], 4-DAMP (pKi 9.2) [458], dicyclomine (pKi 9.1)
[68], scopolamine (pKi 9) [797], trihexyphenidyl (pKi 8.9) [68], tripitramine (pKi 8.8)
[1176], UH-AH 37 (pKi 8.6–8.7) [609, 2012], tolterodine (pKi 8.5–8.7) [609, 1749],
oxybutynin (pKi 8.6) [410, 818, 1749], darifenacin (pKi 7.5–8.3) [609, 730, 759, 818,
1749], pirenzepine (pKi 7.8–8.3) [238, 458, 730, 797, 875, 2012], solifenacin (pKi 7.6)
[818, 1749], AFDX384 (pKi 7.5) [458], AQ-RA 741 (pKi 7.2–7.5) [458, 609],
methoctramine (pKi 6.6–7.3) [458, 493, 730, 1762], himbacine (pKi 6.7–7.1) [458, 875,
1286], muscarinic toxin 3 (pKi 7.1) [875], otenzepad (pKd 6.2) [493]
tiotropium (pKi 9.9) [428], umeclidinium (pKi 9.8) [1035, 1632], propantheline (pKi
9.5) [797], glycopyrrolate (Full agonist) (pIC50 9.3) [1801], atropine (pKi 7.8–9.2) [238,
310, 759, 797, 1002, 1373, 1486], AE9C90CB (pKi 8.6) [1749], tolterodine (Inverse
agonist) (pKi 8.4–8.6) [609, 1373, 1749], AQ-RA 741 (pKi 8.4) [458, 609], himbacine
(pKi 7.9–8.4) [458, 875, 1002, 1286], methoctramine (pKi 7.3–8.4) [238, 458, 493,
730, 1002, 1373], 4-DAMP (pKi 8.3) [1002], AFDX384 (pKi 8.2) [458], biperiden (pKd
8.2) [173], oxybutynin (pKi 7.7–8.1) [818, 1749], darifenacin (Inverse agonist) (pKi
7–7.6) [609, 730, 759, 818, 1373, 1749], UH-AH 37 (pKi 7.3–7.4) [609, 2012],
otenzepad (pKi 6.7–7.2) [238, 1002], solifenacin (pKi 6.9–7.1) [818, 1749], pirenzepine
(pKi 6–6.7) [238, 458, 730, 797, 875, 1002, 1373, 2012], VU0255035 (pKi 6.2) [1717],
muscarinic toxin 3 (pKi <6) [875], guanylpirenzepine (pKi 5.3) [1966] – Rat,
muscarinic toxin 7 (pKi <5) [1414]
Selective
antagonists
biperiden (pKd 9.3) [173], VU0255035 (pKi 7.8) [1717], guanylpirenzepine (pKi
7.3–7.6) [23, 1966] – Rat
tripitramine (pKi 9.6) [1176]
Allosteric
modulators
muscarinic toxin 7 (Negative) (pKi 11–11.1) [1414], benzoquinazolinone 12 (Positive)
(pKB 6.6) [4], KT 5720 (Positive) (pKd 6.4) [1052], brucine (Positive) (pKd 4.5–5.8)
[846, 1051], BQCA (Positive) (pKB 4–4.8) [4, 5, 261, 1161], VU0029767 (Positive)
[1208], VU0090157 (Positive) [1208]
W-84 (Negative) (pKd 6–7.5) [1299, 1908], C7/3-phth (Negative) (pKd 7.1) [335],
alcuronium (Negative) (pKd 6.1–6.9) [846, 1908], gallamine (Negative) (pKd 5.9–6.3)
[348, 1049], LY2119620 (Positive) (pKd 5.7) [383, 1010], LY2033298 (Positive) (pKd
4.4) [1933]
Labelled ligands [3H]QNB (Antagonist) (pKd 10.6–10.8) [336, 1486], Cy3B-telenzepine (Antagonist)
(pKd 10.5) [742], [
3H]N-methyl scopolamine (Antagonist) (pKd 9.4–10.3) [280, 334,
336, 759, 846, 847, 875, 932, 1049], [3H](+)telenzepine (Antagonist) (pKi 9.4) [500] –
Rat, Alexa-488-telenzepine (Antagonist) (pKd 9.3) [742], [
3H]pirenzepine (Antagonist)
(pKd 7.9) [1995], BODIPY-pirenzepine (Antagonist) (pKi 7) [820], [
11C]butylthio-TZTP
(Agonist) [504], [11C]xanomeline (Agonist) [504],
[18F](R,R)-quinuclidinyl-4-fluoromethyl-benzilate (Antagonist) [935] – Rat
[3H]QNB (Antagonist) (pKd 10.1–10.6) [1486], Cy3B-telenzepine (Antagonist) (pKi
10.4) [1380], [3H]tiotropium (Antagonist) (pKd 10.3) [1632],
[3H]N-methyl scopolamine (Antagonist) (pKd 9.3–9.9) [280, 310, 759, 846, 847, 875,
932, 1049, 1985], Alexa-488-telenzepine (Antagonist) (pKi 8.8) [1380],
[3H]acetylcholine (Agonist) (pKd 8.8) [1050], [
3H]oxotremorine-M (Agonist) (pKd 8.7)
[137], [3H]dimethyl-W84 (Allosteric modulator, Positive) (pKd 8.5) [1908], [
18F]FP-TZTP
(Agonist) [845] – Mouse
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Nomenclature M3 receptor M4 receptor M5 receptor
HGNC, UniProt CHRM3, P20309 CHRM4, P08173 CHRM5, P08912
Agonists pilocarpine (Partial agonist) (pKi 5.1) [846], carbachol
(pKi 4–4.4) [310, 846, 2040], bethanechol (pKi 4.2)
[846]
pilocarpine (Partial agonist) (pKi 5.2) [846], carbachol
(pKi 4.3–4.9) [846, 2040], bethanechol (pKi 4) [846]
pilocarpine (Partial agonist) (pKi 5) [639], carbachol
(pKi 4.9) [2040]
Antagonists tiotropium (pKi 9.5–11.1) [428, 442], umeclidinium
(pKi 10.2) [1035, 1632], propantheline (pKi 10) [797],
AE9C90CB (pKi 9.9) [1749], atropine (pKi 8.9–9.8)
[238, 442, 759, 797, 1486, 1762], ipratropium (pKi
9.3–9.8) [442, 759], aclidinium (pIC50 9.8) [1530],
clidinium (pKi 9.6) [442], glycopyrrolate (pIC50 9.6)
[1801], 4-DAMP (pKi 9.3) [458], darifenacin (pKi
8.6–9.1) [609, 730, 759, 818, 1749], dicyclomine (pKi
9) [68], oxybutynin (pKi 8.8–8.9) [410, 818, 1749],
tolterodine (pKi 8.4–8.5) [609, 1749], biperiden (pKd
8.4) [173], UH-AH 37 (pKi 8.1–8.2) [609, 2012],
solifenacin (pKi 7.7–8) [818, 1749], tropicamide (pKi
7.5) [68], AQ-RA 741 (pKi 7.2–7.3) [458, 609],
AFDX384 (pKi 7.2) [458], himbacine (pKi 6.9–7.2)
[458, 875, 1286], methoctramine (pKi 6.1–6.9) [238,
458, 493, 730, 1762], tripitramine (pKi 6.8) [1288],
pirenzepine (pKi 6.5–6.8) [238, 458, 730, 797, 875,
2012], guanylpirenzepine (pKi 6.2) [1966] – Rat,
VU0255035 (pKi 6.1) [1717], otenzepad (pKi 6.1)
[238], muscarinic toxin 3 (pKi <6) [875],
muscarinic toxin 7 (pKi <5) [1414]
umeclidinium (pKi 10.3) [1632], glycopyrrolate (pIC50
9.8) [1801], AE9C90CB (pKi 9.5) [1749], 4-DAMP (pKi
8.9) [458], oxybutynin (pKi 8.7) [1749], biperiden
(pKd 8.6) [173], UH-AH 37 (pKi 8.3–8.4) [609, 2012],
tolterodine (pKi 8.3–8.4) [609, 1749], AQ-RA 741 (pKi
7.8–8.2) [458, 609], himbacine (pKi 7.9–8.2) [458,
875, 1286], darifenacin (pKi 7.3–8.1) [609, 730, 759,
1749], AFDX384 (pKi 8) [458], tripitramine (pKi 7.9)
[1288], pirenzepine (pKi 7–7.6) [458, 730, 797, 875,
2012], methoctramine (pKi 6.6–7.5) [238, 458, 493,
730], otenzepad (pKd 7) [493], solifenacin (pKi 6.8)
[1749], guanylpirenzepine (pKi 6.2) [1966] – Rat,
VU0255035 (pKi 5.9) [1717], muscarinic toxin 7 (pKi
<5) [1414]
umeclidinium (pKi 9.9) [1632], glycopyrrolate (pIC50
9.7) [1801], AE9C90CB (pKi 9.5) [1749], 4-DAMP (pKi
9) [458], tolterodine (pKi 8.5–8.8) [609, 1749],
darifenacin (pKi 7.9–8.6) [609, 730, 759, 1749],
UH-AH 37 (pKi 8.3) [609, 2012], biperiden (pKd 8.2)
[173], oxybutynin (pKi 7.9) [1749], AQ-RA 741 (pKi
6.1–7.8) [458, 609], tripitramine (pKi 7.5) [1176],
methoctramine (pKi 6.3–7.2) [238, 458, 493, 730],
solifenacin (pKi 7.2) [1749], pirenzepine (pKi 6.8–7.1)
[730, 875, 2012], guanylpirenzepine (pKd 6.8) [514] –
Unknown, himbacine (pKi 5.4–6.5) [458, 875, 1286],
AFDX384 (pKi 6.3) [458], muscarinic toxin 3 (pKi <6)
[875], otenzepad (pKi 5.6) [238], muscarinic toxin 7
(pKi <5) [1414]
Selective
antagonists
– – ML381 (pKi 6.3) [593]
Allosteric
modulators
WIN 62,577 (Positive) (pKd 5.1) [1053],
N-chloromethyl-brucine (Positive) (pKd 3.3) [1051]
muscarinic toxin 3 (Negative) (pKi 8.7) [875, 1444],
LY2119620 (Positive) (pKd 5.7) [383], thiochrome
(Positive) (pKd 4) [1050], LY2033298 (Positive) [286],
VU0152099 (Positive) [201], VU0152100 (Positive)
[201]
ML380 (Positive) (pEC50 6.7) [595]
Selective
allosteric
modulators
– – ML375 (Negative) (pIC50 6.5) [594]
Labelled ligands [3H]tiotropium (Antagonist) (pKd 10.7) [1632],
[3H]QNB (Antagonist) (pKd 10.4) [1486],
[3H]N-methyl scopolamine (Antagonist) (pKd
9.7–10.2) [280, 310, 759, 797, 846, 875, 932, 1049],
[3H]darifenacin (Antagonist) (pKd 9.5) [1762]
[3H]QNB (Antagonist) (pKd 9.7–10.5) [336, 1486],
[3H]N-methyl scopolamine (Antagonist) (pKd
9.9–10.2) [280, 310, 336, 759, 846, 875, 932, 1049,
1444, 1985], [3H]acetylcholine (Agonist) (pKd 8.2)
[1050]
[3H]QNB (Antagonist) (pKd 10.2–10.7),
[3H]N-methyl scopolamine (Antagonist) (pKd 9.3–9.7)
[280, 310, 759, 875, 932, 1985]
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Comments: LY2033298 and BQCA have also been shown to di-
rectly activate the M4 and M1 receptors, respectively, via an al-
losteric site [1059, 1060, 1366, 1367]. The allosteric site for
gallamine and strychnine on M2 receptors can be labelled by
[3H]dimethyl-W84 [1908]. McN-A-343 is a functionally selective
partial agonist that appears to interact in a bitopic mode with both
the orthosteric and an allosteric site on the M2 muscarinic recep-
tor [1934]. THRX160209, hybrid 1 and hybrid 2, are multivalent
(bitopic) ligands that also achieve selectivity for M2 receptors by
binding both to the orthosteric and a nearby allosteric site [52,
1796].
Although numerous ligands for muscarinic acetylcholine receptors
have been described, relatively few selective antagonists have been
described, so it is common to assess the rank order of affinity
of a number of antagonists of limited selectivity (e.g. 4-DAMP,
darifenacin, pirenzepine) in order to identify the involvement of par-
ticular subtypes. It should be noted that the measured affinities of
antagonists (and agonists) in radioligand binding studies are sensitive
to ionic strength and can increase over 10-fold at low ionic strength
compared to its value at physiological ionic strengths [151].
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Adenosine receptors
G protein-coupled receptors! Adenosine receptors
Overview: Adenosine receptors (nomenclature as agreed by the NC-IUPHAR Subcommittee on Adenosine Receptors [541]) are activated by the endogenous ligand adenosine (potentially inosine
also at A3 receptors). Crystal structures for the antagonist-bound and agonist-bound A2A adenosine receptors have been described [835, 2065].
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Nomenclature A1 receptor A2A receptor A2B receptor A3 receptor
HGNC, UniProt ADORA1, P30542 ADORA2A, P29274 ADORA2B, P29275 ADORA3, P0DMS8
Agonists cyclopentyladenosine (pKi 6.5–9.4)
[388, 570, 736, 839, 870, 1592, 2141]
– – –
(Sub)family-
selective
agonists
NECA (pKi 5.3–8.2) [570, 870, 1592,
1903, 2077]
NECA (pKi 6.9–8.7) [189, 427, 570,
943, 1021, 2077]
NECA (pKi 5.7–6.9) [146, 189, 862,
1113, 1798, 1945, 2077]
NECA (pKi 7.5–8.4) [189, 570, 840,
1634, 1946, 2077]
Selective agonists 5-Cl-5-deoxy-()-ENBA (pKi 9.3) [536],
GR79236 (pKi 8.5) [839] – Rat, CCPA
(pKi 7.7–8.1) [839, 1419]
apadenoson (pKi 9.3) [1481],
UK-432,097 (pKi 8.3) [2065],
CGS 21680 (pKi 6.7–8.1) [189, 427,
570, 839, 943, 968, 1021, 1419],
regadenoson (pKi 6.5) [839]
BAY 60-6583 (pKi 8–8.5) [460] IB-MECA (pKi 8.7–9.2) [511, 561, 968,
1946], Cl-IB-MECA (pKi 8–8.9) [202,
840, 941], MRS5698 (pKi 8.5) [1898]
Antagonists caffeine (pKi 4.3–5) [6, 409, 838] SCH 58261 (pKi 8.3–9.2) [427, 1021,
1445], theophylline (pKi 5.2–5.8) [427,
838, 968, 1945], caffeine (pKi 4.6–5.6)
[6, 838, 1021]
theophylline (pKi 4.1–5) [141, 511, 944,
1945], caffeine (pKi 4.5–5) [141, 188,
944]
caffeine (pKi 4.9) [838]
(Sub)family-
selective
antagonists
CGS 15943 (pKi 8.5) [1445],
xanthine amine congener (pKd 7.5)
[536]
CGS 15943 (pKi 7.7–9.4) [427, 943,
968, 1445], xanthine amine congener
(pKi 8.4–9) [427, 968]
xanthine amine congener (pKi 6.9–8.8)
[146, 862, 863, 968, 1113, 1798],
CGS 15943 (pKi 6–8.1) [65, 862, 863,
968, 1445, 1798]
CGS 15943 (pKi 7–7.9) [949, 968,
1445, 1946], xanthine amine congener
(pKi 7–7.4) [968, 1634, 1946]
Selective
antagonists
PSB36 (pKi 9.9) [6] – Rat, DPCPX (pKi
7.4–9.2) [826, 1419, 1592, 2015, 2141],
derenofylline (pKi 9) [897], WRC-0571
(pKi 8.8) [1210]
SCH442416 (pKi 8.4–10.3) [1728,
1891], ZM-241385 (pKi 8.8–9.1) [1445]
PSB-0788 (pKi 9.4) [188], PSB603 (pKi
9.3) [188], MRS1754 (pKi 8.8) [862,
948], PSB1115 (pKi 7.3) [723]
MRS1220 (pKi 8.2–9.2) [840, 949,
1818, 2090], VUF5574 (pKi 8.4) [2143],
MRS1523 (pKi 7.7) [1092], MRS1191
(pKi 7.5) [840, 866, 1097]
Labelled ligands [3H]CCPA (Agonist) (pKd 9.2) [968,
1592], [3H]DPCPX (Antagonist) (pKd
8.4–9.2) [388, 511, 968, 1445, 1592,
1903]
[3H]ZM 241385 (Antagonist) (pKd
8.7–9.1) [36, 569], [3H]CGS 21680
(Agonist) (pKd 7.7–7.8) [852, 1976]
[3H]MRS1754 (Antagonist) (pKd 8.8)
[862]
[125I]AB-MECA (Agonist) (pKd 9–9.1)
[1445, 1946]
Comments: Adenosine inhibits many intracellular ATP-utilising en-
zymes, including adenylyl cyclase (P-site). A pseudogene exists for
the A2B adenosine receptor (ADORA2BP1) with 79% identity to the
A2B adenosine receptor cDNA coding sequence, but which is unable
to encode a functional receptor [841]. DPCPX also exhibits antago-
nism at A2B receptors (pKi ca. 7,[34, 968]). Antagonists at A3 recep-
tors exhibit marked species differences, such that only MRS1523 and
MRS1191 are selective at the rat A3 receptor. In the absence of other
adenosine receptors, [3H]DPCPX and [3H]ZM 241385 can also be
used to label A2B receptors (KD ca. 30 and 60 nM respectively).
[125I]AB-MECA also binds to A1 receptors [968]. [
3H]CGS 21680 is
relatively selective for A2A receptors, but may also bind to other sites
in cerebral cortex [384, 871]. [3H]NECA binds to other non-receptor
elements, which also recognise adenosine [1143]. XAC-BY630 has
been described as a fluorescent antagonist for labelling A1 adeno-
sine receptors in living cells, although activity at other adenosine re-
ceptors was not examined [212].
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Adhesion Class GPCRs
G protein-coupled receptors! Adhesion Class GPCRs
Overview: Adhesion GPCRs are structurally identified on the basis of a large extracellular region, similar to the Class B GPCR, but which is linked to the 7TM region by a "stalk" motif containing a GPCR proteolytic
site. The N-terminus often shares structural homology with proteins such as lectins and immunoglobulins, leading to the term adhesion GPCR [543, 2097]. The nomenclature of these receptors was
revised in 2015 as recommended by NC-IUPHAR and the Adhesion GPCR Consortium [683].
Nomenclature ADGRA1 ADGRA2 ADGRA3 ADGRB1 ADGRB2
HGNC, UniProt ADGRA1, Q86SQ6 ADGRA2, Q96PE1 ADGRA3, Q8IWK6 ADGRB1, O14514 ADGRB2, O60241
Endogenous agonists – – – phosphatidylserine [1461] –
Comments – – – ADGRB1 is reported to respond to
phosphatidylserine [1461].
–
Nomenclature ADGRB3 CELSR1 CELSR2 CELSR3 ADGRD1
HGNC, UniProt ADGRB3, O60242 CELSR1, Q9NYQ6 CELSR2, Q9HCU4 CELSR3, Q9NYQ7 ADGRD1, Q6QNK2
Nomenclature ADGRD2 ADGRE1 ADGRE2 ADGRE3 ADGRE4P
HGNC, UniProt ADGRD2, Q7Z7M1 ADGRE1, Q14246 ADGRE2, Q9UHX3 ADGRE3, Q9BY15 ADGRE4P, Q86SQ3
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Nomenclature ADGRE5 ADGRF1 ADGRF2 ADGRF3 ADGRF4
HGNC, UniProt ADGRE5, P48960 ADGRF1, Q5T601 ADGRF2, Q8IZF7 ADGRF3, Q8IZF5 ADGRF4, Q8IZF3
Nomenclature ADGRF5 ADGRG1 ADGRG2 ADGRG3 ADGRG4
HGNC, UniProt ADGRF5, Q8IZF2 ADGRG1, Q9Y653 ADGRG2, Q8IZP9 ADGRG3, Q86Y34 ADGRG4, Q8IZF6
Comments – Reported to bind tissue transglutaminase
2 [2066] and collagen, which activates
the G12/13 pathway [1155].
– – –
Nomenclature ADGRG5 ADGRG6 ADGRG7 ADGRL1
HGNC, UniProt ADGRG5, Q8IZF4 ADGRG6, Q86SQ4 ADGRG7, Q96K78 ADGRL1, O94910
Nomenclature ADGRL2 ADGRL3 ADGRL4 ADGRV1
HGNC, UniProt ADGRL2, O95490 ADGRL3, Q9HAR2 ADGRL4, Q9HBW9 ADGRV1, Q8WXG9
Comments – – – Loss-of-function mutations are associated with
Usher syndrome, a sensory deficit disorder [843].
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Adrenoceptors
G protein-coupled receptors! Adrenoceptors
Overview:
Adrenoceptors, α1
α1-Adrenoceptors (nomenclature as agreed by the
NC-IUPHAR Subcommittee on Adrenoceptors [248],
see also [752]) are activated by the endogenous ago-
nists (-)-adrenaline and (-)-noradrenaline with equal potency.
Phenylephrine, methoxamine and cirazoline are agonists selec-
tive for α1-adrenoceptors relative to α2-adrenoceptors, while
prazosin (8.5-10.5) and corynanthine (6.5-7.5) are antagonists con-
sidered selective for α1-adrenoceptors relative to α2-adrenoceptors.
[3H]prazosin (0.25 nM) and [125I]HEAT (0.1 nM; also known as
BE2254) are relatively selective radioligands. The α1A-adrenoceptor
antagonist S(+)-niguldipine also has high affinity for L-type Ca2+
channels. The conotoxin rho-TIA acts as a negative allosteric mod-
ulator at the α1B-adrenoceptor [1716], while the snake toxin
-Da1a acts as a selective non-competitive antagonist at the α1A-
adrenoceptor [1236, 1548]. Fluorescent derivatives of prazosin
(Bodipy PL-prazosin-QAPB) are increasingly used to examine cellu-
lar localisation of α1-adrenoceptors. The vasoconstrictor effects of
selective α1-adrenoceptor agonists have led to their use as nasal de-
congestants; antagonists are used to treat hypertension (doxazosin,
prazosin) and benign prostatic hyperplasia (alfuzosin, tamsulosin).
The combined α1- and β2-adrenoceptor antagonist carvedilol is
widely used to treat congestive heart failure, although the contri-
bution of α1-adrenoceptor blockade to the therapeutic effect is
unclear. Several anti-depressants and anti-psychotic drugs possess
α1-adrenoceptor blocking properties that are believed to contribute
to side effects such as orthostatic hypotension and extrapyrami-
dal effects.
Nomenclature α1A-adrenoceptor α1B-adrenoceptor α1D-adrenoceptor
HGNC, UniProt ADRA1A, P35348 ADRA1B, P35368 ADRA1D, P25100
Endogenous agonists – – (-)-adrenaline (pKi 7.2) [1722]
Agonists oxymetazoline (pKi 8–8.2) [780, 1420, 1722, 1862],
phenylephrine (pKi 5.2–5.4) [1862], methoxamine (pKi
5–5.2) [1722, 1862]
phenylephrine (pIC50 6.3–7.5) [532, 1289] –
Selective agonists A61603 (pIC50 7.8–8.4) [532, 969], dabuzalgron (pKi 7.4)
[162]
– –
Antagonists prazosin (Inverse agonist) (pKi 9–9.9) [289, 389, 532,
1722, 2029], doxazosin (pKi 9.3) [689], terazosin (pKi
8.7) [1263], phentolamine (pKi 8.6) [1722], alfuzosin (pKi
8.1) [750]
prazosin (Inverse agonist) (pKi 9.6–9.9) [532, 1722, 2029],
tamsulosin (Inverse agonist) (pKi 9.5–9.7) [532, 1722,
2029], doxazosin (pKi 9.1) [689], alfuzosin (pKi 8.6) [751],
terazosin (pKi 8.6) [1263], phentolamine (pKi 7.5) [1722]
prazosin (Inverse agonist) (pKi 9.5–10.2) [532,
1722, 2029], tamsulosin (pKi 9.8–10.2) [532, 1722,
2029], doxazosin (pKi 9.1) [689], terazosin (pKi
9.1) [1263], alfuzosin (pKi 8.4) [750], dapiprazole
(pKi 8.4) [68], phentolamine (Inverse agonist) (pKi
8.2) [1722], RS-100329 (pKi 7.9) [2029], labetalol
(pKi 6.6) [68]
Selective antagonists tamsulosin (pKi 10–10.7) [289, 389, 532, 1722, 2029],
silodosin (pKi 10.4) [1722], S(+)-niguldipine (pKi 9.1–10)
[532, 1722], RS-100329 (pKi 9.6) [2029], SNAP5089 (pKi
8.8–9.4) [750, 1081, 2014], -Da1a (pKi 9.2–9.3) [1236,
1548], RS-17053 (pKi 9.2–9.3) [289, 389, 529, 532]
Rec 15/2615 (pKi 9.5) [1867], L-765314 (pKi 7.7) [1470],
AH 11110 (pKi 7.5) [1652]
BMY-7378 (pKi 8.7–9.1) [268, 2102]
Adrenoceptors, α2
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α2-Adrenoceptors (nomenclature as agreed by NC-IUPHAR
Subcommittee on Adrenoceptors; [248]) are activated by
endogenous agonists with a relative potency of (-)-adrenaline >
(-)-noradrenaline. Brimonidine and talipexole are agonists selective
for α2-adrenoceptors relative to α1-adrenoceptors, rauwolscine and
yohimbine are antagonists selective for α2-adrenoceptors relative
to α1-adrenoceptors. [
3H]rauwolscine (1 nM), [3H]brimonidine (5
nM) and [3H]RX821002 (0.5 nM and 0.1 nM at α2C) are relatively
selective radioligands. There is species variation in the pharmacol-
ogy of the α2A-adrenoceptor; for example, yohimbine, rauwolscine
and oxymetazoline have an 20-fold higher affinity for the human
α2A-adrenoceptor compared to the rat, mouse and bovine recep-
tor. These α2A orthologues are sometimes referred to as α2D-
adrenoceptors. Multiple mutations of α2-adrenoceptors have been
described, some of which are associated with alterations in function.
Presynaptic α2-adrenoceptors are widespread in the nervous system
and regulate many functions, hence the multiplicity of actions. The
effects of classical (not subtype selective) α2-adrenoceptor agonists
such as clonidine, guanabenz and brimonidine on central barore-
flex control (hypotension and bradycardia), as well as their ability
to induce hypnotic effects and analgesia, and their ability to modu-
late seizure activity and platelet aggregation are mediated by α2A-
adrenoceptors. Clonidine has been used as an anti-hypertensive and
also to counteract opioid withdrawal. Actions on imidazoline recog-
nition sites may contribute to the pharmacological effects of cloni-
dine. α2-Adrenoceptor agonists such as dexmedetomidine have
been widely used as sedatives and analgesics in veterinary medicine
(also xylazine) and are now used frequently in humans. Dexmedeto-
midine also has analgesic, sympatholytic and anxiolytic properties
but is notable for the production of sedation without respiratory de-
pression. α2-Adrenoceptor antagonists are relatively little used ther-
apeutically although yohimbine has been used to treat erectile dys-
function and several anti-depressants (e.g. Mirtazapine) that block
α2-adrenoceptors may work through this mechanism. The roles of
α2B and α2C-adrenoceptors are less clear but the α2B subtype ap-
pears to be involved in neurotransmission in the spinal cord and α2C
in regulating catecholamine release from adrenal chromaffin cells.
Nomenclature α2A-adrenoceptor α2B-adrenoceptor α2C-adrenoceptor
HGNC, UniProt ADRA2A, P08913 ADRA2B, P18089 ADRA2C, P18825
Endogenous agonists (-)-adrenaline (pKi 5.6–8.3) [854, 1503] (-)-noradrenaline (Partial agonist) (pKi 5.6–9.1) [854, 1484,
1503]
(-)-noradrenaline (pKi 5.9–8.7) [854, 1484, 1503]
Agonists dexmedetomidine (Partial agonist) (pKi 7.6–9.6) [854,
1163, 1484, 1503], clonidine (Partial agonist) (pKi 7.2–9.2)
[854, 1484, 1503], brimonidine (pKi 6.7–8.7) [854, 1163,
1484, 1503], apraclonidine (pKi 8.5) [1343], guanabenz
(pIC50 7.4) [68], guanfacine (Partial agonist) (pKi 7.1–7.3)
[854, 1165]
dexmedetomidine (pKi 7.5–9.7) [854, 1163, 1484, 1503],
clonidine (Partial agonist) (pKi 6.7–9.5) [854, 1484, 1503],
brimonidine (Partial agonist) (pKi 6–8.3) [854, 1484, 1503],
guanabenz (pIC50 6.8) [68], guanfacine (pKi 5.8–6.5) [854]
dexmedetomidine (pKi 7–9.3) [854, 1484, 1503],
brimonidine (Partial agonist) (pKi 5.7–7.6) [854,
1163, 1484, 1503], apraclonidine (pKi 7.5) [1343],
guanfacine (Partial agonist) (pKi 5.4–6.2) [854],
guanabenz (pIC50 6) [68]
Selective agonists oxymetazoline (Partial agonist) (pKi 8–8.6) [854, 1163,
1922]
– –
Antagonists yohimbine (pKi 8.5–9.5) [247, 416, 1922], WB 4101 (pKi
8.4–9.4) [247, 416, 1922], spiroxatrine (pKi 9) [1922],
mirtazapine (pKi 7.7) [513], tolazoline (pKi 5.4) [854]
yohimbine (pKi 8.4–9.2) [247, 416, 1922] yohimbine (pKi 7.9–8.9) [247, 416, 1922],
phenoxybenzamine (pKi 8.5) [2002], tolazoline
(pKi 5.5) [854]
Selective antagonists BRL 44408 (pKi 8.2–8.8) [1922, 2104] imiloxan (pKi 7.3) [1269] – Rat JP1302 (pKB 7.8) [1631]
Labelled ligands – – [3H]MK-912 (Antagonist) (pKd 10.1) [1922]
Adrenoceptors, β
β-Adrenoceptors (nomenclature as agreed by the
NC-IUPHAR Subcommittee on Adrenoceptors, [248])
are activated by the endogenous agonists (-)-adrenaline and
(-)-noradrenaline. Isoprenaline is a synthetic agonist selective for
β-adrenoceptors relative to α1- and α2-adrenoceptors, while for β1
and β2 adrenoceptors, propranolol (pKi 8.2-9.2) and cyanopindolol
(pKi 10.0-11.0) are relatively selective antagonists. (-)-noradrenaline,
xamoterol and (-)-Ro 363 are agonists that show selectivity for β1-
relative to β2-adrenoceptors. Pharmacological differences exist
between human and mouse β3-adrenoceptors, and the ’rodent
selective’ agonists BRL 37344 and CL316243 have low efficacy at
the human β3-adrenoceptor whereas CGP 12177 and L 755507
activate human β3-adrenoceptors [1649]. β3-Adrenoceptors are
relatively resistant to blockade by propranolol (pKi 5.8-7.0), but can
be blocked by high concentrations of bupranolol (pKi 8.65 [1650]).
SR59230A has reasonably high affinity at β3-adrenoceptors [1197],
but does not discriminate well between the three β-adrenoceptor
subtypes [262] and has been reported to have lower affinity for the
β3-adrenoceptor in some circumstances [913]. L-748337 is themost
selective antagonist for β3 adrenoceptors. [
125I]-cyanopindolol,
[125I]-hydroxybenzylpindolol and [3H]-alprenolol are high affinity
radioligands widely used to label β1- and β2-adrenoceptors and
β3-adrenoceptors can be labelled with higher concentrations (nM)
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of [125I]-cyanopindolol in the presence of appropriate concentra-
tions of β1- and β2-adrenoceptor antagonists. [
3H]L-748337 is a
β3-selective radioligand. Fluorescent ligands such as BODIPY-TMR-
CGP12177 are also increasingly being used to track β-adrenoceptors
at the cellular level [86]. Somewhat selective β1-adrenoceptor se-
lective agonists (denopamine, dobutamine) are used short-term to
treat cardiogenic shock but, in the longer term, reduce survival.
β1-Adrenoceptor-preferring antagonists are used to treat hyper-
tension (atenolol, betaxolol, bisoprolol, metoprolol and nebivolol),
cardiac arrhythmias (atenolol, bisoprolol, esmolol) and cardiac fail-
ure (metoprolol, nebivolol). Cardiac failure is also succesfully treated
with carvedilol which blocks both β1- and β2-adrenoceptors, as
well as α1-adrenoceptors. β2-Adrenoceptor-selective agonists are
powerful bronchodilators widely used to treat respiratory disor-
ders. There are both short (salbutamol, terbutaline) and long acting
drugs (formoterol, salmeterol). Although many first generation
β-adrenoceptor antagonists (propranolol) block both β1- and β2-
adrenoceptors there are no β2-adrenoceptor-selective antagonists
used therapeutically. The β3-adrenoceptor agonist mirabegron is
used to control overactive bladder syndrome.
Nomenclature β1-adrenoceptor β2-adrenoceptor β3-adrenoceptor
HGNC, UniProt ADRB1, P08588 ADRB2, P07550 ADRB3, P13945
Rank order of potency (-)-noradrenaline > (-)-adrenaline (-)-adrenaline > (-)-noradrenaline (-)-noradrenaline = (-)-adrenaline
Endogenous agonists noradrenaline (pKi 6) [549] – –
Agonists pindolol (Partial agonist) (pKi 9.3) [1011], isoprenaline
(pKi 6.6–7) [549, 1651], dobutamine (Partial agonist) (pKi
5.5) [831]
pindolol (Partial agonist) (pKi 9.4) [1011], arformoterol
(pKi 8.6) [37], isoprenaline (pKi 6.4) [1651], dobutamine
(Partial agonist) (pKi 6.2) [1100], ephedrine (Partial
agonist) (pKi 5.6) [851]
carazolol (pKi 8.7) [1256]
Selective agonists (-)-Ro 363 (pKi 8) [1301], xamoterol (Partial agonist) (pKi
7) [831], denopamine (Partial agonist) (pKi 5.8) [831,
1830]
formoterol (pEC50 10.1) [81], salmeterol (pEC50 9.9) [81],
zinterol (pEC50 9.5) [81], vilanterol (pEC50 9.4) [1534],
procaterol (pEC50 8.4) [81], indacaterol (pKi 7.8) [107],
fenoterol (pKi 6.9) [55], salbutamol (Partial agonist) (pKi
5.8–6.1) [83, 831], terbutaline (Partial agonist) (pKi 5.6)
[83], orciprenaline (pKd 5.3) [1784]
L 755507 (pEC50 10.1) [81], L742791 (pEC50 8.8)
[2000], mirabegron (pEC50 7.7) [1849], CGP 12177
(Partial agonist) (pKi 6.1–7.3) [159, 1144, 1256,
1301], SB251023 (pEC50 7.1) [810] – Mouse,
BRL 37344 (pKi 6.4–7) [159, 431, 768, 1256],
CL316243 (pKi 5.2) [2080]
Antagonists carvedilol (pKi 9.5) [262], bupranolol (pKi 7.3–9) [262,
1144], levobunolol (pKi 8.4) [68], labetalol (pKi 8.2) [68],
metoprolol (pKi 7–7.6) [83, 262, 768, 1144], esmolol (pKi
6.9) [68], nadolol (pKi 6.9) [262], practolol (pKi 6.1–6.8)
[83, 1144], propafenone (pKi 6.7) [68], sotalol (pKi 6.1)
[68]
carvedilol (pKi 9.4–9.9) [83, 262], timolol (pKi 9.7) [83],
propranolol (pKi 9.1–9.5) [83, 86, 831, 1144], levobunolol
(pKi 9.3) [68], bupranolol (pKi 8.3–9.1) [262, 1144],
alprenolol (pKi 9) [83], nadolol (pKi 7–8.6) [83, 262],
labetalol (pKi 8) [68], propafenone (pKi 7.4) [68], sotalol
(pKi 6.5) [68]
carvedilol (pKi 9.4) [262], bupranolol (pKi 6.8–7.3)
[159, 262, 1144, 1256], propranolol (pKi 6.3–7.2)
[1144, 1517], levobunolol (pKi 6.8) [1517]
Selective antagonists CGP 20712A (pKi 8.5–9.2) [83, 262, 1144], levobetaxolol
(pKi 9.1) [1715], betaxolol (pKi 8.8) [1144], nebivolol
(pIC50 8.1–8.7) [1476] – Rabbit, atenolol (pKi 6.7–7.6)
[83, 886, 1144], acebutolol (pKi 6.4) [68]
ICI 118551 (Inverse agonist) (pKi 9.2–9.5) [83, 86, 1144] L-748337 (pKi 8.4) [262], SR59230A (pKi 6.9–8.4)
[262, 405, 768], L748328 (pKi 8.4) [262]
Labelled ligands [125I]ICYP (Selective Antagonist) (pKd 10.4–11.3) [831,
1144, 1651]
[125I]ICYP (Antagonist) (pKd 11.1) [1144, 1651] [
125I]ICYP (Agonist, Partial agonist) (pKd 9.2–9.8)
[1144, 1301, 1517, 1651, 1806]
Comments The agonists indicated have less than two orders of
magnitude selectivity [81].
– Agonist SB251023 has a pEC50 of 6.9 for the splice
variant of the mouse β3 receptor, β3b [810].
Comments:
Adrenoceptors, α1
The clone originally called the α1C-adrenoceptor corresponds to
the pharmacologically defined α1A-adrenoceptor [752]. Some tis-
sues possess α1A-adrenoceptors (termed α1L-adrenoceptors [532,
1329]) that display relatively low affinity in functional and bind-
ing assays for prazosin (pKi < 9) indicative of different receptor
states or locations. α1A-adrenoceptor C-terminal splice variants form
homo- and heterodimers, but fail to generate a functional α1L-
adrenoceptor [1557]. α1D-Adrenoceptors form heterodimers with
α1B- or β2-adrenoceptors that show increased cell-surface expres-
sion [1917]. Recombinant α1D-adrenoceptors have been shown in
some heterologous systems to be mainly located intracellularly but
cell-surface localization is attained by truncation of the N-terminus,
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or by co-expression of α1B- or β2-adrenoceptors to form het-
erodimers [670, 1917]. In smooth muscle of native blood vessels
all three α1-adrenoceptor subtypes are located on the surface and
intracellularly [1260, 1261].
Signalling is predominantly via Gq/11 but α1-adrenoceptors also
couple to Gi/o, Gs and G12/13. Several ligands activating α1A-
adrenoceptors display ligand directed signalling bias relative to nora-
drenaline. For example, oxymetazoline is a full agonist for extracellu-
lar acidification rate (ECAR) and a partial agonist for Ca2+ release but
does not stimulate cAMP production. Phenylephrine is biased toward
ECAR versus Ca2+ release or cAMP accumulation but not between
Ca2+ release and cAMP accumulation [495]. There are also differ-
ences between subtypes in coupling efficiency to different pathways-
e.g. in some systems coupling efficiency to Ca2+ signalling is α1A >
α1B > α1D, but for MAP kinase signalling is α1D > α1A > α1B. In
vascular smoothmuscle, the potency of agonists is related to the pre-
dominant subtype, α1D- conveying greater agonist sensitivity than
α1A-adrenoceptors [526].
Adrenoceptors, α2
ARC-239 (pKi 8.0) and prazosin (pKi 7.5) show selectivity for α2B-
and α2C-adrenoceptors over α2A-adrenoceptors.Oxymetazoline is
a reduced efficacy agonist and is one of many α2-adrenoceptor ag-
onists that are imidazolines or closely related compounds. Other
binding sites for imidazolines, distinct from α2-adrenoceptors,
and structurally distinct from the 7TM adrenoceptors, have
been identified and classified as I1, I2 and I3 sites [390]; cat-
echolamines have a low affinity, while rilmenidine and mox-
onidine are selective ligands for these sites, evoking hypoten-
sive effects in vivo. I1-imidazoline receptors are involved in
central inhibition of sympathetic tone, I2-imidazoline recep-
tors are an allosteric binding site on monoamine oxidase B,
and I3-imidazoline receptors regulate insulin secretion from pan-
creatic β-cells. α2A-adrenoceptor stimulation reduces insulin
secretion from β-islets [2083], with a polymorphism in the 5’-UTR
of the ADRA2A gene being associated with increased receptor ex-
pression in β-islets and heightened susceptibility to diabetes [1599].
α2A- and α2C-adrenoceptors form homodimers [1758]. Het-
erodimers between α2A- and either the α2c-adrenoceptor or  opi-
oid peptide receptor exhibit altered signalling and trafficking prop-
erties compared to the individual receptors [1758, 1858, 1956]. Sig-
nalling by α2-adrenoceptors is primarily via Gi/o, however the α2A-
adrenoceptor also couples to Gs [459]. Imidazoline compounds dis-
play bias relative to each other at the α2A-adrenoceptor when as-
sayed by [35S] GTPγS binding compared to inhibition of cAMP accu-
mulation [1477]. The noradrenaline reuptake inhibitor desipramine
acts directly on the α2A-adrenoceptor, promoting internalisation via
recruitment of arrestin without activating G proteins [371].
Adrenoceptors, β
Radioligand binding with [125I]ICYP can be used to define β1-
or β2-adrenoceptors when conducted in the presence of a ’satu-
rating’ concentration of either a β1- or β2-adrenoceptor-selective
antagonist. [3H]CGP12177 or [3H]dihydroalprenolol can be used
in place of [125I]ICYP. Binding of a fluorescent analogue of
CGP 12177 to β2-adrenoceptors in living cells has been described
[84]. [125I]ICYP at higher (nM) concentrations can be used to la-
bel β3-adrenoceptors in systems where there are few if any other β-
adrenoceptor subtypes. Pharmacological differences exist between
human and mouse β3-adrenoceptors, and the ’rodent selective’
agonists BRL 37344 and CL316243 are partial agonists at the hu-
man β3-adrenoceptor whereas CGP 12177 and L 755507 activate
human β3-adrenoceptors with greater potency [1650]. The β3-
adrenoceptor has an intron in the coding region, but splice vari-
ants have only been described for the mouse [496], where the iso-
forms display different signalling characteristics [810]. There are
3 β-adrenoceptors in turkey (termed the tβ, tβ3c and tβ4c) that
have a pharmacology that differs from the human β-adrenoceptors
[82]. Numerous polymorphisms have been described for the three
β-adrenoceptors; some are associated with alterations in agonist-
evoked signalling and trafficking, altered susceptibility to disease
and/or altered responses to pharmacotherapy [1103].
All β-adrenoceptors couple to Gs (activating adenylyl cyclase and
elevating cAMP levels), but it is also clear that they activate other
G proteins such as Gi and many other G protein-independent sig-
nalling pathways, including arrestin-mediated signalling, which may
in turn lead to activation of MAP kinases. Many antagonists at β1-
and β2-adrenoceptors are agonists at β3-adrenoceptors (CL316243,
CGP 12177 and carazolol). Many ‘antagonists’ that block agonist-
stimulated cAMP accumulation, for example carvedilol and bucin-
dolol, are able to activate MAP kinase pathways [85, 497, 559, 560,
1649, 1650] and thus display ’protean agonism’. Bupranolol appears
to act as a neutral antagonist in most systems so far examined. Ago-
nists also display biased signalling at the β2-adrenoceptor via Gs or
arrestins [443].
The X-ray crystal structures have been described of the agonist
bound [1988] and antagonist bound forms of the β1- [1989],
agonist-bound [313] and antagonist-bound forms of the β2-
adrenoceptor [1561, 1598], as well as a fully active agonist-bound,
Gs protein-coupled β2-adrenoceptor [1562]. Carvedilol and bucin-
dolol bind to an extended site of the β1-adrenoceptor involving con-
tacts in TM2, 3, and 7 and extracellular loop 2 that may facilitate
coupling to arrestins [1989]. Compounds displaying arrestin-biased
signalling at the β2-adrenoceptor also have a greater effect on the
conformation of TM7, whereas full agonists for Gs coupling promote
movement of TM5 and TM6 [1127]. Recent studies using NMR spec-
troscopy have demonstrated significant conformational flexibility in
the β2-adrenoceptor which is stabilized by both agonist and G pro-
teins highlighting the dynamic nature of interactions with both lig-
and and downstream signalling partners [946, 1199, 1413]. Such
flexibility will likely have consequences for our understanding of bi-
ased agonism, and for the future therapeutic exploitation of this
phenomenon.
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Angiotensin receptors
G protein-coupled receptors! Angiotensin receptors
Overview: The actions of angiotensin II (AGT, P01019) (Ang II) are mediated by AT1 and AT2 receptors (nomenclature as agreed by the NC-IUPHAR Subcommittee on Angiotensin Receptors
[2137]), which have around 30% sequence similarity. Endogenous ligands are angiotensin II (AGT, P01019) and angiotensin III (AGT, P01019) (Ang III), while angiotensin I (AGT, P01019) is weakly active in some
systems.
Nomenclature AT1 receptor AT2 receptor
HGNC, UniProt AGTR1, P30556 AGTR2, P50052
Selective agonists L-162,313 (pIC50 7.8–7.9) [1490] CGP42112 (pIC50 9.6) [190], [p-aminoPhe6]ang II (pKd 9.1–9.4) [1789, 2139]
– Rat
Antagonists telmisartan (pIC50 8.4) [1241], olmesartan (pIC50 8.1) [981] –
Selective antagonists candesartan (pIC50 9.5–9.7) [1942], EXP3174 (pIC50 7.4–9.5) [1887, 1942],
eprosartan (pIC50 8.4–8.8) [464], irbesartan (pIC50 8.7–8.8) [1942], losartan
(pIC50 7.4–8.7) [1887, 2139], valsartan (pIC50 8.6) [2138], azilsartan (pIC50
8.1–8.1) [1551, 1844]
PD123177 (pIC50 8.5–9.5) [291, 321, 450] – Rat, EMA401 (pIC50 8.5–9.3) [518,
1582, 1767], PD123319 (pKd 8.7–9.2) [449, 2025, 2139]
Labelled ligands [3H]A81988 (Antagonist) (pKd 9.2) [690] – Rat, [
3H]L158809 (Antagonist)
(pKd 9.2) [305] – Rat, [
3H]eprosartan (Antagonist) (pKd 9.1) [21] – Rat,
[3H]valsartan (Antagonist) (pIC50 8.8–9) [1954], [125I]EXP985 (Antagonist)
(pKd 8.8) [322] – Rat, [
3H]losartan (Antagonist) (pKd 8.2) [294] – Rat
[125I]CGP42112 (Agonist) (pKd 10.6) [2017, 2018, 2139]
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Comments: AT1 receptors are predominantly coupled to Gq/11,
however they are also linked to arrestin recruitment and stimulate G
protein-independent arrestin signalling [1156]. Most species express
a single AGTR1 gene, but two related agtr1a and agtr1b receptor
genes are expressed in rodents. The AT2 receptor counteracts sev-
eral of the growth responses initiated by the AT1 receptors. The AT2
receptor is much less abundant than the AT1 receptor in adult tissues
and is upregulated in pathological conditions. AT1 receptor antago-
nists bearing substituted 4-phenylquinoline moieties have been syn-
thesized, which bind to AT1 receptors with nanomolar affinity and
are slightly more potent than losartan in functional studies [264].
The antagonist activity of CGP42112 at the AT2 receptor has also
been reported [2147].
The AT1 and bradykinin B2 receptors have been proposed to form a
heterodimeric complex [3].
There is also evidence for an AT4 receptor that specifically binds
angiotensin IV (AGT, P01019) and is located in the brain and kidney.
An additional putative endogenous ligand for the AT4 receptor has
been described (LVV-hemorphin (HBB, P68871), a globin decapep-
tide) [1296].
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Apelin receptor
G protein-coupled receptors! Apelin receptor
Overview: The apelin receptor (nomenclature as agreed by the NC-IUPHAR Subcommittee on the apelin receptor [1510]) responds to apelin, a 36 amino-acid peptide derived initially from
bovine stomach. Apelin-36 (APLN, Q9ULZ1), apelin-13 (APLN, Q9ULZ1) and [Pyr1]apelin-13 (APLN, Q9ULZ1) are the predominant endogenous ligands which are cleaved from a 77 amino-acid precursor peptide
(APLN, Q9ULZ1) by a so far unidentified enzymatic pathway [1864]. A second family of peptides discovered independently and named Elabela [323] or Toddler, that has little sequence similarity to apelin, has been
proposed as a second endogenous apelin receptor ligand [1475].
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Nomenclature apelin receptor
HGNC, UniProt APLNR, P35414
Rank order of
potency
[Pyr1]apelin-13 (APLN, Q9ULZ1)  apelin-13 (APLN, Q9ULZ1) > apelin-36 (APLN, Q9ULZ1) [503, 1864]
Endogenous agonists apelin-13 (APLN, Q9ULZ1) (Selective) (pIC50 8.8–9.5) [503, 785, 1254], apelin receptor early endogenous ligand (APELA, P0DMC3) (Selective) (pKd 9.3) [412], apelin-17
(APLN, Q9ULZ1) (Selective) (pIC50 7.9–9) [468, 1254], [Pyr1]apelin-13 (APLN, Q9ULZ1) (Selective) (pIC50 7–8.8) [918, 1254], Elabela/Toddler-21 (APELA, P0DMC3) (pIC50
8.7) [2086], Elabela/Toddler-32 (APELA, P0DMC3) (pIC50 8.7) [2086], apelin-36 (APLN, Q9ULZ1) (Selective) (pIC50 8.2–8.6) [503, 785, 918, 1254], Elabela/Toddler-11 (APELA,
P0DMC3) (pIC50 7.2) [2086]
Selective agonists MM07 (Biased agonist) (pEC50 9.5) [203]
Antagonists MM54 (pKi 8.2) [1166]
Labelled ligands [125I][Nle75,Tyr77]apelin-36 (human) (Agonist) (pKd 11.2) [918], [
125I][Glp65Nle75,Tyr77]apelin-13 (Agonist) (pKd 10.7) [785], [
125I](Pyr1)apelin-13 (Agonist) (pKd 9.5)
[911], [125I]apelin-13 (Agonist) (pKd 9.2) [503], [
3H](Pyr1)[Met(0)11]-apelin-13 (Agonist) (pKd 8.6) [1254]
Comments: Potency order determined for heterologously expressed human apelin receptor (pD2 values range from 9.5 to 8.6). The apelin receptor may also act as a co-receptor with CD4 for isolates of human
immunodeficiency virus, with apelin blocking this function [279]. A modified apelin-13 peptide, apelin-13(F13A) was reported to block the hypotensive response to apelin in rat in vivo [1067], however, this peptide
exhibits agonist activity in HEK293 cells stably expressing the recombinant apelin receptor [503].
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Bile acid receptor
G protein-coupled receptors! Bile acid receptor
Overview: The bile acid receptor (GPBA) responds to bile acids produced during the liver metabolism of cholesterol. Selective agonists are promising drugs for the treatment of metabolic disorders, such as type
II diabetes, obesity and atherosclerosis.
Nomenclature GPBA receptor
HGNC, UniProt GPBAR1, Q8TDU6
Rank order of
potency
lithocholic acid > deoxycholic acid > chenodeoxycholic acid, cholic acid (Unknown) [917, 1214]
Selective agonists betulinic acid (pEC50 6) [590], oleanolic acid (pEC50 5.7) [1648]
Comments: The triterpenoid natural product betulinic acid has also been reported to inhibit inflammatory signalling through the NFB pathway [1842]. Disruption of GPBA expression is reported to protect from
cholesterol gallstone formation [1951]. A new series of 5-phenoxy-1,3-dimethyl-1H-pyrazole-4-carboxamides have been reported as highly potent agonists [1138].
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Bombesin receptors
G protein-coupled receptors! Bombesin receptors
Overview: Bombesin receptors (nomenclature recom-
mended by the NC-IUPHAR Subcommittee on bombesin
receptors, [857]) are activated by the endogenous ligands
gastrin-releasing peptide (GRP, P07492) (GRP), neuromedin B (NMB,
P08949) (NMB) and GRP-(18-27) (GRP, P07492) (previously named
neuromedin C). Bombesin is a tetradecapeptide, originally derived
from amphibians, and is an agonist at BB1 and BB2 receptors. These
receptors couple primarily to the Gq/11 family of G proteins (but
see also [857]). Each of these receptors is widely distributed in the
CNS and peripheral tissues [625, 857, 1556, 1642]. Activation of
BB1 and BB2 receptors causes a wide range of physiological actions,
including the stimulation of normal and neoplastic tissue growth,
smooth-muscle contraction, appetite and feeding behavior, secre-
tion and many central nervous system effects [857, 858, 859, 1185,
1317, 1556]. A physiological role for the BB3 receptor has yet to
be fully defined although recently studies using receptor knockout
mice and newly described agonists/antagonists suggest an impor-
tant role in glucose and insulin regulation, metabolic homeostasis,
feeding and other CNS behaviors and growth of normal/neoplastic
tissues [625, 1186, 1430].
Nomenclature BB1 receptor BB2 receptor BB3 receptor
HGNC, UniProt NMBR, P28336 GRPR, P30550 BRS3, P32247
Endogenous agonists neuromedin B (NMB, P08949) (Selective) (pKi
8.1–10.3) [857, 1556, 1919]
neuromedin C (pIC50 9.9) [1919],
gastrin releasing peptide(14-27) (human) (Selective)
(pIC50 9.7–9.8) [1919]
–
Selective agonists – – compound 8a [PMID: 24900283] (pIC50 8.9) [1129],
compound 9g [PMID: 24412111] (pEC50 8.8) [1220],
MK-7725 (pIC50 8.5) [324], MK-5046 (pKi 7.7–8.4)
[1321, 1689],
[D-Tyr6,Apa-4Cl11,Phe13,Nle14]bombesin-(6-14)
(pKi 8.1) [1202], compound 17c [PMID: 25497965]
(pEC50 7.9) [1219], compound 9f [PMID: 24412111]
(pEC50 7.8) [1220], bag-1 (pIC50 7.7) [659],
compound 22e [PMID: 20167483] (pIC50 7.6) [727],
bag-2 (pIC50 7) [659]
Antagonists D-Nal-Cys-Tyr-D-Trp-Lys-Val-Cys-Nal-NH2 (pIC50
6.2–6.6) [624]
– –
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(continued)
Nomenclature BB1 receptor BB2 receptor BB3 receptor
Selective antagonists PD 176252 (pIC50 9.3–9.8) [624],
PD 168368 (pIC50 9.3–9.6) [624],
dNal-cyc(Cys-Tyr-dTrp-Orn-Val)-Nal-NH2
[D-Phe6, Leu13, Cpa14, 13-14]bombesin-(6-14) (pKi 9.8) [624],
JMV641 (pIC50 9.3) [1892] – Mouse,
[(3-Ph-Pr6), His7,D-Ala11,D-Pro13, 13-14),Phe14] bombesin-(6-14)
(pIC50 9.2) [624, 1062],
[D-Tpi6, Leu13  (CH2NH)-Leu
14]bombesin-(6-14) (pIC50 8.9)
[624], Ac-GRP-(20-26)-methylester (pIC50 8.7) [624], JMV594
(pIC50 8.7–8.7) [1133, 1892] – Mouse
bantag-1 (pIC50 8.6–8.7) [659, 1321], ML-18 (pIC50
5.3) [1316]
Labelled ligands [125I]BH-NMB (human, mouse, rat)
(Agonist), [125I][Tyr4]bombesin (Agonist)
[125I][D-Tyr6]bombesin-(6-13)-methyl ester (Selective Antagonist)
(pKd 9.3) [1201] – Mouse, [
125I][Tyr4]bombesin (Agonist) (pKd
8.2) [131], [125I]GRP (human) (Agonist)
[3H]bag-2 (Agonist) (pKd 8.6) [659] – Mouse,
[125I][D-Tyr6,β-Ala11,Phe13,Nle14]bombesin-(6-14)
(Agonist) (pKd 8–8.4) [1203, 1321]
Comments: All three subtypes may be activated by [D-Phe6,β-Ala11,Phe13,Nle14]bombesin-(6-14) [1203]. [D-Tyr6,Apa-4Cl11,Phe13,Nle14]bombesin-(6-14) has more than 200-fold selectivity for BB3 receptors
over BB1 and BB2 [1202].
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Bradykinin receptors
G protein-coupled receptors! Bradykinin receptors
Overview: Bradykinin (or kinin) receptors (nomenclature as agreed by the NC-IUPHAR subcommittee on Bradykinin (kinin) Receptors [1072]) are activated by the endogenous peptides
bradykinin (KNG1, P01042) (BK), [des-Arg9]bradykinin (KNG1, P01042), Lys-BK (kallidin (KNG1, P01042)), [des-Arg10]kallidin (KNG1, P01042), T-kinin (KNG1, P01042) (Ile-Ser-BK), [Hyp3]bradykinin (KNG1,
P01042) and Lys-[Hyp3]-bradykinin (KNG1, P01042). The variation in affinity or inactivity of B2 receptor antagonists could reflect the existence of species homologues of B2 receptors.
Nomenclature B1 receptor B2 receptor
HGNC, UniProt BDKRB1, P46663 BDKRB2, P30411
Rank order of potency [des-Arg10]kallidin (KNG1, P01042) > [des-Arg9]bradykinin (KNG1, P01042) =
kallidin (KNG1, P01042) > bradykinin (KNG1, P01042)
kallidin (KNG1, P01042) > bradykinin (KNG1, P01042) [des-Arg9]bradykinin
(KNG1, P01042), [des-Arg10]kallidin (KNG1, P01042)
Endogenous agonists [des-Arg10]kallidin (KNG1, P01042) (Selective) (pKi 9.6–10) [69, 104, 876] –
Selective agonists [Sar,D-Phe8,des-Arg9]bradykinin (pKi 5.7) [876] [Hyp
3,Tyr(Me)8]BK, [Phe8, (CH2-NH)Arg
9]BK
Antagonists [Leu9,des-Arg10]kallidin (pKi 9.1–9.3) [69, 104] –
Selective antagonists B-9958 (pKi 9.2–10.3) [596, 1570], R-914 (pA2 8.6) [617], R-715 (pA2 8.5) [618] icatibant (pKi 10.2) [39], FR173657 (pA2 8.2) [1593], anatibant (pKi 8.2) [1537]
Labelled ligands [125I]Hpp-desArg10HOE140 (pKd 10), [
3H]Lys-[des-Arg9]BK (Agonist) (pKd 9.4),
[3H]Lys-[Leu8][des-Arg9]BK (Antagonist)
[3H]BK (human, mouse, rat) (Agonist) (pKd 9.4) [2034] – Mouse, [
3H]NPC17731
(Antagonist) (pKd 9.1–9.4) [2119, 2120], [
125I][Tyr8]bradykinin (Agonist)
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Calcitonin receptors
G protein-coupled receptors! Calcitonin receptors
Overview: This receptor family comprises a group of receptors for
the calcitonin/CGRP family of peptides. The calcitonin (CT), amylin
(AMY), calcitonin gene-related peptide (CGRP) and adrenomedullin
(AM) receptors (nomenclature as agreed by the NC-IUPHAR
Subcommittee on CGRP, AM, AMY, and CT receptors
[721, 1528]) are generated by the genes CALCR (which codes for
the CT receptor (CTR)) and CALCRL (which codes for the calcitonin
receptor-like receptor, CLR, previously known as CRLR). Their func-
tion and pharmacology are altered in the presence of RAMPs (recep-
tor activity-modifying proteins), which are single TM domain pro-
teins of ca. 130 amino acids, identified as a family of three mem-
bers; RAMP1, RAMP2 and RAMP3. There are splice variants of CTR;
these in turn produce variants of the AMY receptor [1528], some
of which can be potently activated by CGRP. The endogenous ago-
nists are the peptides calcitonin (CALCA, P01258), α-CGRP (CALCA,
P06881) (formerly known as CGRP-I), β-CGRP (CALCB, P10092)
(formerly known as CGRP-II), amylin (IAPP, P10997) (occasionally
called islet-amyloid polypeptide, diabetes-associated polypeptide),
adrenomedullin (ADM, P35318) and adrenomedullin 2/intermedin
(ADM2, Q7Z4H4). There are species differences in peptide se-
quences, particularly for the CTs. CTR-stimulating peptide {Pig}
(CRSP) is another member of the family with selectivity for the CTR
but it is not expressed in humans [907]. Olcegepant (also known
as BIBN4096BS, pKi 10.5) and telcagepant (also known as MK0974,
pKi 9) are the most selective antagonists available, having a high se-
lectivity for CGRP receptors, with a particular preference for those of
primate origin.
CLR by itself binds no known endogenous ligand, but in the pres-
ence of RAMPs it gives receptors for CGRP, adrenomedullin and
adrenomedullin 2/intermedin.
Nomenclature CT receptor AMY1 receptor AMY2 receptor AMY3 receptor
HGNC, UniProt CALCR, P30988 – – –
Subunits – RAMP1 (Accessory protein),
CT receptor
CT receptor, RAMP2 (Accessory
protein)
CT receptor, RAMP3 (Accessory
protein)
Rank order of
potency
calcitonin (salmon)  calcitonin
(CALCA, P01258)  amylin (IAPP,
P10997), α-CGRP (CALCA, P06881) >
adrenomedullin (ADM, P35318),
adrenomedullin 2/intermedin (ADM2,
Q7Z4H4)
calcitonin (salmon)  amylin (IAPP,
P10997)  α-CGRP (CALCA, P06881)
> adrenomedullin 2/intermedin
(ADM2, Q7Z4H4)  calcitonin
(CALCA, P01258) > adrenomedullin
(ADM, P35318)
Poorly defined calcitonin (salmon)  amylin (IAPP,
P10997) > α-CGRP (CALCA, P06881)
 adrenomedullin 2/intermedin
(ADM2, Q7Z4H4)  calcitonin
(CALCA, P01258) > adrenomedullin
(ADM, P35318)
Endogenous
agonists
calcitonin (CALCA, P01258) (Selective)
(pEC50 9–11.2) [32, 58, 718, 1027,
1087, 1341]
amylin (IAPP, P10997) (pEC50 9–9.7)
[610]
amylin (IAPP, P10997) (pEC50
8.3–9.1) [610]
amylin (IAPP, P10997) (pEC50
8.9–9.6) [610]
Labelled ligands [125I]CT (human) (Agonist) (pKd
9–10), [125I]CT (salmon) (Agonist)
(pKd 10)
[125I]BH-AMY (rat, mouse) (Agonist)
(pKd 9–10)
[125I]BH-AMY (rat, mouse) (Agonist)
(pKd 9–10)
[125I]BH-AMY (rat, mouse) (Agonist)
(pKd 9–10)
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Nomenclature
calcitonin receptor-
like receptor CGRP receptor AM1 receptor AM2 receptor
HGNC, UniProt CALCRL, Q16602 – – –
Subunits – calcitonin receptor-like receptor, RAMP1
(Accessory protein)
calcitonin receptor-like receptor, RAMP2
(Accessory protein)
calcitonin receptor-like receptor, RAMP3
(Accessory protein)
Rank order of
potency
– α-CGRP (CALCA, P06881) >
adrenomedullin (ADM, P35318) 
adrenomedullin 2/intermedin (ADM2,
Q7Z4H4) > amylin (IAPP, P10997) 
calcitonin (salmon)
adrenomedullin (ADM, P35318) >
adrenomedullin 2/intermedin (ADM2,
Q7Z4H4) > α-CGRP (CALCA, P06881),
amylin (IAPP, P10997) >
calcitonin (salmon)
adrenomedullin (ADM, P35318) 
adrenomedullin 2/intermedin (ADM2,
Q7Z4H4)  α-CGRP (CALCA, P06881) >
amylin (IAPP, P10997) >
calcitonin (salmon)
Endogenous
agonists
– β-CGRP (CALCB, P10092) (pKi 9.9–11)
[20, 1251], α-CGRP (CALCA, P06881) (pKi
9.7–10) [20, 1251]
adrenomedullin (ADM, P35318) (pKi
8.3–9.2) [20, 1251]
adrenomedullin (ADM, P35318) (pKi
8.3–9) [20, 539]
Antagonists – olcegepant (pKi 10.2–10.7) [435, 719,
720, 1194], telcagepant (pKi 9.1) [1633]
– –
Selective
antagonists
– – AM-(22-52) (human) (pKi 7–7.8) [20,
720, 1251]
–
Labelled ligands – [125I]αCGRP (human) (Agonist) (pKd 10),
[125I]αCGRP (mouse, rat) (Agonist)
[125I]AM (rat) (Agonist) (pKd 10–9) [
125I]AM (rat) (Agonist) (pKd 9–10)
Comments: It is important to note that a complication with the in-
terpretation of pharmacological studies with AMY receptors in trans-
fected cells is that most of this work has likely used a mixed popula-
tion of receptors, encompassing RAMP-coupled CTR as well as CTR
alone. This means that although in binding assays human calcitonin
(CALCA, P01258) has low affinity for 125I-AMY binding sites, cells
transfected with CTR and RAMPs can display potent CT functional
responses. Transfection of human CTR with any RAMP can gener-
ate receptors with a high affinity for both salmon CT and AMY and
varying affinity for different antagonists [337, 718, 719]. The ma-
jor human CTR splice variant (hCT(a), which does not contain an
insert) with RAMP1 (i.e. the AMY1(a) receptor) has a high affinity
for CGRP, unlike hCT(a)-RAMP3 (i.e. AMY3(a) receptor) [337, 718].
However, the AMY receptor phenotype is RAMP-type, splice variant
and cell-line-dependent [1886]. In particular, CGRP is a more po-
tent agonist than amylin (IAPP, P10997) at increasing cAMP at the
delta 47 hCT(a) receptor, when transfected with RAMP1 (to give the
corresponding AMY1(a) receptor) in Cos 7 cells [1543].
The ligands described represent the best available but their selectivity
is limited. For example, adrenomedullin has appreciable affinity for
CGRP receptors. CGRP can show significant cross-reactivity at AMY
receptors and AM2 receptors. Adrenomedullin 2/intermedin also has
high affinity for the AM2 receptor [779]. CGRP-(8-37) acts as an an-
tagonist of CGRP (pKi 8) and inhibits some AM and AMY responses
(pKi 6-7). It is weak at CT receptors. Salmon CT-(8-32) is an antag-
onist at both AMY and CT receptors. AC187, a salmon CT analogue,
is also an antagonist at AMY and CT receptors. Human AM-(22-52)
has some selectivity towards AM receptors, but with modest potency
(pKi 7), limiting its use [720]. AM-(22-52) is slightly more effective
at AM1 than AM2 receptors but this difference is not sufficient for
this peptide to be a useful discriminator of the AM receptor subtypes.
Olcegepant shows the greatest selectivity between receptors but still
has significant affinity for AMY1 receptors [1973].
Ligand responsiveness at CT and AMY receptors can be affected by
receptor splice variation and can depend on the pathway beingmea-
sured. Particularly for AMY receptors, relative potency can vary with
the type and level of RAMP present and can be influenced by other
factors such as G proteins [1324, 1886].
Gs is a prominent route for effector coupling for CLR and CTR but
other pathways (e.g. Ca2+, ERK, Akt), and G proteins can be acti-
vated [1972]. There is evidence that CGRP-RCP (a 148 amino-acid
hydrophilic protein, ASL (P04424) is important for the coupling of
CLR to adenylyl cyclase [498].
[125I]-Salmon CT is the most common radioligand for CT receptors
but it has high affinity for AMY receptors and is also poorly reversible.
[125I]-Tyr0-CGRP is widely used as a radioligand for CGRP receptors.
Some early literature distinguished between CGRP1 and CGRP2 re-
ceptors. It is now clear that the complex of CALCRL and RAMP1 rep-
resents the CGRP1 subtype and is now known simply as the CGRP re-
ceptor [721]. The CGRP2 receptor is now considered to have arisen
from the actions of CGRP at AM2 and AMY receptors. This term
should not be used [721].
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Calcium-sensing receptors
G protein-coupled receptors! Calcium-sensing receptors
Overview: The calcium-sensing receptor (CaS, provisional nomenclature as recommended by NC-IUPHAR [530]) responds to extracellular calcium and magnesium in the millimolar range and to
gadolinium and some polycations in the micromolar range [229]. The sensitivity of CaS to primary agonists can be increased by aromatic L-amino acids [362] and also by elevated extracellular pH [1544] or decreased
extracellular ionic strength [1545]. This receptor bears no sequence or structural relation to the plant calcium receptor, also called CaS.
Nomenclature CaS receptor GPRC6 receptor
HGNC, UniProt CASR, P41180 GPRC6A, Q5T6X5
Amino-acid rank order of potency L-phenylalanine, L-tryptophan, L-histidine > L-alanine > L-serine, L-proline, L-glutamic acid > L-aspartic acid
(not L-lysine, L-arginine, L-leucine and L-isoleucine) [362]
–
Cation rank order of potency Gd3+ > Ca2+ > Mg2+ [229] –
Polyamine rank order of potency spermine > spermidine > putrescine [1546] –
Allosteric modulators AC265347 (Positive) (pEC50 7.6–8.1) [1160], NPS 2143 (Negative) (pIC50 7.1–7.4) [1377, 2087], cinacalcet
(Positive) (pEC50 7.3) [1378], calindol (Positive) (pEC50 6.5) [1499], calindol (Positive) (pKd 6–6.5) [930],
tecalcet (Positive) (pKd 6.5) [1379], calhex 231 (Negative) (pIC50 6.4) [1500]
–
Comments 2-benzylpyrrolidine derivatives of NPS 2143 are also negative allosteric modulators of the calcium sensing
receptor [2087]. etelcalcetide is a novel peptide agonist of the receptor [1975].
GPRC6 is a related Gq-coupled receptor
which responds to basic amino acids
[2004].
Comments: Positive allosteric modulators of CaS are termed
Type II calcimimetics and can suppress parathyroid hormone (PTH
(PTH, P01270)) secretion [1379]. Negative allosteric modulators are
called calcilytics and can act to increase PTH (PTH, P01270) secre-
tion [1377].
The central role of CaS in the maintenance of extracellular calcium
homeostasis is seen most clearly in patients with loss-of-function CaS
mutations who develop familial hypocalciuric hypercalcaemia (het-
erozygous mutation) or neonatal severe hyperparathyroidism (ho-
mozygous mutation) and in CaS null mice [293, 765], which exhibit
similar increases in PTH secretion and blood Ca2+ levels. A gain-
of-function mutation in the CaS gene is associated with autosomal
dominant hypocalcaemia.
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Cannabinoid receptors
G protein-coupled receptors! Cannabinoid receptors
Overview: Cannabinoid receptors (nomenclature as agreed by the NC-IUPHAR Subcommittee on Cannabinoid Receptors [1494]) are activated by endogenous ligands that include N-
arachidonoylethanolamine (anandamide), N-homo-γ-linolenoylethanolamine, N-docosatetra-7,10,13,16-enoylethanolamine and 2-arachidonoylglycerol. Potency determinations of endogenous agonists at these
receptors are complicated by the possibility of differential susceptibility of endogenous ligands to enzymatic conversion [35].
Nomenclature CB1 receptor CB2 receptor
HGNC, UniProt CNR1, P21554 CNR2, P34972
(Sub)family-
selective
agonists
HU-210 (pKi 9.1–10.2) [509, 1733], CP55940 (pKi 8.3–9.2) [509, 1602, 1733], WIN55212-2
(pKi 6.9–8.7) [509, 1730, 1733], 1
9-tetrahydrocannabinol (Partial agonist) (pKi 7.3–7.4)
[509, 1733]
HU-210 (pKi 9.3–9.8) [509, 1579, 1733], WIN55212-2 (pKi 8.4–9.6) [509, 1730,
1733], CP55940 (pKi 8.6–9.2) [509, 1602, 1733], 1
9-tetrahydrocannabinol
(Partial agonist) (pKi 7.1–7.5) [106, 509, 1579, 1733]
Selective agonists arachidonyl-2-chloroethylamide (pKi 8.9) [755] – Rat, arachidonylcyclopropylamide (pKi 8.7)
[755] – Rat, O-1812 (pKi 8.5) [420] – Rat, R-(+)-methanandamide (pKi 7.7) [931] – Rat
JWH-133 (pKi 8.5) [804, 1493], L-759,633 (pKi 7.7–8.2) [576, 1602], AM1241
(pKi 8.1) [2088], L-759,656 (pKi 7.7–7.9) [576, 1602], HU-308 (pKi 7.6) [699]
Selective
antagonists
rimonabant (pKi 7.9–8.7) [508, 509, 1586, 1613, 1733], AM251 (pKi 8.1) [1038] – Rat,
AM281 (pKi 7.9) [1037] – Rat, LY320135 (pKi 6.9) [508]
SR144528 (pKi 8.3–9.2) [1587, 1602], AM-630 (pKi 7.5) [1602]
Labelled ligands [3H]rimonabant (Antagonist) (pKd 8.9–10) [205, 761, 889, 1498, 1588, 1742, 1873] – Rat –
Comments: Both CB1 and CB2 receptors may be labelled with [
3H]CP55940 (0.5 nM; [1733]) and [3H]WIN55212-2 (2-2.4 nM; [1756, 1783]). Anandamide is also an agonist at vanilloid receptors (TRPV1)
and PPARs [1418, 2135]. There is evidence for an allosteric site on the CB1 receptor [1532]. All of the compounds listed as antagonists behave as inverse agonists in some bioassay systems [1494]. Moreover,
GPR18, GPR55 and GPR119, although showing little structural similarity to CB1 and CB2 receptors, respond to endogenous agents that are structurally similar to the endogenous cannabinoid ligands [1494].
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Chemerin receptor
G protein-coupled receptors! Chemerin receptor
Overview: The chemerin receptor (nomenclature as recommended by NC-IUPHAR [396]) is activated by chemerin [1148, 1253, 2108] and the lipid-derived, anti-inflammatory ligand resolvin E1 (RvE1),
which is the result of sequential metabolism of EPA by aspirin-modified cyclooxygenase and lipoxygenase [56, 57]. In addition, two GPCRs for resolvin D1 (RvD1) have been identified, FPR2/ALX, the lipoxin A4
receptor, and GPR32, an orphan receptor [1006].
Nomenclature chemerin receptor
HGNC, UniProt CMKLR1, Q99788
Rank order of potency resolvin E1 > chemerin C-terminal peptide > 18R-HEPE > EPA [56]
Selective agonists resolvin E1
Labelled ligands [3H]resolvin E1 (Agonist) (pKd 8) [56, 57]
Chemokine receptors
G protein-coupled receptors! Chemokine receptors
Overview: Chemokine receptors (nomenclature as agreed by
the NC-IUPHAR Subcommittee on Chemokine Receptors
[78, 1346, 1347]) comprise a large subfamily of 7TM proteins that
bind one or more chemokines, a large family of small cytokines typ-
ically possessing chemotactic activity for leukocytes. Chemokine re-
ceptors can be divided by function into two main groups: G protein-
coupled chemokine receptors, which mediate leukocyte trafficking,
and “Atypical chemokine receptors”, whichmay signal through non-
G protein-coupled mechanisms and act as chemokine scavengers to
downregulate inflammation or shape chemokine gradients [78].
Chemokines in turn can be divided by structure into four subclasses
by the number and arrangement of conserved cysteines. CC (also
known as β-chemokines; n= 28), CXC (also known as α-chemokines;
n= 17) and CX3C (n= 1) chemokines all have four conserved cys-
teines, with zero, one and three amino acids separating the first two
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cysteines respectively. C chemokines (n= 2) have only the second and
fourth cysteines found in other chemokines. Chemokines can also be
classified by function into homeostatic and inflammatory subgroups.
Most chemokine receptors are able to bind multiple high-affinity
chemokine ligands, but the ligands for a given receptor are almost
always restricted to the same structural subclass. Most chemokines
bind to more than one receptor subtype. Receptors for inflammatory
chemokines are typically highly promiscuous with regard to ligand
specificity, and may lack a selective endogenous ligand. G protein-
coupled chemokine receptors are named acccording to the class of
chemokines bound, whereas ACKR is the root acronym for atypi-
cal chemokine receptors [79]. Listed are those human agonists with
EC50 values<50 nM in either Ca
2+ flux or chemotaxis assays at hu-
man recombinantG protein-coupled chemokine receptors expressed
in mammalian cell lines. There can be substantial cross-species
differences in the sequences of both chemokines and chemokine re-
ceptors, and in the pharmacology and biology of chemokine recep-
tors. Endogenous and microbial non-chemokine ligands have also
been identified for chemokine receptors. Many chemokine receptors
function as HIV co-receptors, but CCR5 is the only one demonstrated
to play an essential role in HIV/AIDS pathogenesis. The tables in-
clude both standard chemokine receptor names [2101] and themost
commonly used aliases. Numerical data quoted are typically pKi
or pIC50 values from radioligand binding to heterologously ex-
pressed receptors.
Nomenclature CCR1 CCR2 CCR3
HGNC, UniProt CCR1, P32246 CCR2, P41597 CCR3, P51677
Endogenous agonists CCL3 (CCL3, P10147) (pKi 7.8–10.2) [328, 357, 747,
2134], CCL23 (CCL23, P55773) (Selective) (pKi 8.9)
[328], CCL5 (CCL5, P13501) (pKi 6.8–8.2) [357, 747],
CCL7 (CCL7, P80098) (pKi 8.1) [328, 667], CCL15
(CCL15, Q16663) (Selective) (pIC50 7.9) [373], CCL14
(CCL14, Q16627) (pKi 7.4) [328], CCL13 (CCL13,
Q99616), CCL8 (CCL8, P80075)
CCL2 (CCL2, P13500) (pIC50 9.3–10.2) [373, 1159,
1291, 1465, 1920], CCL13 (CCL13, Q99616) (pIC50
8.6–8.7) [1159, 1920], CCL7 (CCL7, P80098) (pIC50
8.4–8.7) [373, 1159, 1920], CCL11 (CCL11, P51671)
(Partial agonist) (pIC50 7.1–7.7) [1159, 1465], CCL16
(CCL16, O15467)
CCL13 (CCL13, Q99616) (pIC50 8.7–10.3) [1332,
1920], CCL24 (CCL24, O00175) (Selective) (pIC50
8–9.4) [1332, 1465], CCL5 (CCL5, P13501) (pKi
8.5–9.3) [391], CCL7 (CCL7, P80098) (pKi
8.6–9.2) [391], CCL11 (CCL11, P51671) (Selective)
(pIC50 8.7–9) [452, 961, 1332, 1625, 1920],
CCL26 (CCL26, Q9Y258) (Selective) (pIC50
7.9–8.9) [961, 1332, 1465], CCL15 (CCL15,
Q16663) (pIC50 8.6) [373], CCL28 (CCL28,
Q9NRJ3), CCL8 (CCL8, P80075)
Agonists – – CCL11 {Mouse} (pKi 9.5–10) [391]
Endogenous antagonists CCL4 (CCL4, P13236) (Selective) (pKi 7.1–7.8) [328,
357]
CCL26 (CCL26, Q9Y258) (Selective) (pIC50 8.5) [1465] CXCL10 (CXCL10, P02778) (Selective), CXCL11
(CXCL11, O14625) (Selective), CXCL9 (CXCL9,
Q07325) (Selective)
Antagonists – – –
Selective antagonists BX 471 (pKi 8.2–9) [1098],
compound 2b-1
[PMID: 12614873]
(pIC50 8.7) [1368], CP-481,715 (pKd 8) [614],
UCB35625 (pIC50 8) [1625]
GSK Compound 34 (pKi 7.6) banyu (I) (Inverse agonist) (pKi 8.5) [1977],
SB328437 (pKi 8.4), BMS compound 87b (pKi
8.1) [1964]
Antibodies – – –
Labelled ligands [125I]CCL7 (human) (Agonist) (pKd 9.2) [127],
[125I]CCL3 (human) (Agonist) (pKd 8–8.8) [127, 623,
1646], [125I]CCL5 (human) (Agonist) (pKd 8.2) [1646]
[125I]CCL2 (human) (Agonist), [125I]CCL7 (human)
(Agonist)
[125I]CCL11 (human) (Antagonist) (pKd 8.3)
[1977], [125I]CCL5 (human) (Agonist),
[125I]CCL7 (human) (Agonist)
Searchable database: http://www.guidetopharmacology.org/index.jsp Chemokine receptors 5786
Full Contents of ConciseGuide: http://onlinelibrary.wiley.com/doi/10.1111/bph.13348/full
S.P.H. Alexander et al. The Concise Guide to PHARMACOLOGY 2015/16: G protein-coupled receptors. British Journal of Pharmacology (2015) 172, 5744–5869
Nomenclature CCR4 CCR5
HGNC, UniProt CCR4, P51679 CCR5, P51681
Endogenous agonists CCL22 (CCL22, O00626) (Selective) (pIC50 9.2) [822], CCL17 (CCL17, Q92583)
(Selective) (pIC50 8.7) [822]
CCL5 (CCL5, P13501) (pKi 9.2–9.7) [75, 1364, 1611], CCL4 (CCL4, P13236)
(Selective) (pKi 9.4–9.6) [1364, 1611], CCL8 (CCL8, P80075) (pKi 9.3) [1611], CCL3
(CCL3, P10147) (pKi 8–8.9) [1364, 1611, 2134], CCL11 (CCL11, P51671) (pIC50 7.7)
[157], CCL2 (CCL2, P13500) (pKi 7.5) [1364], CCL14 (CCL14, Q16627) (pKi 7.2)
[1364], CCL16 (CCL16, O15467)
Agonists vMIP-III R5-HIV-1 gp120
Endogenous antagonists – CCL7 (CCL7, P80098) (Selective) (pKi 7.5) [1364]
Antagonists – vicriviroc (pKi 9.1) [1805], ancriviroc (pKi 7.8–8.7) [1173, 1455, 1805]
Selective antagonists – E913 (pIC50 8.7) [1174], aplaviroc (pKi 8.5) [1173], maraviroc (pIC50 8.1) [1364],
TAK-779 (pKi 7.5) [1173], MRK-1 [1023] – Rat
Antibodies mogamulizumab (Inhibition) [51, 1731] –
Labelled ligands [125I]CCL17 (human) (Agonist), [125I]CCL27 (human) (Agonist) [125I]CCL4 (human) (Agonist) (pKd 9.6) [1364], [
125I]CCL3 (human) (Agonist),
[125I]CCL5 (human) (Agonist), [125I]CCL8 (human) (Agonist)
Nomenclature CCR6 CCR7 CCR8 CCR9 CCR10
HGNC, UniProt CCR6, P51684 CCR7, P32248 CCR8, P51685 CCR9, P51686 CCR10, P46092
Endogenous
agonists
CCL20 (CCL20, P78556)
(pIC50 7.9–8.5) [18, 74,
1526], beta-defensin 4A
(DEFB4A DEFB4B, O15263)
(Selective) [2081]
CCL21 (CCL21, O00585)
(Selective) (pIC50 9.3) [2099],
CCL19 (CCL19, Q99731)
(Selective) (pIC50 7.7–9,
median 8.6) [1449, 2098,
2099]
CCL1 (CCL1, P22362)
(Selective) (pIC50 8.5–9.8)
[387, 710, 824], CCL8
{Mouse} – Mouse
CCL25 (CCL25, O15444)
(Selective)
CCL27 (CCL27, Q9Y4X3)
(Selective), CCL28 (CCL28,
Q9NRJ3) (Selective)
Agonists – – vMIP-I (pIC50 8.9–9.9) [387,
824]
– –
Selective
antagonists
– – vMCC-I (pIC50 9.4) [387] – –
Labelled ligands [125I]CCL20 (human)
(Agonist) (pKd 10) [641]
[125I]CCL19 (human)
(Agonist),
[125I]CCL21 (human)
(Agonist) [856]
[125I]CCL1 (human) (Agonist)
(pKd 8.9–9.7) [824, 1597]
[125I]CCL25 (human)
(Agonist)
–
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Nomenclature CXCR1 CXCR2 CXCR3
HGNC, UniProt CXCR1, P25024 CXCR2, P25025 CXCR3, P49682
Endogenous agonists CXCL8 (CXCL8, P10145) (pKi 8.8–9.5) [142, 675,
1068, 2032, 2049], CXCL6 (CXCL6, P80162) (pKi 7)
[2053]
CXCL1 (CXCL1, P09341) (Selective) (pKi 8.4–9.7) [675,
1068, 2049], CXCL8 (CXCL8, P10145) (pKi 8.8–9.5)
[142, 675, 1068, 2032, 2049], CXCL7 (PPBP, P02775)
(Selective) (pIC50 6.3–9.3) [16], CXCL3 (CXCL3,
P19876) (Selective) (pIC50 7.8–9.2) [16], CXCL2
(CXCL2, P19875) (Selective) (pIC50 7–9.1) [16], CXCL5
(CXCL5, P42830) (Selective) (pIC50 6.9–9) [16], CXCL6
(CXCL6, P80162) (pKd 7) [2053]
CXCL11 (CXCL11, O14625) (Selective) (pKi 10.4–10.5)
[734], CXCL10 (CXCL10, P02778) (Selective) (pKi
7.8–9.8) [734, 2006], CXCL9 (CXCL9, Q07325)
(Selective) (pKi 7.3–8.3) [734, 2006]
Agonists vCXCL1 (pIC50 7.4) [1158], HIV-1 matrix protein p17
(pKd 5.7) [602]
vCXCL1 (pIC50 8.2) [1158], HIV-1 matrix protein p17
(pKd 6.9) [602]
–
Selective agonists – – –
Endogenous antagonists – – CCL11 (CCL11, P51671) (Selective) (pKi 7.2) [2006],
CCL7 (CCL7, P80098) (Selective) (pKi 6.6) [2006]
Antagonists – – –
Selective antagonists – navarixin (pIC50 10.3) [78, 456], danirixin (pIC50 7.9)
[1285], SB 225002 (pIC50 7.7) [2016], elubirixin (pIC50
7.7) [78], SX-517 (pIC50 7.2) [1172]
–
Allosteric modulators reparixin (Negative) (pIC50 9) [142] reparixin (Negative) (pIC50 6.4) [142] –
Labelled ligands [125I]CXCL8 (human) (Agonist) (pKd 8.9–9.6) [675,
1584]
[125I]CXCL8 (human) (Agonist) (pKd 9–9.4) [675,
1584], [125I]CXCL1 (human) (Agonist),
[125I]CXCL5 (human) (Agonist),
[125I]CXCL7 (human) (Agonist)
[125I]CXCL10 (human) (Agonist),
[125I]CXCL11 (human) (Agonist)
Comments Reports on the expression of native CXCR1 by mouse
leukocytes are not conclusive. There are reports on the
existence of mouse Cxcr1 and on Cxcr1 knockout mice,
but the distinct function of the gene and of its knockout
phenotype are unclear [118, 351, 1297, 1628, 1794].
– –
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Nomenclature CXCR4 CXCR5 CXCR6
HGNC, UniProt CXCR4, P61073 CXCR5, P32302 CXCR6, O00574
Endogenous agonists CXCL12α (CXCL12, P48061) (Selective) (pKd 7.7–8.2)
[746, 1136], CXCL12β (CXCL12, P48061) (Selective)
(pKd 7.9) [746]
CXCL13 (CXCL13, O43927) (Selective) (pKd 7.3) [97] CXCL16 (CXCL16, Q9H2A7) (Selective) (pKd 9) [2026]
Agonists – –
Selective agonists ALX40-4C (Partial agonist) (pIC50 6.1) [2121],
X4-HIV-1 gp120
–
Endogenous antagonists – –
Antagonists plerixafor (pKi 7) [2121] –
Selective antagonists T134 (pIC50 8.4) [1856], AMD070 (pIC50 7.9) [1750],
HIV-Tat
–
Allosteric modulators – –
Labelled ligands [125I]CXCL12α (human) (Agonist) (pKd 8.1–8.4) [421,
746]
[125I]CXCL13 (mouse) (Agonist) [222] – Mouse [125I]CXCL16 (human) (Agonist)
Comments – – –
Nomenclature CX3CR1 XCR1 ACKR1 ACKR2
HGNC, UniProt CX3CR1, P49238 XCR1, P46094 ACKR1, Q16570 ACKR2, O00590
Endogenous ligands – – CXCL5 (CXCL5, P42830), CXCL6
(CXCL6, P80162), CXCL8 (CXCL8,
P10145), CXCL11 (CXCL11, O14625),
CCL2 (CCL2, P13500), CCL5 (CCL5,
P13501), CCL7 (CCL7, P80098),
CCL11 (CCL11, P51671), CCL14
(CCL14, Q16627), CCL17 (CCL17,
Q92583)
CCL2 (CCL2, P13500), CCL3 (CCL3,
P10147), CCL4 (CCL4, P13236), CCL5
(CCL5, P13501), CCL7 (CCL7, P80098),
CCL8 (CCL8, P80075), CCL11 (CCL11,
P51671), CCL13 (CCL13, Q99616),
CCL14 (CCL14, Q16627), CCL17
(CCL17, Q92583), CCL22 (CCL22,
O00626)
Endogenous agonists CX3CL1 (CX3CL1, P78423) (Selective)
(pIC50 8.9) [577]
XCL1 (XCL1, P47992) (Selective), XCL2
(XCL2, Q9UBD3) (Selective)
– –
Labelled ligands [125I]CX3CL1 (human) (Agonist) – –
Comments – When fused with secreted alkaline
phophatase (SEAP), XCL1 functions as
a probe at XCR1
ACKR1 is used by Plasmodium vivax
and Plasmodium knowlsei for entering
erythrocytes.
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Nomenclature ACKR3 ACKR4 CCRL2
HGNC, UniProt ACKR3, P25106 ACKR4, Q9NPB9 CCRL2, O00421
Endogenous ligands – – chemerin C-terminal peptide, CCL19 (CCL19, Q99731) [95]
Endogenous agonists CXCL12α (CXCL12, P48061) (pEC50 7.5–7.9) [640,
1785], CXCL11 (CXCL11, O14625), adrenomedullin
{Mouse} [965] – Mouse
CCL19 (CCL19, Q99731) (pKi 8.4) [1997], CCL25
(CCL25, O15444) (pKi 7.6) [1997], CCL21 (CCL21,
O00585) (pKi 6.9) [1997]
–
Comments: Mouse Cxcr binds iodinated mouse KC (CXCL1
{Mouse}) and mouse MIP-2 (CXCL2 {Mouse}) with high affinity
(mouse KC and MIP-2 are homologues of human CXCL1 (CXCL1,
P09341), CXCL2 (CXCL2, P19875) and CXCL3 (CXCL3, P19876)),
but shows low affinity for human IL-8 (CXCL8 (CXCL8, P10145)).
Specific chemokine receptors facilitate cell entry by microbes, such
as ACKR1 for Plasmodium vivax, and CCR5 for HIV-1. Virally encoded
chemokine receptors are known (e.g. US28, a homologue of CCR1
from human cytomegalovirus and ORF74, which encodes a homolog
of CXCR2 in Herpesvirus saimiri and Herpesvirus-68), but their role in
viral life cycles is not established. Viruses can exploit or subvert the
chemokine system by producing chemokine antagonists and scav-
engers.
The CC chemokine family (CCL1-28) includes I309 (CCL1 (CCL1,
P22362)), MCP-1 (CCL2 (CCL2, P13500)), MIP-1α (CCL3 (CCL3,
P10147)), MIP-1β (CCL4 (CCL4, P13236)), RANTES (CCL5 (CCL5,
P13501)), MCP-3 (CCL7 (CCL7, P80098)), MCP-2 (CCL8 (CCL8,
P80075)), eotaxin (CCL11 (CCL11, P51671)), MCP-4 (CCL13
(CCL13, Q99616)), HCC-1 (CCL14 (CCL14, Q16627)), Lkn-1/HCC-2
(CCL15 (CCL15, Q16663)), TARC (CCL17 (CCL17, Q92583)), ELC
(CCL19 (CCL19, Q99731)), LARC (CCL20 (CCL20, P78556)), SLC
(CCL21 (CCL21, O00585)), MDC (CCL22 (CCL22, O00626)), MPIF-
1 (CCL23 (CCL23, P55773)), eotaxin-2 (CCL24 (CCL24, O00175)),
TECK (CCL25 (CCL25, O15444)), eotaxin (CCL26 (CCL26, Q9Y258)),
eskine/CTACK (CCL27 (CCL27, Q9Y4X3)) and MEC (CCL28 (CCL28,
Q9NRJ3)). The CXC chemokine family (CXCL1-17) includes GROα
(CXCL1 (CXCL1, P09341)), GROβ (CXCL2 (CXCL2, P19875)), GROγ
(CXCL3 (CXCL3, P19876)), platelet factor 4 (CXCL4 (PF4, P02776)),
ENA78 (CXCL5 (CXCL5, P42830)), GCP-2 (CXCL6 (CXCL6, P80162)),
NAP-2 (CXCL7 (PPBP, P02775)), IL-8 (CXCL8 (CXCL8, P10145)), MIG
(CXCL9 (CXCL9, Q07325)), IP10 (CXCL10 (CXCL10, P02778)), I-
TAC (CXCL11 (CXCL11, O14625)), SDF-1 (CXCL12, i.e. CXCL12α
(CXCL12, P48061) and CXCL12β (CXCL12, P48061)), BLC (CXCL13
(CXCL13, O43927)), BRAK (CXCL14 (CXCL14, O95715)), mouse
lungkine (CXCL15 {Mouse}) SR-PSOX (CXCL16 (CXCL16, Q9H2A7))
and CXCL17 (CXCL17, Q6UXB2). The CX3C chemokine (CX3CL1
(CX3CL1, P78423)) is also known as fractalkine (neurotactin in
the mouse). Like CXCL16 (CXCL16, Q9H2A7), and unlike other
chemokines, CX3CL1 (CX3CL1, P78423) is multimodular contain-
ing a chemokine domain, an elongated mucin-like stalk, a trans-
membrane domain and a cytoplasmic tail. Both plasma membrane-
associated and shed forms have been identified. The C chemokine
(XCL1 (XCL1, P47992)) is also known as lymphotactin.
Two chemokine receptor antagonists have now been approved by
the FDA: the CCR5 antagonist maraviroc (Pfizer) for treatment of
HIV/AIDS in patients with CCR5-using strains; and the CXCR4 an-
tagonist plerixafor (Sanofi) for hematopoietic stem cell mobilization
with G-CSF (CSF3, P09919) in patients undergoing transplantation in
the context of chemotherapy for lymphoma and multiple myeloma.
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Cholecystokinin receptors
G protein-coupled receptors! Cholecystokinin receptors
Overview: Cholecystokinin receptors (nomenclature as
agreed by the NC-IUPHAR Subcommittee on CCK re-
ceptors [1403]) are activated by the endogenous peptides
cholecystokinin-8 (CCK-8 (CCK, P06307)), CCK-33 (CCK, P06307),
CCK-58 (CCK, P06307) and gastrin (gastrin-17 (GAST, P01350)).
There are only two distinct subtypes of CCK receptors, CCK1 and
CCK2 receptors [992, 1986], with some alternatively spliced forms
most often identified in neoplastic cells. The CCK receptor subtypes
are distinguished by their peptide selectivity, with the CCK1 receptor
requiring the carboxyl-terminal heptapeptide-amide that includes a
sulfated tyrosine for high affinity and potency, while the CCK2 recep-
tor requires only the carboxyl-terminal tetrapeptide shared by both
CCK and gastrin peptides. These receptors have characteristic and
distinct distributions, with both present in both the central nervous
system and peripheral tissues.
Nomenclature CCK1 receptor CCK2 receptor
HGNC, UniProt CCKAR, P32238 CCKBR, P32239
Rank order of potency CCK-8 (CCK, P06307) gastrin-17 (GAST, P01350),
desulfated cholecystokinin-8 > CCK-4 (CCK, P06307)
CCK-8 (CCK, P06307)  gastrin-17 (GAST, P01350),
desulfated cholecystokinin-8, CCK-4 (CCK, P06307)
Endogenous agonists – desulfated cholecystokinin-8 (pIC50 8.3–8.7) [1071], gastrin-17 (GAST, P01350)
(Selective) (pIC50 8.3) [805] – Mouse, CCK-4 (CCK, P06307) (pIC50 7.5) [832],
desulfated gastrin-14 (GAST, P01350), desulfated gastrin-17 (GAST, P01350),
desulfated gastrin-34 (GAST, P01350), desulfated gastrin-71 (GAST, P01350),
gastrin-14 (GAST, P01350), gastrin-34 (GAST, P01350), gastrin-71 (GAST,
P01350)
Selective agonists A-71623 (pIC50 8.4) [63] – Rat, JMV180 (pIC50 8.3) [926], GW-5823 (pIC50 7.6)
[737]
RB-400 (pKi 9.1) [123] – Rat, PBC-264 (pIC50 9.1) [844] – Rat
Antagonists lintitript (pIC50 8.3) [632] –
Selective antagonists devazepide (pIC50 9.7) [805] – Rat, T-0632 (pIC50 9.6) [1861] – Rat, PD-140548
(pIC50 8.6) [1748] – Rat, lorglumide (pIC50 6.7–8.2) [805, 834] – Rat
YF-476 (pIC50 9.7) [196, 1854], GV150013 (pIC50 9.4) [1930], L-740093 (pIC50
9.2) [1398], YM-022 (pIC50 9.2) [1398], JNJ-26070109 (pIC50 8.5) [1336],
L-365260 (pIC50 8.4) [1071], RP73870 (pIC50 8) [1115] – Rat, LY262691 (pIC50
7.5) [1561] – Rat
Labelled ligands [3H]devazepide (Antagonist) (pKd 9.7) [292],
[125I]DTyr-Gly-[(Nle28,31)CCK-26-33 (Agonist) (pIC50 9) [1527]
[3H]PD140376 (Antagonist) (pKi 9.7–10) [809] – Guinea pig, [
125I]PD142308
(Antagonist) (pKd 9.6) [781] – Guinea pig,
[125I]DTyr-Gly-[(Nle28,31)CCK-26-33 (Agonist) (pIC50 9) [1527], [125I]gastrin
(Agonist) (pIC50 9), [3H]gastrin (Agonist) (pIC50 9), [3H]L365260 (Antagonist)
(pKd 8.2–8.5) [1398], [
125I]-BDZ2 (Antagonist) (pKi 8.4) [25]
Comments: While a cancer-specific CCK receptor has been postu-
lated to exist, which also might be responsive to incompletely pro-
cessed forms of CCK (Gly-extended forms), this has never been iso-
lated. An alternatively spliced form of the CCK2 receptor in which
intron 4 is retained, adding 69 amino acids to the intracellular loop 3
(ICL3) region, has been described to be present particularly in certain
neoplasms where mRNA mis-splicing has been commonly observed
[1764], but it is not clear that this receptor splice form plays a spe-
cial role in carcinogenesis. Another alternative splicing event for the
CCK2 receptor was reported [1782], with alternative donor sites in
exon 4 resulting in long (452 amino acids) and short (447 amino
acids) forms of the receptor differing by five residues in ICL3, how-
ever, no clear functional differences have been observed.
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Class Frizzled GPCRs
G protein-coupled receptors! Class Frizzled GPCRs
Overview: Receptors of the Class Frizzled (FZD, nomencla-
ture as agreed by the NC-IUPHAR subcommittee on the
Class Frizzled GPCRs [1676]), are GPCRs originally identified
inDrosophila [285], which are highly conserved across species. FZDs
are activated by WNTs, which are cysteine-rich lipoglycoproteins
with fundamental functions in ontogeny and tissue homeostatis.
FZD signalling was initially divided into two pathways, being ei-
ther dependent on the accumulation of the transcription regula-
tor β-catenin (CTNNB1, P35222) or being β-catenin-independent
(often referred to as canonical vs. non-canonical WNT/FZD sig-
nalling, respectively). WNT stimulation of FZDs can, in cooperation
with the low density lipoprotein receptors LRP5 (O75197) and LRP6
(O75581), lead to the inhibition of a constitutively active destruc-
tion complex, which results in the accumulation of β-catenin and
subsequently its translocation to the nucleus. β-Catenin, in turn,
modifies gene transcription by interactingwith TCF/LEF transcription
factors. β-Catenin-independent FZD signalling is far more complex
with regard to the diversity of the activated pathways. WNT/FZD
signalling can lead to the activation of pertussis toxin-sensitive het-
erotrimeric G proteins [939], the elevation of intracellular calcium
[1757], activation of cGMP-specific PDE6 [17] and elevation of cAMP
as well as RAC-1, JNK, Rho and Rho kinase signalling [695]. Fur-
thermore, the phosphoprotein Disheveled constitutes a key player in
WNT/FZD signalling. As with other GPCRs, members of the Friz-
zled family are functionally dependent on the arrestin scaffolding
protein for internalization [306], as well as for β-catenin-dependent
[235] and -independent [236, 940] signalling. The pattern of cell sig-
nalling is complicated by the presence of additional ligands, which
can enhance or inhibit FZD signalling (secreted Frizzled-related pro-
teins (sFRP), Wnt-inhibitory factor (WIF1, Q9Y5W5) (WIF), sclerostin
(SOST, Q9BQB4) or Dickkopf (DKK)), as well as modulatory (co)-
receptors with Ryk, ROR1, ROR2 and Kremen, which may also func-
tion as independent signalling proteins.
Nomenclature FZD1 FZD2 FZD3 FZD4 FZD5
HGNC, UniProt FZD1, Q9UP38 FZD2, Q14332 FZD3, Q9NPG1 FZD4, Q9ULV1 FZD5, Q13467
Nomenclature FZD6 FZD7 FZD8 FZD9 FZD10
HGNC, UniProt FZD6, O60353 FZD7, O75084 FZD8, Q9H461 FZD9, O00144 FZD10, Q9ULW2
Searchable database: http://www.guidetopharmacology.org/index.jsp Class Frizzled GPCRs 5792
Full Contents of ConciseGuide: http://onlinelibrary.wiley.com/doi/10.1111/bph.13348/full
S.P.H. Alexander et al. The Concise Guide to PHARMACOLOGY 2015/16: G protein-coupled receptors. British Journal of Pharmacology (2015) 172, 5744–5869
Nomenclature SMO
HGNC, UniProt SMO, Q99835
Antagonists saridegib (pIC50 8.9) [1904], glasdegib (pIC50 8.3) [1342], erismodegib (pKi 8.2) [1979]
Selective antagonists vismodegib (pKi 7.8) [1979]
Comments: There is limited knowledge aboutWNT/FZD specificity
and which molecular entities determine the signalling outcome of a
specific WNT/FZD pair. Understanding of the coupling to G pro-
teins is incomplete (see [423]). There is also a scarcity of informa-
tion on basic pharmacological characteristics of FZDs, such as bind-
ing constants, ligand specificity or concentration-response relation-
ships [937].
Ligands associated with FZD signalling
WNTs: Wnt-1 (WNT1, P04628), Wnt-2 (WNT2, P09544) (also
known as Int-1-related protein), Wnt-2b (WNT2B, Q93097) (also
known as WNT-13), Wnt-3 (WNT3, P56703) , Wnt-3a (WNT3A,
P56704), Wnt-4 (WNT4, P56705), Wnt-5a (WNT5A, P41221)
, Wnt-5b (WNT5B, Q9H1J7), Wnt-6 (WNT6, Q9Y6F9), Wnt-7a
(WNT7A, O00755), Wnt-7b (WNT7B, P56706), Wnt-8a (WNT8A,
Q9H1J5), Wnt-8b (WNT8B, Q93098), Wnt-9a (WNT9A, O14904)
(also known as WNT-14), Wnt-9b (WNT9B, O14905) (also known
as WNT-15 or WNT-14b), Wnt-10a (WNT10A, Q9GZT5), Wnt-10b
(WNT10B, O00744) (also known as WNT-12), Wnt-11 (WNT11,
O96014) and Wnt-16 (WNT16, Q9UBV4).
Extracellular proteins that interact with FZDs: norrin
(NDP, Q00604), R-spondin-1 (RSPO1, Q2MKA7), R-spondin-2
(RSPO2, Q6UXX9) , R-spondin-3 (RSPO3, Q9BXY4), R-spondin-4
(RSPO4, Q2I0M5), sFRP-1 (SFRP1, Q8N474), sFRP-2 (SFRP2,
Q96HF1), sFRP-3 (FRZB, Q92765), sFRP-4 (SFRP4, Q6FHJ7), sFRP-5
(SFRP5, Q6FHJ7).
Extracellular proteins that interact with WNTs or LRPs:
Dickkopf 1 (DKK1, O94907), WIF1 (Q9Y5W5), sclerostin (SOST,
Q9BQB4), kremen 1 (KREMEN1, Q96MU8) and kremen 2 (KREMEN2,
Q8NCW0)
Small exogenous ligands: Foxy-5 [1835], Box-5, UM206 [1031],
and XWnt8 (P28026) also known as mini-Wnt8.
Further Reading
Dijksterhuis JP et al. (2013) WNT/Frizzled signaling: receptor-ligand selectivity with focus on FZD-G pro-
tein signaling and its physiological relevance. Br J Pharmacol [PMID:24032637]
King TD et al. (2012) The Wnt/β-catenin signaling pathway: a potential therapeutic target in the treat-
ment of triple negative breast cancer. J. Cell. Biochem. 113: 13-8 [PMID:21898546]
King TD et al. (2012) Frizzled7 as an emerging target for cancer therapy. Cell. Signal. 24: 846-51
[PMID:22182510]
Koval A et al. (2011) Yellow submarine of the Wnt/Frizzled signaling: submerging from the G protein
harbor to the targets. Biochem. Pharmacol. 82: 1311-9 [PMID:21689640]
Schuijers J et al. (2012) Adult mammalian stem cells: the role of Wnt, Lgr5 and R-spondins. EMBO J. 31:
2685-96 [PMID:22617424]
Schulte G. (2010) International Union of Basic and Clinical Pharmacology. LXXX. The class Frizzled re-
ceptors. Pharmacol. Rev. 62: 632-67 [PMID:21079039]
Schulte G et al. (2010) beta-Arrestins - scaffolds and signalling elements essential for WNT/Frizzled sig-
nalling pathways? Br. J. Pharmacol. 159: 1051-8 [PMID:19888962]
Complement peptide receptors
G protein-coupled receptors! Complement peptide receptors
Overview: Complement peptide receptors (nomenclature as agreed by the NC-IUPHAR subcommittee on Complement peptide receptors [967]) are activated by the endogenous 75 amino-acid
anaphylatoxin polypeptides C3a (C3, P01024). C4a (C4A, P0C0L4) and C5a (C5, P01031), generated upon stimulation of the complement cascade.
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Nomenclature C3a receptor C5a1 receptor C5a2 receptor
HGNC, UniProt C3AR1, Q16581 C5AR1, P21730 C5AR2, Q9P296
Rank order of potency C3a (C3, P01024) > C5a (C5, P01031) [41] C5a (C5, P01031), C5a des-Arg (C5) > C3a (C3, P01024)
[41]
–
Endogenous agonists – ribosomal protein S19 (RPS19, P39019) [2071] –
Agonists E7 (pEC50 8.7) [43], compound 21 [PMID: 25259874]
(pEC50 7.7) [1571], SQ007-5 (Partial agonist) (pEC50 6.7)
[124], Ac-RHYPLWR (pEC50 6) [672]
N-methyl-Phe-Lys-Pro-D-Cha-Cha-D-Arg-CO2H (pIC50
7.6) [916, 989]
–
Antagonists SB290157 (pIC50 7.6) [40],
compound 4 [PMID: 25259874] (pIC50 5.9) [1571]
CHIPS (pKd 9) [1522], W54011 (pKi 8.7) [1819],
AcPhe-Orn-Pro-D-Cha-Trp-Arg (pIC50 7.9) [2039],
N-methyl-Phe-Lys-Pro-D-Cha-Trp-D-Arg-CO2H (pIC50
7.2) [989]
–
Labelled ligands [125I]C3a (human) (Agonist) (pKd 8.4) [296] [
125I]C5a (human) (Agonist) (pKd 8.7) [803] [
125I]C5a (human) (Agonist)
Comments – – Binds C5a complement factor, but appears to
lack G protein signalling and has been termed
a decoy receptor [1684].
Comments: SB290157 has also been reported to have agonist
properties at the C3a receptor [1218]. The putative chemoattractant
receptor termedC5a2 (also known as GPR77, C5L2) binds [
125I]C5a
with no clear signalling function, but has a putative role opposing in-
flammatory responses [257, 568, 585]. Binding to this site may be
displaced with the rank order C5a des-Arg (C5)> C5a (C5, P01031)
[257, 1440] while there is controversy over the ability of C3a (C3,
P01024) and C3a des Arg (C3, P01024) to compete [778, 894, 895,
1440]. C5a2 appears to lack G protein signalling and has been
termed a decoy receptor [1684]. However, C5a2 does recruit ar-
restin after ligand binding, which might provide a signaling pathway
for this receptor [89, 1937], and forms heteromers with C5a1. C5a,
but not C5a-des Arg, induces upregulation of heteromer formation
between complement C5a receptors C5aR and C5L2 [380]. There
are also reports of pro-inflammatory activity of C5a2, mediated by
HMGB1, but the signaling pathway that underlies this is currently
unclear (reviewed in [1095]).
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Corticotropin-releasing factor receptors
G protein-coupled receptors! Corticotropin-releasing factor receptors
Overview: Corticotropin-releasing factor (CRF, nomen-
clature as agreed by the NC-IUPHAR subcommit-
tee on Corticotropin-releasing Factor Receptors
[716]) receptors are activated by the endogenous peptides
corticotrophin-releasing hormone (CRH, P06850), a 41 amino-acid
peptide, urocortin 1 (UCN, P55089), 40 amino-acids, urocortin 2
(UCN2, Q96RP3), 38 amino-acids and urocortin 3 (UCN3, Q969E3),
38 amino-acids. CRF1 and CRF2 receptors are activated non-
selectively by corticotrophin-releasing hormone (CRH, P06850)
and urocortin 1 (UCN, P55089). Binding to CRF receptors can be
conducted using [125I]Tyr0-CRF or [125I]Tyr0-sauvagine with Kd
values of 0.1-0.4 nM. CRF1 and CRF2 receptors are non-selectively
antagonized by α-helical CRF, D-Phe-CRF-(12-41) and astressin.
Nomenclature CRF1 receptor CRF2 receptor
HGNC, UniProt CRHR1, P34998 CRHR2, Q13324
Endogenous agonists – urocortin 2 (UCN2, Q96RP3) (Selective) (pKd 8.5–8.6) [392], urocortin 3 (UCN3,
Q969E3) (Selective) (pKd 7.9–8) [392]
Antagonists SSR125543A (pKi 8.7) [663] –
Selective antagonists CP 154,526 (pIC50 9.3–10.4) [1153] – Rat, DMP696 (pKi 8.3–9) [726], NBI27914
(pKi 8.3–9) [298], R121919 (pKi 8.3–9) [2133], antalarmin (pKi 8.3–9) [2001],
CP376395 (pIC50 8.3) [307] – Rat, CRA1000 (pIC50 6.4–7.1) [284]
antisauvagine (pKd 8.8–9.6) [394], K41498 (pKi 9.2) [1048], K31440 (pKi 8.7–8.8)
[1622]
Comments: A CRF binding protein has been identified (CRHBP, P24387) to which both corticotrophin-releasing hormone (CRH, P06850) and urocortin 1 (UCN, P55089) bind with high affinities, which has been
suggested to bind and inactivate circulating corticotrophin-releasing hormone (CRH, P06850) [1489].
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Dopamine receptors
G protein-coupled receptors! Dopamine receptors
Overview: Dopamine receptors (nomenclature as agreed by the NC-IUPHAR Subcommittee on Dopamine Receptors [1677]) are commonly divided into D1-like (D1 and D5) and D2-like (D2,
D3 and D4) families, where the endogenous agonist is dopamine.
Nomenclature D1 receptor D2 receptor
HGNC, UniProt DRD1, P21728 DRD2, P14416
Endogenous agonists dopamine (pKi 4.3–5.6) [1823, 1884] dopamine (pKi 4.7–7.2) [245, 545, 1653]
Agonists fenoldopam (pKi 6.5–7.9) [1884] rotigotine (pKi 10.2) [424], cabergoline (Partial agonist) (pKi 9–9.2) [1279],
aripiprazole (Partial agonist) (pKi 9.1) [2111], bromocriptine (pKi 7.3–8.3) [545,
1279, 1653], MLS1547 (Biased agonist) (pKi 8.2) [544], ropinirole (pKi 8.1) [732],
apomorphine (Partial agonist) (pKi 5.7–7.5) [245, 545, 1279, 1653, 1776],
pramipexole (pKi 5.1–7.4) [1273, 1653], benzquinamide (pKi 5.4) [643]
(Sub)family-selective
agonists
A68930 (pEC50 6.8) [1381], SKF-38393 (Partial agonist) (pKi 6.2–6.8) [1823,
1884]
quinpirole (pKi 4.9–7.7) [245, 1273, 1473, 1776, 1778, 1940]
Selective agonists SKF-83959 (Biased agonist) (pEC50 9.7) [364], SKF-81297 (pKi 8.7) [46] –
Rat
sumanirole (pKi 8.1) [1239]
Antagonists flupentixol (pKi 7–8.4) [1823, 1884] blonanserin (pKi 9.9) [1421], pipotiazine (pKi 9.7) [1777], perphenazine (pKi
8.9–9.6) [1008, 1691], risperidone (pKi 9.4) [60], perospirone (pKi 9.2) [1692],
trifluoperazine (pKi 8.9–9) [1008, 1693], asenapine (pKi 8.9) [1711], sertindole
(pKi 8–8.9) [986, 1008, 1691], fluphenazine (pKi 8.8) [1647], flupentixol (pKi 8.8)
[545], pimozide (pKi 7–8.8) [545, 1776], olanzapine (pKi 8.7) [60], mesoridazine
(pKi 8.7) [326], ziprasidone (pKi 8.6) [60], prochlorperazine (pKi 8.4) [68],
loxapine (pKi 7.9–8.3) [1008, 1693], (-)-sulpiride (pKi 6.3–8) [545, 1776, 1860],
amisulpride (pKi 7.9–8) [1195, 1776], metoclopramide (pKi 7.5) [1221] – Mouse,
quetiapine (pKi 7.2) [60], trans-flupenthixol (pKi 6.9) [545], clozapine (pKi
5.8–6.9) [545, 1164, 1711, 1776, 1860], promazine (pKi 6.5) [246]
(Sub)family-selective
antagonists
SCH-23390 (pKi 7.4–9.5) [1823, 1884], SKF-83556 (pKi 9.5) [1823],
ecopipam (pKi 8.3) [1885]
haloperidol (pKi 7.4–8.8) [545, 1164, 1273, 1776, 1885]
Selective antagonists – L-741,626 (pKi 7.9–8.5) [655, 1020], domperidone (pKi 7.9–8.4) [545, 1776],
raclopride (pKi 8) [1281], ML321 (pKi 7) [2058, 2059]
Labelled ligands [3H]SCH-23390 (Antagonist) (pKd 9.5) [2127] [
3H]spiperone (Antagonist) (pKd 10.2) [239, 767, 2125] – Rat
Labelled ligands [125I]SCH23982 (Antagonist) (pKd 9.5) [408] [
3H]raclopride (Antagonist) (pKd 8.9) [1028] – Rat
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Nomenclature D3 receptor D4 receptor D5 receptor
HGNC, UniProt DRD3, P35462 DRD4, P21917 DRD5, P21918
Endogenous agonists dopamine (pKi 6.4–7.3) [245, 545, 1653, 1778] dopamine (pKi 7.6) [1940] dopamine (pKi 6.6) [1823]
Agonists pramipexole (pKi 8.4–8.7) [1273, 1653],
bromocriptine (Partial agonist) (pKi 7.1–8.2) [545,
1279, 1653], ropinirole (pKi 7.7) [732], apomorphine
(Partial agonist) (pKi 6.1–7.6) [245, 545, 1279, 1653,
1776]
apomorphine (Partial agonist) (pKi 8.4) [1279] –
(Sub)family-selective
agonists
quinpirole (pKi 6.4–8) [245, 1273, 1281, 1473, 1653,
1776, 1778, 1940]
quinpirole (pKi 7.5) [1279, 1473, 1940] A68930 (pEC50 6.6) [1381]
Selective agonists PD 128907 (pKi 7.6–7.7) [1539, 1653] PD168,077 (Partial agonist) (pKi 8.8) [995] – Rat,
A412997 (pKi 8.1) [1319] – Rat, A412997 (pKi 8.1)
[1319]
–
Antagonists perospirone (pKi 9.6) [1776], sertindole (pKi 8–8.8)
[60, 1675, 1691], prochlorperazine (pKi 8.4) [68],
(-)-sulpiride (pKi 6.7–7.7) [545, 1776, 1860], loxapine
(pKi 7.7) [1691], domperidone (pKi 7.1–7.6) [545,
1776], promazine (pKi 6.8) [246]
perospirone (pKi 10.1) [1694], sertindole (pKi 7.8–9.1)
[246, 1691, 1693, 1694], sonepiprazole (pKi 8.9)
[1668], loxapine (pKi 8.1) [1693]
–
(Sub)family-selective
antagonists
haloperidol (pKi 7.5–8.6) [545, 1711, 1776, 1885] haloperidol (pKi 8.7–8.8) [1033, 1711, 1885] SCH-23390 (pKi 7.5–9.5) [1823], SKF-83556
(pKi 9.4) [1823], ecopipam (pKi 8.3) [1823]
Selective antagonists S33084 (pKi 9.6) [1278], nafadotride (pKi 9.5) [1654],
PG01037 (pKi 9.2) [656], NGB 2904 (pKi 8.8) [2055],
SB 277011-A (pKi 8) [1569], (+)-S-14297 (pKi 6.9–7.9)
[1275, 1281]
L745870 (pKi 9.4) [1020], A-381393 (pKi 8.8) [1361],
L741742 (pKi 8.5) [1609], ML398 (pKi 7.4) [138]
–
Selective allosteric
modulators
SB269652 (Negative) (pKi 9) [558] – –
Labelled ligands – [3H]spiperone (Antagonist) (pKd 9.5) [749, 1940] [
3H]SCH-23390 (Antagonist) (pKd 9.2) [1580]
Labelled ligands [3H]spiperone (Antagonist) (pKd 9.9) [767, 2125] –
Rat, [3H]7-OH-DPAT (Agonist) (pKd 9.6) [1581],
[3H]PD128907 (Agonist) (pKd 9) [27]
[125I]L750667 (Antagonist) (pKd 9.8) [1473],
[3H]NGD941 (Antagonist) (pKd 8.3) [1533]
[125I]SCH23982 (Antagonist) (pKd 9.1) –
Unknown
Comments: The selectivity of many of these agents is less than
two orders of magnitude. [3H]raclopride exhibits similar high affin-
ity for D2 and D3 receptors (low affinity for D4), but has been used
to label D2 receptors in the presence of a D3-selective antagonist.
[3H]7-OH-DPAT has similar affinity for D2 and D3 receptors, but la-
bels only D3 receptors in the absence of divalent cations. The phar-
macological profile of the D5 receptor is similar to, yet distinct from,
that of the D1 receptor. The splice variants of the D2 receptor are
commonly termed D2S and D2L (short and long). The DRD4 gene
encoding the D4 receptor is highly polymorphic in humans, with
allelic variations of the protein from amino acid 387 to 515.
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Endothelin receptors
G protein-coupled receptors! Endothelin receptors
Overview: Endothelin receptors (nomenclature as agreed by the NC-IUPHAR Subcommittee on Endothelin Receptors [395]) are activated by the endogenous 21 amino-acid peptides endothelins
1-3 (endothelin-1 (EDN1, P05305), endothelin-2 (EDN2, P20800) and endothelin-3 (EDN3, P14138)).
Nomenclature ETA receptor ETB receptor
HGNC, UniProt EDNRA, P25101 EDNRB, P24530
Family selective agonists endothelin-1 (EDN1, P05305) = endothelin-2 (EDN2, P20800) > endothelin-3
(EDN3, P14138) [1178]
endothelin-1 (EDN1, P05305) = endothelin-2 (EDN2, P20800), endothelin-3
(EDN3, P14138)
Selective agonists – sarafotoxin S6c (pKd 8.8–9.8) [1016, 1616], BQ 3020 (pKi 9.7) [1576],
[Ala1,3,11,15]ET-1 (pKd 8.7–9.2) [1300], IRL 1620 (pKi 8.7) [1991]
(Sub)family-selective
antagonists
SB209670 (pKB 9.4) [474] – Rat, TAK 044 (pA2 8.4) [1993] – Rat, bosentan (pA2
7.2) [354] – Rat
SB209670 (pKB 9.4) [474] – Rat, TAK 044 (pA2 8.4) [1993] – Rat, bosentan (pKi
7.1) [1349]
Selective antagonists atrasentan (pA2 9.2–10.5) [1446], PD-156707 (pKd 9–9.8) [1180], macitentan
(pIC50 9.3) [174], sitaxsentan (pA2 8) [2047], FR139317 (Inverse agonist) (pIC50
7.3–7.9) [1178], ambrisentan (pIC50 7.7) [175], BQ123 (pA2 6.9–7.4) [1178],
avosentan (pIC50 7.3) [210], ambrisentan (pA2 7.1) [175]
A192621 (pKd 8.1) [2145], BQ788 (pKd 7.9–8) [1616], IRL 2500 (pKd 7.2)
[1616], Ro 46-8443 (pIC50 7.2) [209]
Labelled ligands [125I]PD164333 (Antagonist) (pKd 9.6–9.8) [398], [
3H]S0139 (Antagonist) (pKd
9.2), [125I]PD151242 (Antagonist) (pKd 9–9.1) [399], [
3H]BQ123 (Antagonist)
(pKd 8.5) [817]
[125I]IRL1620 (Agonist) (pKd 9.9–10.1) [1362], [
125I]BQ3020 (Agonist) (pKd
8.3–10) [702, 1300, 1495], [125I][Ala1,3,11,15]ET-1 (Agonist) (pKd 9.7) [1300]
Comments: Splice variants of the ETA receptor have been identified in rat pituitary cells; one of these, ETAR-C13, appeared to show loss of function with comparable plasma membrane expression to wild type
receptor [713]. Subtypes of the ETB receptor have been proposed, although gene disruption studies in mice suggest that only a single gene product exists [1295].
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G protein-coupled estrogen receptor
G protein-coupled receptors! G protein-coupled estrogen receptor
Overview: The G protein-coupled estrogen receptor (GPER, nomenclature as agreed by the NC-IUPHAR Subcommittee on the G protein-coupled estrogen receptor [1536]) was identified
following observations of estrogen-evoked cyclic AMP signalling in breast cancer cells [61], which mirrored the differential expression of an orphan 7-transmembrane receptor GPR30 [265]. There are observations
of both cell-surface and intracellular expression of the GPER receptor [1573, 1877].
Nomenclature GPER
HGNC, UniProt GPER1, Q99527
Selective agonists G1 (pKi 8) [176]
Selective antagonists G36 (pIC50 6.8–6.9) [414], G15 (pIC50 6.7) [413]
Labelled ligands [3H]17β-estradiol (Agonist) (pKd 8.5–8.6) [1877]
Comments: Antagonists at the nuclear estrogen receptor, such as fulvestrant and tamoxifen [515], as well as the flavonoid ‘phytoestrogens’ genistein and quercetin [1177], are agonists at GPER receptors.
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Formylpeptide receptors
G protein-coupled receptors! Formylpeptide receptors
Overview: The formylpeptide receptors (nomenclature agreed by the NC-IUPHAR Subcommittee on the formyl peptide receptor family [2092]) respond to exogenous ligands such as the
bacterial product fMet-Leu-Phe (fMLP) and endogenous ligands such as annexin I (ANXA1, P04083) , cathepsin G (CTSG, P08311), amyloid β42, serum amyloid A and spinorphin, derived from β-haemoglobin (HBB,
P68871).
Nomenclature FPR1 FPR2/ALX FPR3
HGNC, UniProt FPR1, P21462 FPR2, P25090 FPR3, P25089
Rank order of potency fMet-Leu-Phe > cathepsin G (CTSG, P08311) > annexin I
(ANXA1, P04083) [1058, 1821]
LXA4=aspirin triggered lipoxin A4=ATLa2>LTC4=LTD4
15-deoxy-LXA4fMet-Leu-Phe [352, 519, 521, 651, 1846]
–
Endogenous agonists – LXA4 (Selective) (pEC50 12) [1006], resolvin D1 (Selective) (pEC50
11.9) [1006], aspirin triggered lipoxin A4 (Selective)
F2L (HEBP1, Q9NRV9)
(Selective) (pEC50 8–8.2) [1274]
Agonists fMet-Leu-Phe (pEC50 10.1–10.2) [546, 1734] – –
Selective agonists – ATLa2 [662] –
Endogenous antagonists spinorphin (Selective) (pIC50 4.3) [1099, 1348] – –
Antagonists t-Boc-FLFLF (pKi 6–6.5) [2008] – –
Selective antagonists cyclosporin H (pKi 6.1–7.1) [2008, 2078] – –
Labelled ligands [3H]fMet-Leu-Phe (Agonist) (pKd 7.6–9.3) [990] [
3H]LXA4 (Agonist) (pKd 9.2–9.3) [519, 520] –
Comments A FITC-conjugated fMLP analogue has been used for binding to
the mouse recombinant receptor [724].
The agonist activity of the lipid mediators described has been
questioned [697, 1513], which may derive from batch-to-batch
differences, partial agonism or biased agonism. Recent results from
Cooray et al. (2013) [365] have addressed this issue and the role of
homodimers and heterodimers in the intracellular signaling .
–
Comments: Note that the data for FPR2/ALX are also reproduced on the leukotriene receptor page.
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Free fatty acid receptors
G protein-coupled receptors! Free fatty acid receptors
Overview: Free fatty acid receptors (FFA, nomenclature
as agreed by the NC-IUPHAR Subcommittee on free
fatty acid receptors [396, 1803]) are activated by free fatty
acids. Long-chain saturated and unsaturated fatty acids (C14.0
(myristic acid), C16:0 (palmitic acid), C18:1 (oleic acid), C18:2
(linoleic acid), C18:3, (α-linolenic acid), C20:4 (arachidonic acid),
C20:5,n-3 (EPA), C22:6,n-3 (docosahexaenoic acid)) activate FFA1
[218, 833, 998] and FFA4 receptors [757, 812, 1427], while
short chain fatty acids (C2 (acetic acid), C3 (propanoic acid), C4
(butyric acid) and C5 (pentanoic acid)) activate FFA2 [226, 1057,
1399] and FFA3 [226, 1057] receptors. In addition, thiazolidine-
dione PPARγ agonists such as rosiglitazone activate FFA1 (pEC50 5.2;
[999, 1768, 1802]) and small molecule allosteric modulators, such
as 4-CMTB, have recently been characterised for FFA2 [801, 1070,
1769].
Nomenclature FFA1 receptor FFA2 receptor FFA3 receptor FFA4 receptor GPR42
HGNC, UniProt FFAR1, O14842 FFAR2, O15552 FFAR3, O14843 FFAR4, Q5NUL3 GPR42, O15529
Endogenous agonists docosahexaenoic acid
(pEC50 5.4–6) [218, 833]
– – α-linolenic acid (pEC50 5.5)
[1727]
–
Agonists fasiglifam (pEC50 7.1)
[893, 1791, 1909]
– – – –
(Sub)family-selective agonists α-linolenic acid (pEC50
4.6–5.7) [218, 833, 998],
oleic acid (pEC50
3.9–5.7) [218, 833, 998],
myristic acid (pEC50
4.5–5.1) [218, 833, 998]
propanoic acid (pEC50 3–4.9)
[226, 1057, 1399, 1670],
acetic acid (pEC50 3.1–4.6) [226,
1057, 1399, 1670], butyric acid
(pEC50 2.9–4.6) [226, 1057,
1399, 1670],
trans-2-methylcrotonic acid
(pEC50 3.8) [1670],
1-methylcyclopropanecarboxylic acid
(pEC50 2.6) [1670]
propanoic acid (pEC50 3.9–5.7)
[226, 1057, 1670, 2063],
butyric acid (pEC50 3.8–4.9)
[226, 1057, 1670, 2063],
1-methylcyclopropanecarboxylic acid
(pEC50 3.9) [1670], acetic acid
(pEC50 2.8–3.9) [226, 1057,
1670, 2063]
myristic acid (pEC50 5.2)
[1996], oleic acid (pEC50 4.7)
[1996]
–
Selective agonists AMG-837 (pEC50 8.5)
[1110], TUG-770 (pEC50
8.2) [332], GW9508
(pEC50 7.3) [217],
linoleic acid (pEC50
4.4–5.7) [218, 833, 998]
compound 1 [PMID: 23589301]
(pEC50 7.1) [800] – Rat,
(S)-4-CMTB (pEC50 6.4) [801,
1070]
–
compound A [PMID 24997608]
(pEC50 7.6) [1428], TUG-891
(pEC50 7) [1727] – Unknown,
NCG21 (pEC50 5.9) [1829]
–
Searchable database: http://www.guidetopharmacology.org/index.jsp Free fatty acid receptors 5801
Full Contents of ConciseGuide: http://onlinelibrary.wiley.com/doi/10.1111/bph.13348/full
S.P.H. Alexander et al. The Concise Guide to PHARMACOLOGY 2015/16: G protein-coupled receptors. British Journal of Pharmacology (2015) 172, 5744–5869
(continued)
Nomenclature FFA1 receptor FFA2 receptor FFA3 receptor FFA4 receptor GPR42
Selective antagonists GW1100 (pIC50 6) [217] GLPG0974 (pIC50 8.1)
[1512], CATPB (pIC50 6.5)
[801]
– – –
Comments Antagonist GW1100 has been
shown to reduce [35S]GTPγS
binding in FFAR1-expressing
cells [1802]. GW1100 is also
an oxytocin receptor
antagonist [217]. TUG-770
and GW9508 are both
approximately 100 fold
selective for FFA1 over FFA4
[217, 332]. AMG-837 and
the related analogue AM6331
have been suggested to have
an allosteric mechanism of
action at FFA1, with respect
to the orthosteric fatty acid
binding site [1110, 2064].
– Beta-hydroxybutyrate has
been reported to antagonise
FFA3 responses to short chain
fatty acids [951]. A range of
FFA3 selective molecules with
agonist and antagonist
properties, but which bind at
sites distinct from the short
chain fatty acid binding site,
have recently been described
[799].
compound A [PMID 24997608]
exhibits more than 1000 fold
selectivity [1428], and TUG-891
50-1000 fold selectivity for FFA4
over FFA1 [1727], dependent on
the assay. NGC21 exhibits
approximately 15 fold selectivity
for FFA4 over FFA1 [1820].
–
Comments: Short (361 amino acids) and long (377 amino acids)
splice variants of human FFA4 have been reported [1318], which dif-
fer by a 16 amino acid insertion in intracellular loop 3, and exhibit
differences in intracellular signalling properties in recombinant sys-
tems [1996]. The long FFA4 splice variant has not been identified in
other primates or rodents to date [757, 1318].
GPR42 was originally described as a pseudogene within the family
(ENSFM00250000002583), but the recent discovery of several poly-
morphisms suggests that some versions of GPR42 may be functional
[1101]. GPR84 is a structurally-unrelated G protein-coupled recep-
tor which has been found to respond to medium chain fatty acids
[1981].
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GABAB receptors
G protein-coupled receptors! GABAB receptors
Overview: Functional GABAB receptors (nomenclature as
agreed by the NC-IUPHAR Subcommittee on GABAB re-
ceptors [194, 1507]) are formed from the heterodimerization of
two similar 7TM subunits termed GABAB1 and GABAB2 [194, 478,
1506, 1507, 1926]. GABAB receptors are widespread in the CNS and
regulate both pre- and postsynaptic activity. The GABAB1 subunit,
when expressed alone, binds both antagonists and agonists, but the
affinity of the latter is generally 10-100-fold less than for the native
receptor. The GABAB1 subunit when expressed alone is not trans-
ported to the cell membrane and is non-functional. However, Richer
et al.. (2008) report that GABAB1 alone can control ERK/MAPK
pathway activity [1585]. Co-expression of GABAB1 and GABAB2
subunits allows transport of GABAB1 to the cell surface and gen-
erates a functional receptor that can couple to signal transduction
pathways such as high-voltage-activated Ca2+ channels (Cav2.1,
Cav2.2), or inwardly rectifying potassium channels (Kir3) [144, 194,
195]. The GABAB2 subunit also determines the rate of internalisa-
tion of the dimeric GABAB receptor [693]. The GABAB1 subunit har-
bours the GABA (orthosteric)-binding site within an extracellular do-
main (ECD) venus flytrap module (VTM), whereas the GABAB2 sub-
unit mediates G protein-coupled signalling [194, 591, 592, 1506].
The two subunits interact by direct allosteric coupling [1313], such
that GABAB2 increases the affinity of GABAB1 for agonists and re-
ciprocally GABAB1 facilitates the coupling of GABAB2 to G proteins
[591, 1013, 1506]. GABAB1 and GABAB2 subunits assemble in a
1:1 stoichiometry by means of a coiled-coil interaction between α-
helices within their carboxy-termini that masks an endoplasmic retic-
ulum retention motif (RXRR) within the GABAB1 subunit but other
domains of the proteins also contribute to their heteromerization
[144, 243, 1506]. Recent evidence indicates that higher order as-
semblies of GABAB receptor comprising dimers of heterodimers oc-
cur in recombinant expression systems and in vivo and that such
complexes exhibit negative functional cooperativity between het-
erodimers [361, 1505]. Adding further complexity, KCTD (potas-
sium channel tetramerization proteins) 8, 12, 12b and 16 associate
as tetramers with the carboxy terminus of the GABAB2 subunit to im-
part altered signalling kinetics and agonist potency to the receptor
complex [102, 1680, 1914] and reviewed by [1508]. Four isoforms
of the human GABAB1 subunit have been cloned. The predominant
GABAB1(a) and GABAB1(b) isoforms, which are most prevalent in
neonatal and adult brain tissue respectively, differ in their ECD se-
quences as a result of the use of alternative transcription initiation
sites. GABAB1(a)-containing heterodimers localise to distal axons
and mediate inhibition of glutamate release in the CA3-CA1 termi-
nals, and GABA release onto the layer 5 pyramidal neurons, whereas
GABAB1(b)-containing receptors occur within dendritic spines and
mediate slow postsynaptic inhibition [1541, 1955]. Isoforms gener-
ated by alternative splicing are GABAB1(c) that differs in the ECD,
and GABAB1(e), which is a truncated protein that can heterodimer-
ize with the GABAB2 subunit but does not constitute a functional
receptor. Only the 1a and 1b variants are identified as compo-
nents of native receptors [194]. Additional GABAB1 subunit isoforms
have been described in rodents and humans [1065] and reviewed
by [144].
Nomenclature GABAB receptor
Subunits kcdt12b (Accessory protein), KCTD16 (Accessory protein), KCTD12 (Accessory protein), GABAB2, GABAB1, KCTD8 (Accessory protein)
Agonists CGP 44532 (pIC50 8.6) [551] – Rat, (-)-baclofen (pIC50 8.5) [551] – Rat, 3-APPA (pKi 5.2–7.2) [762], baclofen (pKi 4.3–6.2) [762, 2041], 3-APMPA (pKi 5.1) [2041]
Antagonists CGP 62349 (pKi 8.5–8.9) [762, 2041], CGP 55845 (pKi 7.8) [2041], SCH 50911 (pKi 5.5–6) [762, 2041], CGP 35348 (pKi 4.4) [2041], 2-hydroxy-saclofen (pIC50 4.1) [914] – Rat
Labelled ligands [3H]CGP 54626 (Antagonist) (pKi 9.1) [879] – Rat, [
3H]CGP 62349 (Antagonist) (pKd 9.1) [922] – Rat, [
125I]CGP 64213 (Antagonist) (pKd 9) [563] – Rat, [
125I]CGP 71872
(Antagonist) (pKd 9) [914] – Rat, [
3H](R)-(-)-baclofen (Agonist)
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Subunits
Nomenclature GABAB1 GABAB2
HGNC, UniProt GABBR1, Q9UBS5 GABBR2, O75899
Comments: Potencies of agonists and antagonists listed in the ta-
ble, quantified as IC50 values for the inhibition of [
3H]CGP27492
binding to rat cerebral cortex membranes, are from [194, 550, 551].
Radioligand KD values relate to binding to rat brain membranes.
CGP 71872 is a photoaffinity ligand for the GABAB1 subunit [122].
CGP27492 (3-APPA), CGP35024 (3-APMPA) and CGP 44532 act as
antagonists at humanGABAA 1 receptors, with potencies in the low
micromolar range [550]. In addition to the ligands listed in the table,
Ca2+ binds to the VTM of the GABAB1 subunit to act as a positive
allosteric modulator of GABA [563]. In cerebellar Purkinje neurones,
the interaction of Ca2+ with the GABAB receptor enhances the ac-
tivity of mGlu1, through functional cross-talk involving G-protein
Gβγ subunits [1590, 1837]. Synthetic positive allosteric modula-
tors with low, or no, intrinsic activity include CGP7930, GS39783,
BHF-177 and (+)-BHFF [9, 144, 150, 550]. The site of action of
CGP7930 and GS39783 appears to be on the heptahelical domain
of the GABAB2 subunit [455, 1506]. In the presence of CGP7930
or GS39783, CGP 35348 and 2-hydroxy-saclofen behave as partial
agonists [550]. A negative allosteric modulator of GABAB activity
has been reported [302]. Knock-out of the GABAB1 subunit in C57B
mice causes the development of severe tonic-clonic convulsions that
prove fatal within a month of birth, whereas GABAB1
 /  BALB/c
mice, although also displaying spontaneous epileptiform activity, are
viable. The phenotype of the latter animals additionally includes hy-
peralgesia, hyperlocomotion (in a novel, but not familiar, environ-
ment), hyperdopaminergia, memory impairment and behaviours in-
dicative of anxiety [482, 1932]. A similar phenotype has been found
for GABAB2
 /  BALB/c mice [582].
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Galanin receptors
G protein-coupled receptors! Galanin receptors
Overview: Galanin receptors (provisional nomenclature as recommended by NC-IUPHAR [530]) are activated by the endogenous peptides galanin (GAL, P22466) and galanin-like peptide (GALP,
Q9UBC7). Human galanin (GAL, P22466) is a 30 amino-acid non-amidated peptide [499]; in other species, it is 29 amino acids long and C-terminally amidated. Amino acids 1-14 of galanin are highly conserved in
mammals, birds, reptiles, amphibia and fish. Shorter peptide species (e.g. human galanin-1-19 [139] and porcine galanin-5-29 [1740]) and N-terminally extended forms (e.g. N-terminally seven and nine residue
elongated forms of porcine galanin [140, 1740]) have been reported.
Nomenclature GAL1 receptor GAL2 receptor GAL3 receptor
HGNC, UniProt GALR1, P47211 GALR2, O43603 GALR3, O60755
Rank order of potency galanin (GAL, P22466) > galanin-like peptide
(GALP, Q9UBC7) [1433]
galanin-like peptide (GALP, Q9UBC7)  galanin
(GAL, P22466) [1433]
galanin-like peptide (GALP, Q9UBC7) > galanin
(GAL, P22466) [1039]
Agonists – galanin(2-29) (rat/mouse) (pKi 7.2–8.7) [1457,
1982, 1983, 1984] – Rat
–
Selective agonists – [D-Trp2]galanin-(1-29) (pKi 8.1) [1765] – Rat –
Selective antagonists 2,3-dihydro-1,4-dithiin-1,1,4,4-tetroxide (pIC50
5.6) [1688]
M871 (pKi 7.9) [1780] SNAP 398299 (pKi 8.3) [987, 988, 1833],
SNAP 37889 (pKi 7.8–7.8) [987, 988, 1833]
Selective allosteric
modulators
– CYM2503 (Positive) (pEC50 9.2) [1147] – Rat –
Labelled ligands [125I][Tyr26]galanin (human) (Agonist) (pKd
10.3) [525], [125I][Tyr26]galanin (human)
(Agonist) (pKd 7.8) [525]
[125I][Tyr26]galanin (human) (Agonist) (pKd 9.2)
[1983] – Rat
[125I][Tyr26]galanin (pig) (Agonist) (pKd 8.6)
[187, 1766]
Comments – The CYM2503 PAM potentiates the anticonvulsant
activity of endogenous galanin in mouse seizure
models [1147].
–
Comments: galanin-(1-11) is a high-affinity agonist at GAL1/GAL2
(pKi 9), and galanin(2-11) is selective for GAL2 and GAL3 com-
pared with GAL1 [1146]. [
125I]-[Tyr26]galanin binds to all three
subtypes with Kd values generally reported to range from 0.05 to
1 nM, depending on the assay conditions used [525, 1752, 1765,
1766, 1983]. Porcine galanin-(3-29) does not bind to cloned GAL1,
GAL2 or GAL3 receptors, but a receptor that is functionally acti-
vated by porcine galanin-(3-29) has been reported in pituitary and
gastric smooth muscle cells [658, 2054]. Additional galanin recep-
tor subtypes are also suggested from studies with chimeric peptides
(e.g. M15, M35 and M40), which act as antagonists in functional
assays in the cardiovascular system [1924], spinal cord [2024], lo-
cus coeruleus, hippocampus [100] and hypothalamus [101, 1078],
but exhibit agonist activity at some peripheral sites [101, 658].
The chimeric peptides M15, M32, M35, M40 and C7 are ago-
nists at GAL1 receptors expressed endogenously in Bowes human
melanoma cells [1433], and at heterologously expressed recombi-
nant GAL1, GAL2 and GAL3 receptors [525, 1765, 1766]. Recent
studies have described the synthesis of a series of novel, systemically-
active, galanin analogues, with modest preferential binding at the
GAL2 receptor. Specific chemical modifications to the galanin back-
bone increased brain levels of these peptides after i.v. injection and
several of these peptides exerted a potent antidepressant-like effect
in mouse models of depression [1623].
Searchable database: http://www.guidetopharmacology.org/index.jsp Galanin receptors 5805
Full Contents of ConciseGuide: http://onlinelibrary.wiley.com/doi/10.1111/bph.13348/full
S.P.H. Alexander et al. The Concise Guide to PHARMACOLOGY 2015/16: G protein-coupled receptors. British Journal of Pharmacology (2015) 172, 5744–5869
Further Reading
Foord SM et al. (2005) International Union of Pharmacology. XLVI. G protein-coupled receptor list. Phar-
macol Rev 57: 279-288 [PMID:15914470]
Lang R et al. (2015) Physiology, signaling, and pharmacology of galanin peptides and receptors: three
decades of emerging diversity. Pharmacol. Rev. 67: 118-75 [PMID:25428932]
Lang R et al. (2011) The galanin peptide family in inflammation. Neuropeptides 45: 1-8 [PMID:21087790]
Lawrence C et al. (2011) Galanin-like peptide (GALP) is a hypothalamic regulator of energy homeostasis
and reproduction. Front Neuroendocrinol 32: 1-9 [PMID:20558195]
Webling KE et al. (2012) Galanin receptors and ligands. Front Endocrinol (Lausanne) 3: 146
[PMID:23233848]
Ghrelin receptor
G protein-coupled receptors! Ghrelin receptor
Overview: The ghrelin receptor (nomenclature as agreed by
the NC-IUPHAR Subcommittee for the Ghrelin receptor
[397]) is activated by a 28 amino-acid peptide originally isolated
from rat stomach, where it is cleaved from a 117 amino-acid precur-
sor (GHRL, Q9UBU3). The human gene encoding the precursor pep-
tide has 83% sequence homology to rat prepro-ghrelin, although
the mature peptides from rat and human differ by only two amino
acids [1222]. Alternative splicing results in the formation of a second
peptide, [des-Gln14]ghrelin (GHRL, Q9UBU3) with equipotent bio-
logical activity [783]. A unique post-translational modification (oc-
tanoylation of Ser3, catalysed by ghrelinO-acyltransferase (MBOAT4,
Q96T53) [2082] occurs in both peptides, essential for full activity in
binding to ghrelin receptors in the hypothalamus and pituitary, and
for the release of growth hormone from the pituitary [983]. Struc-
ture activity studies showed the first five N-terminal amino acids to
be the minimum required for binding [116], and receptor mutage-
nesis has indicated overlap of the ghrelin binding site with those for
small molecule agonists and allosteric modulators of ghrelin (GHRL,
Q9UBU3) function [776]. In cell systems, the ghrelin receptor is con-
stitutively active [777], but this is abolished by a naturally occurring
mutation (A204E) that results in decreased cell surface receptor ex-
pression and is associated with familial short stature [1458].
Nomenclature ghrelin receptor
HGNC, UniProt GHSR, Q92847
Rank order of potency ghrelin (GHRL, Q9UBU3) = [des-Gln14]ghrelin (GHRL, Q9UBU3) [115, 1222]
Selective antagonists GSK1614343 (pIC50 8.4) [1624], GSK1614343 (pKB 8) [1487] – Rat
Labelled ligands [125I][His9]ghrelin (human) (Agonist) (pKd 9.4) [912], [
125I][Tyr4]ghrelin (human) (Agonist) (pKd 9.4) [1339]
Comments: [des-octanoyl]ghrelin (GHRL, Q9UBU3) has been
shown to bind (as [125I]Tyr4-des-octanoyl-ghrelin) and have effects
in the cardiovascular system [115], which raises the possible exis-
tence of different receptor subtypes in peripheral tissues and the cen-
tral nervous system. A potent inverse agonist has been identified
([D-Arg1,D-Phe5,D-Trp7,9,Leu11]substance P, pD2 8.3; [774]).
Ulimorelin, described as a ghrelin receptor agonist (pKi 7.8 and pD2
7.5 at human recombinant ghrelin receptors), has been shown to
stimulate ghrelin receptor mediated food intake and gastric emp-
tying but not elicit release of growth hormone, or modify ghrelin
stimulated growth hormone release, thus pharmacologically discrim-
inating the orexigenic and gastrointestinal actions of ghrelin (GHRL,
Q9UBU3) from the release of growth hormone [538]. A number of
selective antagonists have been reported, including peptidomimetic
[1338] and non-peptide small molecules including GSK1614343
[1487, 1624].
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Glucagon receptor family
G protein-coupled receptors! Glucagon receptor family
Overview: The glucagon family of receptors (nomenclature as agreed by the NC-IUPHAR Subcommittee on the Glucagon receptor family [1234]) are activated by the endogenous peptide (27-
44 aa) hormonesglucagon (GCG, P01275), glucagon-like peptide 1 (GCG, P01275), glucagon-like peptide 2 (GCG, P01275), glucose-dependent insulinotropic polypeptide (also known as gastric inhibitory polypeptide
(GIP, P09681)), GHRH (GHRH, P01286) and secretin (SCT, P09683). One common precursor (GCG) generates glucagon (GCG, P01275), glucagon-like peptide 1 (GCG, P01275) and glucagon-like peptide 2 (GCG,
P01275) peptides [827].
Nomenclature GHRH receptor GIP receptor GLP-1 receptor
HGNC, UniProt GHRHR, Q02643 GIPR, P48546 GLP1R, P43220
Endogenous agonists – gastric inhibitory polypeptide (GIP, P09681)
(Selective) (pKd 8.7) [1961]
glucagon-like peptide 1-(7-36) amide (GCG, P01275)
(Selective) (pKi 9.2) [885], glucagon-like peptide 1-(7-37)
(GCG, P01275) (Selective) [425]
Agonists JI-38 [255], sermorelin – liraglutide (pEC50 10.2) [972], lixisenatide (pKi 8.9)
[2010], WB4-24 (pA2 4.9) [502]
Selective agonists BIM28011 [379], tesamorelin – exendin-4 (pIC50 9.2) [1290], exendin-4 (pKi 8.7–9)
[885], exendin-3 (P20394) [1564]
Selective antagonists JV-1-36 (pKi 10.1–10.4) [1662, 1947, 1948] – Rat,
JV-1-38 (pKi 10.1) [1662, 1947, 1948] – Rat
[Pro3]GIP [584] – Mouse exendin-(9-39) (pKi 8.1) [885], GLP-1-(9-36) (pIC50 6.9)
[1314] – Rat, T-0632 (pIC50 4.7) [1883]
Labelled ligands [125I]GHRH (human) (Agonist) (pKd 7.6) [192] – Rat [
125I]GIP (human) (Agonist) (pKd 8.6) [562] – Rat [
125I]GLP-1-(7-36)-amide (Agonist) (pKd 9.3) [885],
[125I]exendin-(9-39) (Antagonist) (pKd 8.3) [885],
[125I]GLP-1-(7-37) (human) (Agonist)
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Nomenclature GLP-2 receptor glucagon receptor secretin receptor
HGNC, UniProt GLP2R, O95838 GCGR, P47871 SCTR, P47872
Endogenous agonists glucagon-like peptide 2 (GCG, P01275)
(Selective) (pIC50 8.5) [1880]
glucagon (GCG, P01275) (Selective) (pEC50 9) [1515] secretin (SCT, P09683) (Selective) (pEC50 9.7) [329]
Agonists teduglutide [1248] – –
Selective antagonists – L-168,049 (pIC50 8.4) [269],
des-His1-[Glu9]glucagon-NH2 (pA2 7.2) [1928, 1929] –
Rat, NNC 92-1687 (pKi 5) [1170], BAY27-9955 [1496]
[(CH2NH)
4,5]secretin (pKi 5.3) [668]
Labelled ligands – [125I]glucagon (human, mouse, rat) (Agonist) [125I](Tyr10)secretin-27 (rat) (Agonist) [1925] – Rat
Comments: The glucagon receptor has been reported to interact with receptor activity modifying proteins (RAMPs), specifically RAMP2, in heterologous expression systems [333], although the physiological
significance of this has yet to be established.
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Glycoprotein hormone receptors
G protein-coupled receptors! Glycoprotein hormone receptors
Overview: Glycoprotein hormone receptors (provisional
nomenclature [530]) are activated by a non-covalent het-
erodimeric glycoprotein made up of a common α chain
(glycoprotein hormone common alpha subunit (CGA, P01215) CGA,
P01215), with a unique β chain that confers the biological speci-
ficity to FSH (CGA FSHB, P01215 P01225), LH (CGA LHB, P01215
P01229), hCG (CGA CGB, P01215 P01233) or TSH (CGA TSHB,
P01215 P01222). There is binding cross-reactivity across the en-
dogenous agonists for each of the glycoprotein hormone receptors.
The deglycosylated hormones appear to exhibit reduced efficacy at
these receptors [1626].
Nomenclature FSH receptor LH receptor TSH receptor
HGNC, UniProt FSHR, P23945 LHCGR, P22888 TSHR, P16473
Endogenous agonists – hCG (CGA CGB, P01215 P01233) (Selective) (pKd
9.9–11.8) [864, 1353], LH (CGA LHB, P01215 P01229)
(Selective) (pIC50 9.9–10.9) [864, 1353]
–
Antagonists FSH deglycosylated α/β (pKd 10) [527, 921] – –
Labelled ligands [125I]FSH (human) (Agonist) [125I]LH (Agonist),
[125I]chorionic gonadotropin (human) (Agonist)
[125I]TSH (human) (Agonist)
Comments Animal follitropins are less potent than the human
hormone as agonists at the human FSH receptor. Gain-
and loss-of-function mutations of the FSH receptor are
associated with human reproductive disorders [19, 109,
650, 1900]. The rat FSH receptor also stimulates
phosphoinositide turnover through an unidentified G
protein [1547].
Loss-of-function mutations of the LH receptor are
associated with Leydig cell hypoplasia and
gain-of-function mutations are associated with
male-limited gonadotropin-independent precocious
puberty (e.g. [1044, 1720]) and Leydig cell tumours
[1126].
Autoimmune antibodies that act as agonists of the TSH
receptor are found in patients with Graves’ disease (e.g.
[1558]). Mutants of the TSH receptor exhibiting
constitutive activity underlie hyperfunctioning thyroid
adenomas [1464] and congenital hyperthyroidism
[993]. TSH receptor loss-of-function mutations are
associated with TSH resistance [1824].
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Gonadotrophin-releasing hormone receptors
G protein-coupled receptors! Gonadotrophin-releasing hormone receptors
Overview: GnRH1 and GnRH2 receptors (provisonal nomen-
clature [530], also called Type I and Type II GnRH receptor, re-
spectively [1284]) have been cloned from numerous species, most
of which express two or three types of GnRH receptor [1283,
1284, 1741]. GnRH I (GNRH1, P01148) (p-Glu-His-Trp-Ser-Tyr-Gly-
Leu-Arg-Pro-Gly-NH2) is a hypothalamic decapeptide also known
as luteinizing hormone-releasing hormone, gonadoliberin, luliberin,
gonadorelin or simply as GnRH. It is a member of a family of sim-
ilar peptides found in many species [1283, 1284, 1741] includ-
ing GnRH II (GNRH2, O43555) (pGlu-His-Trp-Ser-His-Gly-Trp-Tyr-
Pro-Gly-NH2 (which is also known as chicken GnRH-II). Receptors
for three forms of GnRH exist in some species but only GnRH I and
GnRH II and their cognate receptors have been found in mammals
[1283, 1284, 1741]. GnRH1 receptors are expressed primarily by
pituitary gonadotrophs, and mediate central control of mammalian
reproduction. They are selectively activated by GnRH I and all lack
the COOH-terminal tails found in other GPCRs. GnRH2 receptors do
have COOH-terminal tails and (where tested) are selective for GnRH
II over GnRH I. GnRH2 receptors are expressed by some primates but
are thought not to be expressed by humans because the human GN-
RHR2 gene contains a frame shift and an internal stop codon [1325].
An alternative phylogenetic classification divides GnRH receptors into
three classes and includes both GnRH I-selective mammalian and
GnRH II-selective non-mammalian GnRH receptors as GnRH1 recep-
tors [1284]. A more recent phylogenetic classification groups ver-
tebrate GnRH receptors into five subfamilies [2028] and highlights
examples of gene loss through evolution, with humans notably re-
taining only one ancient gene. Although thousands of peptide ana-
logues of GnRH I have been synthesized and several (agonists and
antagonists) are used therapeutically [934], the potency of most of
these peptides at GnRH2 receptors is unknown.
Nomenclature GnRH1 receptor GnRH2 receptor
HGNC, UniProt GNRHR, P30968 GNRHR2, Q96P88
Rank order of potency GnRH I (GNRH1, P01148) > GnRH II (GNRH2, O43555) [1284] GnRH II (GNRH2, O43555) > GnRH I (GNRH1, P01148) (Monkey) [1282]
Endogenous agonists – GnRH II (GNRH2, O43555) (pIC50 9) [1282] – Monkey, GnRH I (GNRH1, P01148)
(pIC50 7.4) [1282] – Monkey
Selective agonists triptorelin (pKi 9.3–9.5) [112], leuprolide (pKi 8.5–9.1) [1807], buserelin,
goserelin, histrelin, nafarelin
–
Antagonists iturelix (pKi 9.5) [1591] –
Selective antagonists cetrorelix (pKi 9.3–10) [113, 114, 1807], abarelix (pKi 9.1–9.5) [1807], degarelix
(pKi 8.8) [1938], ganirelix
trptorelix-1 [1183] – Monkey
Labelled ligands [125I]buserelin (Agonist) (pKd 7.4) [1024] – Rat,
[125I]GnRH I (human, mouse, rat) (Agonist)
–
Comments – Probable transcribed pseudogene in man [1284].
Comments: GnRH1 and GnRH2 receptors couple primarily to
Gq/11 [653] but coupling to Gs and Gi is evident in some systems
[1009, 1024]. GnRH2 receptors may also mediate (heterotrimeric)
G protein-independent signalling to protein kinases [276]. There is
increasing evidence for expression of GnRH receptors on hormone-
dependent cancer cells where they can exert antiproliferative and/or
proapoptotic effects and mediate effects of cytotoxins conjugated to
GnRH analogues [309, 706, 1108, 1661]. In some human cancer
cell models GnRH II (GNRH2, O43555) is more potent than GnRH I
(GNRH1, P01148), implying mediation by GnRH2 receptors [657].
However, GnRH2 receptors that are expressed by some primates
are probably not expressed in humans because the human GNRHR2
gene contains a frame shift and internal stop codon [1325]. The
possibility remains that this gene generates GnRH2 receptor-related
proteins (other than the full-length receptor) that mediate responses
to GnRH II (GNRH2, O43555) (see [1372]). Alternatively, there is
evidence for multiple active GnRH receptor conformations [276,
277, 516, 1231, 1284] raising the possibility that GnRH1 receptor-
mediated proliferation inhibition in hormone-dependent cancer cells
is dependent upon different conformations (with different ligand
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specificity and ligand biased signalling) than effects on Gq/11 in pi-
tuitary cells [277, 1231]. Loss-of-function mutations in the GnRH1
receptor and deficiency of GnRH I (GNRH1, P01148) are associ-
ated with hypogonadotropic hypogonadism although some ‘loss of
function’ mutations may actually prevent trafficking of ‘functional’
GnRH1 receptors to the cell surface, as evidenced by recovery of
function by nonpeptide antagonists [1061]. Human GnRH1 recep-
tors appear to be poorly expressed at the cell surface because of fail-
ure to meet structural quality control criteria for endoplasmic reticu-
lum exit [517, 1061]. This may increase susceptibility to point muta-
tions that further impair trafficking and also increase effects of non-
peptide antagonists on GnRH1 receptor trafficking to the plasma
membrane [517, 1061]. GnRH receptor signalling may be depen-
dent upon receptor oligomerisation [363, 1007].
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GPR18, GPR55 and GPR119
G protein-coupled receptors! GPR18, GPR55 and GPR119
Overview: GPR18, GPR55 and GPR119 (provisional nomenclature), although showing little structural similarity to CB1 and CB2 cannabinoid receptors, respond to endogenous agents analogous to the
endogenous cannabinoid ligands, as well as some natural/synthetic cannabinoid receptor ligands [1494]. Although there are multiple reports to indicate that GPR18, GPR55 and GPR119 can be activated in vitro
by N-arachidonoylglycine, lysophosphatidylinositol and N-oleoylethanolamide, respectively, there is a lack of evidence for activation by these lipid messengers in vivo. As such, therefore, these receptors retain their
orphan status.
Nomenclature GPR18 GPR55 GPR119
HGNC, UniProt GPR18, Q14330 GPR55, Q9Y2T6 GPR119, Q8TDV5
Rank order of potency – – N-oleoylethanolamide, N-palmitoylethanolamine >
SEA (anandamide is ineffective) [1452]
Endogenous agonists N-arachidonoylglycine [980] lysophosphatidylinositol (pEC50 5.5–7.3) [738, 1435,
1785], 2-arachidonoylglycerolphosphoinositol
(Selective) [1437]
N-oleoylethanolamide (pEC50 5.4–6.3) [338, 1452,
1785], N-palmitoylethanolamine, SEA
Selective agonists – AM251 (pEC50 5–7.4) [738, 905, 1620] AS1269574 (pEC50 5.6) [2100], PSN632408 (pEC50
5.3) [1452], PSN375963 (pEC50 5.1) [1452]
Selective antagonists – CID16020046 (apparent pA2) (pA2 7.3) [906] –
Comments The pairing of N-arachidonoylglycine with GPR18
was not replicated in two studies based on arrestin
assays [1785, 2093]. See [396] for discussion.
See reviews [396] and [1732]. In addition to those shown above, further small
molecule agonists have been reported [687].
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Comments: GPR18 failed to respond to a variety of lipid-
derived agents in an in vitro screen [2093], but has been re-
ported to be activated by 19-tetrahydrocannabinol [1246].
GPR55 responds to AM251 and rimonabant at micromolar
concentrations, compared to their nanomolar affinity as CB1 re-
ceptor antagonists/inverse agonists [1494]. It has been reported
that lysophosphatidylinositol acts at other sites in addition to
GPR55 [2075]. N-Arachidonoylserine has been suggested to act
as a low efficacy agonist/antagonist at GPR18 in vitro [1244]. It
has also been suggested oleoyl-lysophosphatidylcholine acts, at
least in part, through GPR119 [1400]. Although PSN375963 and
PSN632408 produce GPR119-dependent responses in heterolo-
gous expression systems, comparison with N-oleoylethanolamide-
mediated responses suggests additional mechanisms of
action [1400].
Further Reading
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Davenport AP et al. (2013) International Union of Basic and Clinical Pharmacology. LXXXVIII. G protein-
coupled receptor list: recommendations for new pairings with cognate ligands. Pharmacol. Rev. 65:
967-86 [PMID:23686350]
Hansen HS et al. (2012) GPR119 as a fat sensor. Trends Pharmacol. Sci. 33: 374-81 [PMID:22560300]
McHugh D. (2012) GPR18 in Microglia: implications for the CNS and endocannabinoid system signalling.
Br J Pharmacol [PMID:22563843]
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receptors. Life Sci. 92: 453-7 [PMID:22820167]
Histamine receptors
G protein-coupled receptors! Histamine receptors
Overview: Histamine receptors (nomenclature as agreed by the NC-IUPHAR Subcommittee on Histamine Receptors [754, 1459]) are activated by the endogenous ligand histamine. Marked
species differences exist between histamine receptor orthologues [754].
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Nomenclature H1 receptor H2 receptor H3 receptor H4 receptor
HGNC, UniProt HRH1, P35367 HRH2, P25021 HRH3, Q9Y5N1 HRH4, Q9H3N8
Selective agonists methylhistaprodifen (pKi 6.4) [1695],
histaprodifen (pKi 5.7) [1107]
amthamine (pEC50 6.4) [1003] immethridine (pKi 9.1) [963],
methimepip (pKi 9) [962], MK-0249
(Inverse agonist) (pKi 8.8) [1354]
clobenpropit (Partial agonist) (pKi
7.4–8.3) [490, 1107, 1122, 1123,
1335], 4-methylhistamine (pKi
7.3–8.2) [586, 1107], VUF 8430
(pKi 7.5) [1106]
Antagonists cyproheptadine (pKi 10.2) [1298],
promethazine (pKi 9.6) [601], pyrilamine
(Inverse agonist) (pKi 8.7–9) [184, 1563],
hydroxyzine (pKi 8.7) [608], ketotifen (pKi
8.6) [1014], cetirizine (Inverse agonist)
(pKi 8.2) [1298], diphenhydramine (pKi
7.9) [184]
– iodophenpropit (pKi 8.2–8.7) [2022,
2051], thioperamide (pKi 7.1–7.7)
[355, 489, 490, 1104, 1145, 2022,
2051]
–
Selective
antagonists
clemastine (pKi 10.3) [68], desloratadine
(pKi 9) [1090], triprolidine (pKi 8.5–9)
[184, 1298], azelastine (pKi 8.9) [1535],
astemizole (pKi 8.5) [1480], cyclizine (pKi
8.4) [68], chlorpheniramine (pKi 8.1)
[1535], fexofenadine (pKi 7.6) [64],
loratadine (pKi 7.4) [850], terfenadine
(pKi 7.4) [64], tripelennamine (pIC50 7.4)
[635]
tiotidine (pKi 7.5) [145] – Rat,
ranitidine (pKi 7.1) [1086],
cimetidine (pKi 6.8) [263]
clobenpropit (pKi 8.4–9.4) [355, 490,
1104, 1122, 1145, 2022, 2051],
A331440 (pKi 8.5) [688]
JNJ 7777120 (pKi 7.8–8.3) [1107,
1771, 1881]
Labelled ligands [3H]pyrilamine (Antagonist, Inverse
agonist) (pKd 8.4–9.1) [403, 1298, 1675,
1695], [11C]doxepin (Antagonist) (pKd 9)
[830], [11C]pyrilamine (Antagonist,
Inverse agonist)
[125I]iodoaminopotentidine
(Antagonist) (pKd 8.7) [1029] –
Rat, [3H]tiotidine (Antagonist)
(pKd 7.7–8.7) [1310]
[123I]iodoproxyfan (Antagonist) (pKd
10.2) [1104], [125I]iodophenpropit
(Antagonist) (pKd 9.2) [849] – Rat,
[3H](R)-α-methylhistamine (Agonist)
(pKd 9.2) [1122],
N-[3H]α-methylhistamine (Agonist)
(pKd 9) [301] – Mouse
[3H]JNJ 7777120 (Antagonist)
(pKd 8.4) [1881]
Comments: histaprodifen and methylhistaprodifen are reduced ef-
ficacy agonists. The H4 receptor appears to exhibit broadly simi-
lar pharmacology to the H3 receptor for imidazole-containing lig-
ands, although (R)-α-methylhistamine and N-α-methylhistamine are
less potent, while clobenpropit acts as a reduced efficacy agonist
at the H4 receptor and an antagonist at the H3 receptor [1122,
1360, 1390, 1422, 2132]. Moreover, 4-methylhistamine is identi-
fied as a high affinity, full agonist for the human H4 receptor [1107].
[3H]histamine has been used to label the H4 receptor in heterolo-
gous expression systems.
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Hydroxycarboxylic acid receptors
G protein-coupled receptors! Hydroxycarboxylic acid receptors
Overview: The hydroxycarboxylic acid family of receptors (ENSFM00500000271913, nomenclature as agreed by the NC-IUPHAR Subcommittee on Hydroxycarboxylic acid receptors [396,
1424]) respond to organic acids, including the endogenous hydroxy carboxylic acids 3-hydroxy butyric acid and L-lactic acid, as well as the lipid lowering agents nicotinic acid (niacin), acipimox and acifran [1774,
1913, 2036]. These receptors were provisionally described as nicotinic acid receptors, although nicotinic acid shows submicromolar potency at HCA2 receptors only and is unlikely to be the natural ligand [1913,
2036].
Nomenclature HCA1 receptor HCA2 receptor HCA3 receptor
HGNC, UniProt HCAR1, Q9BXC0 HCAR2, Q8TDS4 HCAR3, P49019
Endogenous agonists L-lactic acid (Selective) (pEC50 1.3–2.9) [14, 256,
1124, 1785]
β-D-hydroxybutyric acid (pEC50 3.1) [1838] 3-hydroxyoctanoic acid (pEC50 5.1) [13]
Agonists compound 2 [PMID: 24486398] (pEC50 7.2) [1630],
3,5-dihydroxybenzoic acid (pEC50 3.7) [1121]
SCH 900271 (pEC50 8.7) [1454], GSK256073 (pEC50 7.5)
[1790]
–
Selective agonists – MK 6892 (pEC50 7.8) [1719], MK 1903 (pEC50 7.6) [163],
nicotinic acid (pEC50 6–7.2) [1774, 1913, 2036], acipimox
(pEC50 5.2–5.6) [1774, 2036], monomethylfumarate (pEC50
5) [1859]
compound 6o [PMID: 19524438] (pEC50 8.5)
[1751], IBC 293 (pEC50 6.4) [1697]
Labelled ligands – [3H]nicotinic acid (Agonist) (pKd 7–7.3) [1774, 1913, 2036] –
Comments: Further closely-related GPCRs include the 5-oxoeicosanoid receptor (OXER1, Q8TDS5) and GPR31 (O00270).
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Kisspeptin receptor
G protein-coupled receptors! Kisspeptin receptor
Overview: The kisspeptin receptor (nomenclature as agreed by the NC-IUPHAR Subcommittee on the kisspeptin receptor [958]), like neuropeptide FF (NPFF), prolactin-releasing peptide
(PrP) and QRFP receptors (provisional nomenclature) responds to endogenous peptides with an arginine-phenylalanine-amide (RFamide) motif. Kisspeptin-54 (KISS1, Q15726) (KP54, originally named metastin),
kisspeptin-13 (KISS1, Q15726) (KP13) and kisspeptin-10 (KISS1) (KP10) are biologically-active peptides cleaved from the KISS1 (Q15726) gene product.
Nomenclature kisspeptin receptor
HGNC, UniProt KISS1R, Q969F8
Endogenous agonists kisspeptin-10 (KISS1) (Selective) (pKi 8.6–10.4) [996, 1434], kisspeptin-54 (KISS1, Q15726) (Selective) (pKi 8.8–9.5) [996, 1434], kisspeptin-14 (KISS1, Q15726) (pKi 8.8)
[996], kisspeptin-13 (KISS1, Q15726) (Selective) (pKi 8.4) [996]
Selective agonists 4-fluorobenzoyl-FGLRW-NH2 (pEC50 9.2) [1894], [dY]1KP-10 (pIC50 8.4) [385] – Mouse
Selective antagonists peptide 234 [1600]
Labelled ligands [125I]Tyr45-kisspeptin-15 (Agonist) (pKd 10) [1434], [
125I]kisspeptin-13 (human) (Agonist) (pKd 9.7) [1252], [
125I]kisspeptin-10 (human) (Agonist) (pKd 8.7) [996],
[125I]kisspeptin-14 (human) (Agonist) [1252]
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Leukotriene receptors
G protein-coupled receptors! Leukotriene receptors
Overview: Leukotriene receptors (nomenclature as agreed
by the NC-IUPHAR subcommittee on Leukotriene Re-
ceptors [249, 250]) is activated by the endogenous ligands
leukotrienes (LT), synthesized from lipoxygenase metabolism of
arachidonic acid.
The human BLT1 receptor is the high affinity LTB4 receptor whereas
the BLT2 receptor in addition to being a low-affinity LTB4 re-
ceptor also binds several other lipoxygenase-products, such as
12S-HETE, 12S-HPETE, 15S-HETE, and the thromboxane synthase
product 12-hydroxyheptadecatrienoic acid. The BLT receptors me-
diate chemotaxis and immunomodulation in several leukocyte pop-
ulations and are in addition expressed on non-myeloid cells, such
as vascular smooth muscle and endothelial cells. In addition to BLT
receptors, LTB4 has been reported to bind to the peroxisome pro-
liferator activated receptor (PPAR) α [1112] and the vanilloid TRPV1
ligand-gated nonselective cation channel [1245].
The receptors for the cysteinyl-leukotrienes (i.e. LTC4, LTD4 and
LTE4) are termed CysLT1 and CysLT2 and exhibit distinct expression
patterns in human tissues, mediating for example smoothmuscle cell
contraction, regulation of vascular permeability, and leukocyte acti-
vation. There is also evidence in the literature for additional CysLT
receptor subtypes, derived from functional in vitro studies, radioli-
gand binding and in mice lacking both CysLT1 and CysLT2 recep-
tors [250]. Cysteinyl-leukotrienes have also been suggested to signal
through the P2Y12 receptor [542, 1407, 1466], GPR17 [344] and
GPR99 [900].
Nomenclature BLT1 receptor BLT2 receptor CysLT1 receptor CysLT2 receptor
HGNC, UniProt LTB4R, Q15722 LTB4R2, Q9NPC1 CYSLTR1, Q9Y271 CYSLTR2, Q9NS75
Rank order of potency LTB4 >20-hydroxy-LTB4
12R-HETE [2096] 12-hydroxyheptadecatrienoic acid
> LTB4 > 12S-HETE = 12S-HPETE
> 15S-HETE > 12R-HETE >
20-hydroxy-LTB4 [1442, 2096]
LTD4 > LTC4 > LTE4 [1157, 1643] LTC4  LTD4  LTE4 [733,
1411, 1847]
Endogenous agonists – 12S-HETE (Partial agonist) (pEC50
<7.5) [2096]
– –
Antagonists – – ICI198615 (- 8.4–8.6) BAYu9773 (against LTC4 and
LTD4 induced contraction in
smooth muscle preparation) (pA2
6.8–7.7) [1912] – Rat
Selective antagonists BIIL 260 (pKi 8.8) [152, 457],
CP105696 (pIC50 8.1) [1735],
U75302 (pKi 6.4) [172]
LY255283 (pIC50 6–7.1) [744,
2096]
zafirlukast (against [3H]LTD4 in COS-7 or HEK-293
cells) (pIC50 8.6–8.7) [1157, 1643], SR2640 (pKi
8.7), montelukast (against [3H]LTD4 in COS-7 or
HEK-293 cells) (pIC50 8.3–8.6) [1157, 1643],
sulukast (pKi 8.3), pobilukast (against [
3H]LTD4 in
HEK-293) (pIC50 7.5) [1643]
BayCysLT2 (against 30-300nM
LTD4 β-arrestin assay in C2C12
myofibroblasts) (pIC50 6.6–7.3)
[1391]
Labelled ligands [3H]LTB4 (Agonist) (pKd 9.8)
[2095], [3H]CGS23131
(Antagonist) (pKd 7.9) [836]
[3H]LTB4 (pKd 7.6–9.7) [
3H]LTD4 (Agonist) (pKd 8–10.7), [
3H]ICI-198615
(Antagonist) (pKd 10.6) [1608]
[3H]LTD4 (Agonist) (pKd
7.3–9.4) [733]
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Nomenclature FPR2/ALX OXE receptor
HGNC, UniProt FPR2, P25090 OXER1, Q8TDS5
Rank order of potency LXA4=aspirin triggered lipoxin A4
=ATLa2>LTC4=LTD415-deoxy-LXA4
fMet-Leu-Phe [352, 519, 521, 651, 1846]
5-oxo-ETE, 5-oxo-C20:3, 5-oxo-ODE > 5-oxo-15-HETE
> 5S-HPETE > 5S-HETE [784, 877, 1472]
Endogenous agonists LXA4 (Selective) (pEC50 12) [1006], resolvin D1
(Selective) (pEC50 11.9) [1006],
aspirin triggered lipoxin A4 (Selective)
5-oxo-ETE (Selective) (pEC50 8.3–8.5) [638, 1417,
1472, 1525, 1681]
Selective agonists ATLa2 [662] –
Endogenous antagonists – 5-oxo-12-HETE (Selective) (pIC50 6.3) [1524]
Antagonists – –
Selective antagonists – –
Labelled ligands [3H]LXA4 (Agonist) (pKd 9.2–9.3) [519, 520] [
3H]5-oxo-ETE (Agonist) (pKd 8.4) [1417]
Comments The agonist activity of the lipid mediators described has
been questioned [697, 1513], which may derive from
batch-to-batch differences, partial agonism or biased
agonism. Recent results from Cooray et al. (2013) [365]
have addressed this issue and the role of homodimers
and heterodimers in the intracellular signaling .
–
Comments: The FPR2/ALX receptor (nomenclature as agreed
by the NC-IUPHAR subcommittee on Leukotriene and
Lipoxin Receptors [250]) is activated by the endogenous lipid-
derived, anti-inflammatory ligands lipoxin A4 (LXA4) and 15-epi-
LXA4 (aspirin triggered lipoxin A4, ATL). The FPR2/ALX receptor also
interacts with endogenous peptide and protein ligands, such as
MHC binding peptide [315] as well as annexin I (ANXA1, P04083)
(ANXA1) and its N-terminal peptides [365, 1491]. In addition, a
soluble hydrolytic product of protease action on the urokinase-type
plasminogen activator receptor has been reported to activate the
FPR2/ALX receptor [1572]. Furthermore, FPR2/ALX has been sug-
gested to act as a receptor mediating the proinflammatory actions of
the acute-phase reactant, serum amyloid A [1772, 1809]. A receptor
selective for LXB4 has been suggested from functional studies [53,
1168, 1596]. Note that the data for FPR2/ALX are also reproduced
on the Formylpeptide receptor pages.
Oxoeicosanoid receptors (OXE, nomenclature agreed by the
NC-IUPHAR subcommittee on Oxoeicosanoid Receptors
[214]) are activated by endogenous chemotactic eicosanoid ligands
oxidised at the C-5 position, with 5-oxo-ETE the most potent ag-
onist identified for this receptor. Initial characterization of the het-
erologously expressed OXE receptor suggested that polyunsaturated
fatty acids, such as docosahexaenoic acid and EPA, acted as receptor
antagonists [784]
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Lysophospholipid (LPA) receptors
G protein-coupled receptors! Lysophospholipid (LPA) receptors
Overview: Lysophosphatidic acid (LPA) receptors (nomencla-
ture as agreed by the NC-IUPHAR Subcommittee on
Lysophospholipid Receptors [396, 936]) are activated by the
endogenous phospholipid metabolite LPA. The first receptor, LPA1,
was identified as ventricular zone gene-1 (vzg-1), leading to deor-
phanisation of members of the endothelial differentiation gene (edg)
family as other LPA receptors along with sphingosine 1-phosphate
(S1P) receptors. Additional LPA receptor GPCRs were later identi-
fied. Gene names have been codified as LPAR1, etc. to reflect the
receptor function of proteins. The crystal structure of LPA1 was re-
cently solved and demonstrates ligand access characteristics that al-
lows for extracellular LPA binding [331]; these studies have also im-
plicated cross-talk with endocannabinoids via phosphorylated inter-
mediates that can activate this receptor. The identified receptors can
account for most, although not all, LPA-induced phenomena in the
literature, indicating that a majority of LPA-dependent phenomena
are receptor-mediated. Radioligand binding has been conducted in
heterologous expression systems using [3H]LPA (e.g. [556]). In na-
tive systems, analysis of binding data is complicated by metabolism
and high levels of nonspecific binding, and therefore the relation-
ship between recombinant and endogenously expressed receptors
is unclear. Targeted deletion of LPA receptors has clarified signalling
pathways and identified physiological and pathophysiological roles.
Independent validation by multiple groups has been reported in the
peer-reviewed literature for all six LPA receptors described in the ta-
bles, including further validation using a distinct read-out via a novel
TGFα “shedding” assay [825]. LPA has also been described as an ag-
onist at other orphan GPCRs (PSP24, GPR87 and GPR35), as well as
at the nuclear hormone PPARγ receptors [1247, 1743], although the
physiological significance of these observations remain unclear.
Nomenclature LPA1 receptor LPA2 receptor LPA3 receptor
HGNC, UniProt LPAR1, Q92633 LPAR2, Q9HBW0 LPAR3, Q9UBY5
Selective agonists – dodecylphosphate (pEC50 6.2) [1958],
decyl dihydrogen phosphate (pEC50 5.4) [1958],
GRI977143 (pEC50 4.5) [959]
OMPT (pEC50 7.2) [709]
Selective antagonists AM966 (pIC50 6.7–7.8) [1832] – dioctanoylglycerol pyrophosphate (pKi 5.5–7) [522, 1432]
Comments – Virtual screening experiments have shown H2L5186303 to
be a potent antagonist of LPA2 [510]. dodecylphosphate is
also an antagonist at LPA3 receptors [1958].
–
Nomenclature LPA4 receptor LPA5 receptor LPA6 receptor
HGNC, UniProt LPAR4, Q99677 LPAR5, Q9H1C0 LPAR6, P43657
Comments: Ki16425 [1432], VPC12249 [735] and VPC32179 [729] have antagonist activity at LPA1 and LPA3 receptors. There is growing evidence for in vivo efficacy of these chemical antagonists in several
disorders, including fetal hydrocephalus [2107], lung fibrosis [1429], and systemic sclerosis [1429].
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Lysophospholipid (S1P) receptors
G protein-coupled receptors! Lysophospholipid (S1P) receptors
Overview: Sphingosine 1-phosphate (S1P) receptors (nomen-
clature as agreed by the NC-IUPHAR Subcommittee
on Lysophospholipid receptors [936]) are activated by the
endogenous lipid sphingosine 1-phosphate (S1P) and with lower
apparent affinity, sphingosylphosphorylcholine (SPC). Originally
cloned as orphan members of the endothelial differentiation gene
(edg) family, deorphanisation as lysophospholipid receptors for S1P
was based on sequence homology to LPA receptors. Current gene
names have been codified as S1PR1, etc. to reflect the receptor func-
tion of these proteins. Most cellular phenomena ascribed to S1P can
be explained by receptor-mediated mechanisms; S1P has also been
described to act at intracellular sites [1841], and awaits precise def-
inition. Previously-proposed SPC (or lysophophosphatidylcholine)
receptors- G2A, TDAG8, OGR1 and GPR4 - continue to lack confir-
mation of these roles [396]. The relationship between recombinant
and endogenously expressed receptors is unclear. Radioligand bind-
ing has been conducted in heterologous expression systems using
[32P]S1P (e.g [1438]). In native systems, analysis of binding data is
complicated by metabolism and high levels of nonspecific binding.
Targeted deletion of several S1P receptors and key enzymes involved
in S1P biosynthesis or degradation has clarified signalling pathways
and physiological roles. A crystal structure of an S1P1-T4 fusion pro-
tein has been described [698].
The S1P receptor modulator, fingolimod (FTY720, Gilenya), has re-
ceived world-wide approval as the first oral therapy for relapsing
forms of multiple sclerosis. This drug has a novel mechanism of ac-
tion involving modulation of S1P receptors in both the immune and
nervous systems [325, 356, 654], although the precise nature of its
interaction requires clarification.
Nomenclature S1P1 receptor S1P2 receptor S1P3 receptor S1P4 receptor S1P5 receptor
HGNC, UniProt S1PR1, P21453 S1PR2, O95136 S1PR3, Q99500 S1PR4, O95977 S1PR5, Q9H228
Rank order of
potency
sphingosine 1-phosphate >
dihydrosphingosine-1-phosphate
> sphingosylphosphorylcholine
[45, 1438]
sphingosine 1-phosphate >
dihydrosphingosine-1-phosphate
> sphingosylphosphorylcholine
[45, 1438]
sphingosine 1-phosphate >
dihydrosphingosine-1-phosphate
> sphingosylphosphorylcholine
[1438]
sphingosine 1-phosphate >
dihydrosphingosine-1-phosphate
> sphingosylphosphorylcholine
[1936]
sphingosine 1-phosphate >
dihydrosphingosine-1-phosphate
> sphingosylphosphorylcholine
[821]
Agonists SEW2871 (pKi 5.5–7.7) [1640] – – – –
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(continued)
Nomenclature S1P1 receptor S1P2 receptor S1P3 receptor S1P4 receptor S1P5 receptor
Antagonists VPC44116 (pKi 8.5) [533],
VPC23019 (pKi 7.9) [400]
– VPC44116 (pKi 6.5) [533],
VPC23019 (pKi 5.9) [400]
– –
Selective antagonists W146 (pKi 7.1) [1641] JTE-013 (pIC50 7.8) [1447] – – –
Selective agonists AUY954 (pEC50 8.9) [1456] – – – –
Comments: The approved immunomodulator drug fingolimod can be phosphorylated in vivo [31] to generate a relatively potent agonist with activity at S1P1, S1P3, S1P4 and S1P5 receptors [215, 1198],
although its biological activity appears to involve an element of functional antagonism [339, 356, 1405].
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Melanin-concentrating hormone receptors
G protein-coupled receptors!Melanin-concentrating hormone receptors
Overview: Melanin-concentrating hormone (MCH) receptors (provisional nomenclature as recommended by NC-IUPHAR [530]) are activated by an endogenous nonadecameric cyclic peptide
identical in humans and rats (DFDMLRCMLGRVYRPCWQV) generated from a precursor (PMCH, P20382), which also produces neuropeptide EI (PMCH, P20382) and neuropeptide GE (PMCH, P20382).
Nomenclature MCH1 receptor MCH2 receptor
HGNC, UniProt MCHR1, Q99705 MCHR2, Q969V1
Rank order of potency melanin-concentrating hormone (PMCH, P20382) >MCH (salmon) melanin-concentrating hormone (PMCH, P20382) = MCH (salmon) [753]
Selective antagonists GW803430 (pIC50 9.3) [745], SNAP-7941 (pA2 9.2) [186], T-226296 (pIC50
8.3) [1853], ATC0175 (pIC50 7.9–8.1) [283]
–
Labelled ligands [125I]S36057 (Antagonist) (pKd 9.2–9.5) [66], [
125I][Phe13,Tyr19]MCH
(Agonist) (pKd 9.2) [242], [
3H]MCH (human, mouse, rat) (Agonist) [242]
–
Comments: The MCH2 receptor appears to be a non-functional pseudogene in rodents [1857].
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Melanocortin receptors
G protein-coupled receptors!Melanocortin receptors
Overview: Melanocortin receptors (provisional nomenclature as recommended by NC-IUPHAR [530]) are activated by members of the melanocortin family (α-MSH (POMC, P01189), β-MSH (POMC,
P01189) and γ-MSH (POMC, P01189) forms; -Æ form is not found in mammals) and adrenocorticotrophin (ACTH (POMC, P01189)). Endogenous antagonists include agouti (ASIP, P42127) and agouti-related protein
(AGRP, O00253).
Nomenclature MC1 receptor MC2 receptor MC3 receptor MC4 receptor MC5 receptor
HGNC, UniProt MC1R, Q01726 MC2R, Q01718 MC3R, P41968 MC4R, P32245 MC5R, P33032
Rank order of
potency
α-MSH (POMC, P01189) >
β-MSH (POMC, P01189) >
ACTH (POMC, P01189),
γ-MSH (POMC, P01189)
ACTH (POMC, P01189) γ-MSH (POMC, P01189), β-MSH
(POMC, P01189) > ACTH (POMC,
P01189), α-MSH (POMC, P01189)
β-MSH (POMC, P01189) >
α-MSH (POMC, P01189), ACTH
(POMC, P01189) > γ-MSH
(POMC, P01189)
α-MSH (POMC, P01189) >
β-MSH (POMC, P01189) >
ACTH (POMC, P01189) >
γ-MSH (POMC, P01189)
Selective agonists –
corticotropin zinc
hydroxide [D-Trp8]γ-MSH (pIC50 8.2) [645] THIQ (pIC50 8.9) [1690] –
Antagonists – – PG-106 (pIC50 6.7) [646] – –
Selective
antagonists
– – – MBP10 (pIC50 10) [117], HS014
(pKi 8.5) [1667]
–
Labelled ligands [125I]NDP-MSH (Agonist)
(pKd 9.5) [991]
[125I]ACTH-(1-24)
(Agonist)
[125I]NDP-MSH (Agonist) (pKd
9.7) [991], [125I]SHU9119
(Antagonist) [1392]
[125I]SHU9119 (Antagonist)
(pKd 9.2) [1392],
[125I]NDP-MSH (Agonist) (pKd
8.4–8.9) [991, 1665]
[125I]NDP-MSH (Agonist)
(pKd 8.6) [991]
Comments: Polymorphisms of the MC1 receptor have been linked to variations in skin pigmentation. Defects of the MC2 receptor underlie familial glucocorticoid deficiency. Polymorphisms of the MC4 receptor
have been linked to obesity [282, 505].
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Melatonin receptors
G protein-coupled receptors!Melatonin receptors
Overview: Melatonin receptors (nomenclature as agreed by the NC-IUPHAR Subcommittee onMelatonin Receptors [446]) are activated by the endogenous ligandsmelatonin andN-acetylserotonin.
Nomenclature MT1 receptor MT2 receptor
HGNC, UniProt MTNR1A, P48039 MTNR1B, P49286
Endogenous agonists melatonin (pKi 9.1–9.7) [67, 445, 447] melatonin (pKi 9.4–9.8) [67, 445, 447]
Agonists ramelteon (pKi 10.9) [909], agomelatine (pKi 10–10.4) [67, 132] agomelatine (pKi 9.9–10.5) [67, 132], ramelteon (pKi 10) [909, 1565]
Selective agonists – IIK7 (pKi 10.3) [506, 1814], 5-methoxy-luzindole (Partial agonist) (pKi 9.6) [447]
Selective antagonists – 4P-PDOT (pKi 8.8–9.4) [67, 447, 448], K185 (pKi 9.3) [506, 1814], DH97 (pKi 8) [1865]
Labelled ligands [125I]SD6 (Agonist) (pKd 10.9) [1074], 2-[
125I]melatonin (Agonist) (pKd
9.9–10.7) [67, 447], [3H]melatonin (Agonist) (pKd 9.4–9.9) [230]
[125I]SD6 (Agonist) (pKd 10.2) [1074], 2-[
125I]melatonin (Agonist) (pKd 9.7–10) [67, 447],
[125I]DIV880 (Agonist, Partial agonist) (pKd 9.7) [1074], [
3H]melatonin (Agonist) (pKd
9–9.6) [230]
Comments: melatonin, 2-iodo-melatonin, agomelatine,
GR 196429, LY 156735 and ramelteon [909] are nonselective ago-
nists for MT1 and MT2 receptors. (-)-AMMTC displays an ˜400-fold
greater agonist potency than (+)-AMMTC at rat MT1 receptors (see
AMMTC for structure) [1888]. Luzindole is an MT1/MT2 melatonin
receptor-selective competitive antagonist with some selectivity for
the MT2 receptor [448]. MT1/MT2 heterodimers present different
pharmacological profiles from MT1 and MT2 receptors [72].
The MT3 binding site of hamster brain and peripheral tissues such
as kidney and testis, also termed the ML2 receptor, binds selectively
2-iodo-[125I]5MCA-NAT [1302]. Pharmacological investigations of
MT3 binding sites have primarily been conducted in hamster tis-
sues. At this site, N-acetylserotonin [467, 1149, 1302, 1516] and
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5MCA-NAT [1516] appear to function as agonists, while prazosin
[1149] functions as an antagonist. The MT3 binding site of ham-
ster kidney was also identified as the hamster homologue of human
quinone reductase 2 (NQO2, P16083 [1408, 1409]). TheMT3 bind-
ing site activated by 5MCA-NAT in eye ciliary body is positively cou-
pled to adenylyl cyclase and regulates chloride secretion [802]. Xeno-
pusmelanophores and chick brain express a distinct receptor (x420,
P49219; c346, P49288, initially termed Mel1C) coupled to the Gi/o
family of G proteins, for which GPR50 has recently been suggested
to be a mammalian counterpart [451] although melatonin does not
bind to GPR50 receptors.
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Metabotropic glutamate receptors
G protein-coupled receptors!Metabotropic glutamate receptors
Overview: Metabotropic glutamate (mGlu) receptors (nomen-
clature as agreed by the NC-IUPHAR Subcommittee on
Metabotropic Glutamate Receptors [1672]) are activated by
the endogenous ligands L-glutamic acid, L-serine-O-phosphate, N-
acetylaspartylglutamate (NAAG) and L-cysteine sulphinic acid. Ex-
amples of agonists selective for mGlu receptors compared with
ionotropic glutamate receptors are (1S,3R)-ACPD and L-CCG-I,
which show limited selectivity for Group-II receptors. An example of
an antagonist selective for mGlu receptors is LY341495, which blocks
mGlu2 and mGlu3 at low nanomolar concentrations, mGlu8 at high
nanomolar concentrations, and mGlu4, mGlu5, and mGlu7 in the
micromolar range [955]. Three groups of native receptors are distin-
guishable on the bases of similarities of agonist pharmacology, pri-
mary sequence and G protein coupling to effector: Group-I (mGlu1
and mGlu5), Group-II (mGlu2 and mGlu3) and Group-III (mGlu4,
mGlu6, mGlu7 and mGlu8) (see Further reading). Group-I mGlu
receptors may be activated by 3,5-DHPG and (S)-3HPG [198] and
antagonized by (S)-hexylhomoibotenic acid [1171]. Group-II mGlu
receptors may be activated by LY389795 [1311], LY379268 [1311],
eglumegad [1673, 2050], DCG-IV and (2R,3R)-APDC [1674], and an-
tagonised by eGlu (4.3, [848] and LY307452 [491, 2009]. Group-III
mGlu receptors may be activated by L-AP4 and (R,S)-4-PPG [579].
In addition to orthosteric ligands that directly interact with the glu-
tamate recognition site directly, allosteric modulators have been de-
scribed. Negative allosteric modulators are listed separately. The
positive allosteric modulators most often act as ‘potentiators’ of an
orthosteric agonist response, without significantly activating the re-
ceptor in the absence of agonist.
Although mGlu receptors have been thought to only form homod-
imers, recent studies revealed the possible formation of heterodimers
between either group-I receptors, or within and between group-
II and -III receptors [441]. Although well characterized in trans-
fected cells, co-localization and specific pharmacological properties
also suggest the existence of such heterodimers in the brain [2094].
The structure of the 7 transmembrane (TM) domains of both mGlu1
and mGlu5 have been solved, and confirm a general helical orga-
nization similar to that of other GPCRs, although the helices appear
more compacted [438, 2048].
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Nomenclature mGlu1 receptor mGlu2 receptor mGlu3 receptor mGlu4 receptor
HGNC, UniProt GRM1, Q13255 GRM2, Q14416 GRM3, Q14832 GRM4, Q14833
Endogenous
agonists
– – NAAG (Selective) (pKi 4.7)
[1679]
–
Agonists – – – L-AP4 (pEC50 6.5) [2050],
L-serine-O-phosphate (pEC50 5.9)
[2050]
Selective agonists – – – LSP4-2022 (pEC50 7) [631]
Antagonists LY367385 (pIC50 5.1) [349] – – MAP4 (pKi 4.6) [686] – Rat
Selective
antagonists
3-MATIDA (pIC50 5.2) [1333] – Rat,
(S)-(+)-CBPG (pIC50 4.2) [1200] – Rat,
(S)-TBPG (pIC50 4.2) [367] – Rat,
AIDA (pA2 4.2) [1334]
PCCG-4 (pIC50 5.1) [1483] – Rat – –
Allosteric
modulators
YM298198 (Negative) (pIC50 7.8)
[979] – Rat
CBiPES (Positive) (pEC50 7) [874],
4-MPPTS (Positive) (pIC50 5.8) [94,
873, 874, 1660]
– SIB-1893 (Positive) (pEC50 6.3–6.8)
[1217], MPEP (Positive) (pEC50
6.3–6.6) [1217], PHCCC (Positive)
(pEC50 4.5) [1184]
Selective allosteric
modulators
BAY 367620 (Negative) (pKi 9.5)
[267] – Rat, JNJ16259685 (Negative)
(pIC50 8.9) [1047], A-841720
(Negative) (pIC50 8) [2126],
Ro67-7476 (Positive) (pKi 7.5–7.9)
[971] – Rat, 3,5-dimethyl PPP
(Negative) (pIC50 7.8) [1271] – Rat,
EM-TBPC (Negative) (pKi 7.8) [1191]
– Rat, Ro01-6128 (Positive) (pKi
7.5–7.7) [971] – Rat, LY456236
(Negative) (pIC50 6.9) [1094],
CPCCOEt (Negative) (pIC50 5.2–5.8)
[1116], Ro67-4853 (Positive) (pKi 5.1)
[971] – Rat, PHCCC (Positive)
Ro64-5229 (Negative) (pIC50 7) [985]
– Rat, biphenylindanone A (Positive)
(pEC50 7) [183]
– VU0361737 (Positive) (pEC50 6.6)
[480], VU0155041 (Positive) (pEC50
6.1) [1402]
Comments – – – pEC50 values for MPEP and SIB-1893
were obtained in the presence of
L-AP4 [1217].
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Nomenclature mGlu5 receptor mGlu6 receptor mGlu7 receptor mGlu8 receptor
HGNC, UniProt GRM5, P41594 GRM6, O15303 GRM7, Q14831 GRM8, O00222
Endogenous agonists – – – L-serine-O-phosphate (pIC50 6.2–7.2)
[1192, 2050]
Agonists – – LSP4-2022 (pEC50 4.9) [631],
L-serine-O-phosphate (pEC50 4.5)
[2050], L-AP4 (pEC50 3.8) [2050]
(S)-3,4-DCPG (pEC50 7.5) [1876],
L-AP4 (pIC50 7–7.2) [1192]
Selective agonists (S)-(+)-CBPG (Partial agonist) (pEC50
4.3) [1200] – Rat, CHPG (pIC50 3.4)
[1350]
1-benzyl-APDC (pEC50 4.7) [1911] –
Rat, homo-AMPA (pEC50 4.1) [237]
– –
Antagonists – MAP4 (pIC50 3.5) [1504] – Rat, THPG
[1879] – Unknown
– MPPG (pIC50 4.3) [2050]
Selective antagonists ACDPP (pIC50 6.9) [182] – – –
Allosteric modulators 3,3’-difluorobenzaldazine (Positive)
(pIC50 5.6–8.5) [1415, 1416],
alloswitch-1 (Negative) (pIC50 8.1)
[1511] – Rat, CDPPB (Positive) (pEC50
7.6–8) [956, 1114], MTEP (Negative)
(pKi 7.8) [223], MPEP (Negative)
(pIC50 7.4–7.7) [578, 580], fenobam
(Negative) (pIC50 7.2) [1519],
SIB-1893 (Negative) (pIC50 5.9–6.5)
[578, 1949], SIB-1757 (Negative)
(pIC50 6–6.4) [578, 1949], CPPHA
(Positive) (pIC50 6.3) [1416]
– MMPIP (Negative) (pIC50 6.1–7.6)
[1401, 1827] – Rat, AMN082
(Positive) (pEC50 6.5–6.8) [1293],
XAP044 (Negative) (pIC50 5.6) [587]
–
Selective allosteric
modulators
VU-1545 (Positive) (pEC50 8) [2142] – – –
Comments: The activity of NAAG as an agonist at mGlu3 receptors
was questioned on the basis of contamination with glutamate [327,
547], but this has been refuted [1369].
Radioligand binding using a variety of radioligands has been
conducted on recombinant receptors (for example, [3H]R214127
[1046] and [3H]YM298198 [979] at mGlu1 receptors and
[3H]M-MPEP [578] and [3H]methoxymethyl-MTEP [47] at mGlu5
receptors. Although a number of radioligands have been used to ex-
amine binding in native tissues, correlation with individual subtypes
is limited. Many pharmacological agents have not been fully tested
across all known subtypes of mGlu receptors. Potential differences
linked to the species (e.g. human versus rat or mouse) of the recep-
tors and the receptor splice variants are generally not known. The
influence of receptor expression level on pharmacology and selec-
tivity has not been controlled for in most studies, particularly those
involving functional assays of receptor coupling.
(S)-(+)-CBPG is an antagonist at mGlu1, but is an agonist (albeit
of reduced efficacy) at mGlu5 receptors. DCG-IV also exhibits ag-
onist activity at NMDA glutamate receptors [1931], and is an an-
tagonist at all group-III mGluRs with an IC50 of 30M. A poten-
tial novel metabotropic glutamate receptor coupled to phospho-
inositide turnover has been observed in rat brain; it is activated by
4-methylhomoibotenic acid (ineffective as an agonist at recombi-
nant Group I metabotropic glutamate receptors), but resistant to
LY341495 [341]. There are also reports of a distinct metabotropic
glutamate receptor coupled to phospholipase D in rat brain, which
does not readily fit into the current classification [964, 1482]
A related class C receptor composed of two distinct subunits, T1R1
+ T1R3 is also activated by glutamate and is responsible for umami
taste detection.
All selective antagonists at metabotropic glutamate receptors are
competitive.
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Motilin receptor
G protein-coupled receptors!Motilin receptor
Overview: Motilin receptors (provisional nomenclature) are activated by a 22 amino-acid peptide derived from a precursor (MLN, P12872), which may also generate a motilin-associated peptide (MLN,
P12872). These receptors are also suggested to be responsible for the gastrointestinal prokinetic effects of certain macrolide antibiotics (often called motilides; e.g. erythromycin), although for many of these
molecules the evidence is sparse.
Nomenclature motilin receptor
HGNC, UniProt MLNR, O43193
Endogenous agonists motilin (MLN, P12872) (pKi 8.4–8.7) [372, 1223, 1224, 1225]
Agonists alemcinal (pIC50 7.2) [1872], erythromycin-A (pIC50 5.5–6.5) [507, 1872], azithromycin (pEC50 5.5) [220]
Selective agonists camicinal (pEC50 7.9) [99, 1639], mitemcinal (pEC50 7.5–7.8) [977, 1845] – Rabbit
Selective antagonists MA-2029 (pA2 9.2) [1811], GM-109 (pIC50 8) [701] – Pig
Labelled ligands [125I]motilin (human) (Agonist) (pKd 10) [507]
Comments: In laboratory rodents, the gene encoding the motilin
percursor appears to be absent, while the receptor appears to be a
pseudogene [725, 1637]. Functions of motilin (MLN, P12872) are
not usually detected in rodents, although brain and other responses
to motilin and the macrolide alemcinal have been reported and the
mechanism of these actions are obscure [1249, 1396]. Marked dif-
ferences in ligand affinities for the motilin receptor in dogs and hu-
mans may be explained by significant differences in receptor struc-
ture [1638]. Note that for the complex macrolide structures, selec-
tivity of action has often not been rigorously examined and other
actions are possible (e.g. P2X inhibition by erythromycin; [2123]).
Small molecule motilin receptor agonists are now described [1093,
1639, 2013]. The motilin receptor does not appear to have consti-
tutive activity [774]. Although not proven, the existence of biased
agonism at the receptor has been suggested [1225, 1292, 1636]. A
truncated 5-transmembrane structure has been identified but this is
without activity when transfected into a host cell [507].
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Neuromedin U receptors
G protein-coupled receptors! Neuromedin U receptors
Overview: Neuromedin U receptors (provisional nomen-
clature as recommended by NC-IUPHAR [530]) are acti-
vated by the endogenous 25 amino acid peptide neuromedin U
(neuromedin U-25 (NMU, P48645), NmU-25), a peptide originally
isolated from pig spinal cord [1287]. In humans, NmU-25 appears
to be the sole product of a precursor gene (NMU, P48645) showing
a broad tissue distribution, but which is expressed at highest lev-
els in the upper gastrointestinal tract, CNS, bone marrow and fetal
liver. Much shorter versions of NmU are found in some species, but
not in human, and are derived at least in some instances from the
proteolytic cleavage of the longer NmU. Despite species differences
in NmU structure, the C-terminal region (particularly the C-terminal
pentapeptide) is highly conserved and contains biological activity.
Neuromedin S (neuromedin S-33 (NMS, Q5H8A3)) has also been
identified as an endogenous agonist [1326]. NmS-33 is, as its name
suggests, a 33 amino-acid product of a precursor protein derived
from a single gene and contains an amidated C-terminal heptapep-
tide identical to NmU. NmS-33 appears to activate NMU receptors
with equivalent potency to NmU-25.
Nomenclature NMU1 receptor NMU2 receptor
HGNC, UniProt NMUR1, Q9HB89 NMUR2, Q9GZQ4
Antagonists – R-PSOP (pKB 7) [1128]
Comments: NMU1 and NMU2 couple predominantly to Gq/11 although there is evidence of good coupling to Gi/o [213, 786, 794]. NMU1 and NMU2 can be labelled with [
125I]-NmU and [125I]-NmS (of
various species, e.g. [1259]), BODIPY R TMR-NMU or Cy3B-NMU-8 [213]. A range of radiolabelled (125I-), fluorescently labelled (e.g. Cy3, Cy5, rhodamine and FAM) and biotin labelled versions of neuromedin U-25
(NMU, P48645) and neuromedin S-33 (NMS, Q5H8A3) are now commercially available.
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Neuropeptide FF/neuropeptide AF receptors
G protein-coupled receptors! Neuropeptide FF/neuropeptide AF receptors
Overview: The Neuropeptide FF receptor family contains two subtypes, NPFF1 and NPFF2 (provisional nomenclature [530]), which exhibit high affinities for neuropeptide FF (NPFF, O15130) and RFamide
related peptides (RFRP: precursor gene symbol NPVF, Q9HCQ7). NPFF1 is broadly distributed in the central nervous system with the highest levels found in the limbic system and the hypothalamus. NPFF2 is present
in high density in the superficial layers of the mammalian spinal cord where it is involved in nociception and modulation of opioid functions.
Nomenclature NPFF1 receptor NPFF2 receptor
HGNC, UniProt NPFFR1, Q9GZQ6 NPFFR2, Q9Y5X5
Rank order of potency RFRP-1 (NPVF, Q9HCQ7) > RFRP-3 (NPVF, Q9HCQ7) >
FMRFneuropeptide FF (NPFF, O15130) > neuropeptide AF (NPFF, O15130) >
neuropeptide SF (NPFF, O15130), QRFP43 (QRFP, P83859), PrRP-31 (PRLH,
P81277) [628]
neuropeptide AF (NPFF, O15130), neuropeptide FF (NPFF, O15130) >
PrRP-31 (PRLH, P81277) > FMRF, QRFP43 (QRFP, P83859) >
neuropeptide SF (NPFF, O15130) [628]
Endogenous agonists neuropeptide FF (NPFF, O15130) (Selective) (pKi 8.5–9.9) [628, 629, 1306],
RFRP-3 (NPVF, Q9HCQ7) (Selective) (pKi 9.2–9.3) [629, 630, 1306]
neuropeptide FF (NPFF, O15130) (Selective) (pKi 9.7) [629, 1305]
Selective agonists – dNPA (pKi 10.6) [1607], AC263093 (pEC50 5.2–5.9) [1036]
Antagonists RF9 (pKi 7.2) [1745] –
Selective antagonists AC262620 (pKi 7.7–8.1) [1036], AC262970 (pKi 7.4–8.1) [1036] –
Labelled ligands [125I]Y-RFRP-3 (Agonist) (pKd 9.7) [629], [
3H]NPVF (Agonist) (pKd 8.6)
[1855], [125I]NPFF (Agonist) [628]
[125I]EYF (Agonist) (pKd 10.2) [1306], [
3H]EYF (Agonist) (pKd 9.3) [1855],
[125I]NPFF (Agonist) [628]
Comments: An orphan receptor GPR83 (Q9NYM4) shows sequence similarities with NPFF1, NPFF2, PrRP and QRFP receptors. The antagonist RF9 is selective for NPFF receptors, but does not distinguish between
the NPFF1 and NPFF2 subtypes (pKi 7.1 and 7.2, respectively, [1745]).
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Neuropeptide S receptor
G protein-coupled receptors! Neuropeptide S receptor
Overview: The neuropeptide S receptor (NPS, provisional nomenclature [530]) responds to the 20 amino-acid peptide neuropeptide S derived from the precursor (NPS, P0C0P6).
Nomenclature NPS receptor
HGNC, UniProt NPSR1, Q6W5P4
Endogenous agonists neuropeptide S (NPS, P0C0P6) (pEC50 8) [2070]
Labelled ligands [125I]Tyr10NPS (human) (Agonist) (pKd 9.5) [2070]
Comments: Polymorphisms in the NPS receptor have been suggested to be associated with asthma [1953] and irritable bowel syndrome [386].
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Neuropeptide W/neuropeptide B receptors
G protein-coupled receptors! Neuropeptide W/neuropeptide B receptors
Overview: The neuropeptide BW receptor 1 (NPBW1, pro-
visional nomenclature [530]) is activated by two 23-
amino-acid peptides, neuropeptide W (neuropeptide W-23 (NPW,
Q8N729)) and neuropeptide B (neuropeptide B-23 (NPB, Q8NG41))
[554, 1725]. C-terminally extended forms of the peptides
(neuropeptide W-30 (NPW, Q8N729) and neuropeptide B-29 (NPB,
Q8NG41)) also activate NPBW1 [211]. Unique to both forms of
neuropeptide B is the N-terminal bromination of the first trypto-
phan residue, and it is from this post-translational modification that
the nomenclature NPB is derived. These peptides were first iden-
tified from bovine hypothalamus and therefore are classed as neu-
ropeptides. Endogenous variants of the peptides without the N-
terminal bromination, des-Br-neuropeptide B-23 (NPB, Q8NG41)
and des-Br-neuropeptide B-29 (NPB, Q8NG41), were not found to
be major components of bovine hypothalamic tissue extracts. The
NPBW2 receptor is activated by the short and C-terminal extended
forms of neuropeptide W and neuropeptide B [211].
Searchable database: http://www.guidetopharmacology.org/index.jsp Neuropeptide W/neuropeptide B receptors 5829
Full Contents of ConciseGuide: http://onlinelibrary.wiley.com/doi/10.1111/bph.13348/full
S.P.H. Alexander et al. The Concise Guide to PHARMACOLOGY 2015/16: G protein-coupled receptors. British Journal of Pharmacology (2015) 172, 5744–5869
Nomenclature NPBW1 receptor NPBW2 receptor
HGNC, UniProt NPBWR1, P48145 NPBWR2, P48146
Rank order of potency neuropeptide B-29 (NPB, Q8NG41) > neuropeptide B-23 (NPB, Q8NG41) >
neuropeptide W-23 (NPW, Q8N729) > neuropeptide W-30 (NPW, Q8N729) [211]
neuropeptide W-23 (NPW, Q8N729) > neuropeptide W-30 (NPW, Q8N729) >
neuropeptide B-29 (NPB, Q8NG41) > neuropeptide B-23 (NPB, Q8NG41) [211]
Selective agonists Ava3 (pKi 9.4–9.4) [902], Ava5 (pKi 8.8–9) [902] –
Labelled ligands [125I]NPW-23 (human) (Agonist) (pKd 9.4) [1747] [
125I]NPW-23 (human) (Agonist) (pKd 7.7) [1725]
Comments: Potency measurements were conducted with heterologously-expressed receptors with a range of 0.14-0.57 nM (NPBW1) and 0.98-21 nM (NPBW2).
NPBW1-/- mice show changes in social behavior, suggesting that the NPBW1 pathway may have an important role in the emotional responses of social interaction [1355].
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Neuropeptide Y receptors
G protein-coupled receptors! Neuropeptide Y receptors
Overview: Neuropeptide Y (NPY) receptors (nomenclature as
agreed by the NC-IUPHAR Subcommittee on Neuropep-
tide Y Receptors [1270]) are activated by the endogenous
peptides neuropeptide Y (NPY, P01303), neuropeptide Y-(3-36),
peptide YY (PYY, P10082), PYY-(3-36) and pancreatic polypeptide
(PPY, P01298) (PP). The receptor originally identified as the Y3 re-
ceptor has been identified as the CXCR4 chemokine recepter (orig-
inally named LESTR, [1135]). The y6 receptor is a functional
gene product in mouse, absent in rat, but contains a frame-shift
mutation in primates producing a truncated non-functional gene
[642]. Many of the agonists exhibit differing degrees of selectiv-
ity dependent on the species examined. For example, the po-
tency of PP is greater at the rat Y4 receptor than at the hu-
man receptor [485]. In addition, many agonists lack selectiv-
ity for individual subtypes, but can exhibit comparable potency
against pairs of NPY receptor subtypes, or have not been exam-
ined for activity at all subtypes. [125I]-PYY or [125I]-NPY can be
used to label Y1, Y2, Y5 and y6 subtypes non-selectively, while
[125I][cPP(1-7), NPY(19-23), Ala31, Aib32, Gln34]hPPmay be used
to label Y5 receptors preferentially (note that cPP denotes chicken
peptide sequence and hPP is the human sequence).
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Nomenclature Y1 receptor Y2 receptor Y4 receptor Y5 receptor y6 receptor
HGNC, UniProt NPY1R, P25929 NPY2R, P49146 NPY4R, P50391 NPY5R, Q15761 NPY6R, Q99463
Rank order of
potency
neuropeptide Y > peptide YY
 pancreatic polypeptide
neuropeptide Y > peptide YY
 pancreatic polypeptide
pancreatic polypeptide >
neuropeptide Y = peptide YY
neuropeptide Y > peptide YY
> pancreatic polypeptide
neuropeptide Y = peptide YY
> pancreatic polypeptide
Endogenous
agonists
neuropeptide Y (NPY,
P01303), peptide YY (PYY,
P10082)
PYY-(3-36) (PYY, P10082)
(pKi 9.2–9.7) [588, 599],
neuropeptide Y (NPY,
P01303),
neuropeptide Y-(3-36) (NPY,
P01303), peptide YY (PYY,
P10082)
pancreatic polypeptide (PPY,
P01298) (pKi 8.7–10.9) [92,
1152, 1899, 2076]
– –
Selective agonists [Leu31,Pro34]NPY (pEC50
7.1) [378],
[Leu31,Pro34]PYY (human),
[Pro34]NPY,
[Pro34]PYY (human)
– – [Ala31,Aib32]NPY (pig)
(pIC50 8.2) [254]
–
Selective
antagonists
BIBO3304 (pIC50 9.5)
[2020], BIBP3226 (pKi
8.1–9.3) [436, 2021]
BIIE0246 (pIC50 8.5) [434],
JNJ-5207787 (pIC50 6.9–7.1)
[178]
– L-152,804 (pKi 7.6) [901] –
Labelled ligands [3H]BIBP3226 (Antagonist)
(pKd 8.7),
[125I][Leu31,Pro34]NPY
(Agonist)
[125I]PYY-(3-36) (human)
(Agonist)
[125I]PP (human) (Agonist)
[125I][cPP(1-7), NPY(19-23),
Ala31, Aib32, Gln34]hPP
(Agonist) (pKd 9.2–9.3)
[453] – Rat
–
Comments Note that Pro34-containing
NPY and PYY can also bind
Y4 and Y5 receptors, so
strictly speaking are not
selective, but are the
’preferred’ agonists.
– – – The y6 receptor is a
pseudogene in humans, but
is functional in mouse, rabbit
and some other mammals.
Comments: The Y1 agonists indicated are selective relative to Y2 receptors. BIBP3226 is selective relative to Y2, Y4 and Y5 receptors [598]. NPY-(13-36) is Y2 selective relative to Y1 and Y5 receptors. PYY-(3-36)
is Y2 selective relative to Y1 receptors.
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Neurotensin receptors
G protein-coupled receptors! Neurotensin receptors
Overview: Neurotensin receptors (nomenclature as recommended by NC-IUPHAR [530]) are activated by the endogenous tridecapeptide neurotensin (pGlu-Leu-Tyr-Glu-Asn-Lys-Pro-Arg-Arg-Pro-Tyr-
Ile-Leu) derived from a precursor (NTS, 30990), which also generates neuromedin N, an agonist at the NTS2 receptor. A nonpeptide antagonist, SR142948A, shows high affinity (pKi˜9) at both NTS1 and NTS2
receptors [664]. [3H]neurotensin (human, mouse, rat) and [125I]neurotensin (human, mouse, rat) may be used to label NTS1 and NTS2 receptors at 0.1-0.3 and 3-5 nM concentrations respectively.
Nomenclature NTS1 receptor NTS2 receptor
HGNC, UniProt NTSR1, P30989 NTSR2, O95665
Rank order of potency neurotensin (NTS, P30990) > neuromedin N {Mouse, Rat} [741] neurotensin (NTS, P30990) = neuromedin N {Mouse, Rat} [1235]
Selective agonists JMV449 (pKi 10) [1753] – Rat levocabastine (pKi 6.8) [1235, 1583]
Antagonists meclinertant (pIC50 7.5–8.2) [664] –
Labelled ligands [3H]meclinertant (Antagonist) (pKd 8.5) [1030] – Rat –
Comments – A splice variant of the NTS2 receptor bearing 5 transmembrane domains has
been identified in mouse [191] and later in rat [1492].
Comments: neurotensin (NTS, P30990) appears to be a low-efficacy agonist at the NTS2 receptor [1959], while the NTS1 receptor antagonist meclinertant is an agonist at NTS2 receptors [1959]. An additional
protein, provisionally termed NTS3 (also known as NTR3, gp95 and sortilin; ENSG00000134243), has been suggested to bind lipoprotein lipase and mediate its degradation [1395]. It has been reported to interact
with the NTS1 receptor [1211] and has been implicated in hormone trafficking and/or neurotensin uptake.
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Opioid receptors
G protein-coupled receptors! Opioid receptors
Overview: Opioid and opioid-like receptors are activated by
a variety of endogenous peptides including [Met]enkephalin
(PENK, P01210) (met), [Leu]enkephalin (PENK, P01210) (leu),
β-endorphin (POMC, P01189) (β-end), α-neodynorphin (PDYN,
P01213), dynorphin A (PDYN, P01213) (dynA), dynorphin B
(PDYN, P01213) (dynB), big dynorphin (PDYN, P01213) (Big dyn),
nociceptin/orphanin FQ (PNOC, Q13519) (N/OFQ); endomorphin-1
and endomorphin-2 are also potential endogenous peptides. The
Greek letter nomenclature for the opioid receptors, , Æ and , is well
established, and NC-IUPHAR considers this nomenclature most
appropriate [376, 417, 530]. The human N/OFQ receptor is con-
sidered ’opioid-related’ rather than opioid because while it exhibits
a high degree of structural homology with the conventional opioid
receptors [1308], it displays a distinct pharmacology.
Nomenclature Æ receptor  receptor  receptor NOP receptor
HGNC, UniProt OPRD1, P41143 OPRK1, P41145 OPRM1, P35372 OPRL1, P41146
Principal endogenous
agonists
β-endorphin (POMC, P01189),
[Leu]enkephalin (PENK, P01210),
[Met]enkephalin (PENK, P01210)
big dynorphin (PDYN, P01213),
dynorphin A (PDYN, P01213)
β-endorphin (POMC, P01189),
[Met]enkephalin (PENK, P01210),
[Leu]enkephalin (PENK, P01210),
endomorphin-1, endomorphin-2
–
Endogenous agonists – – endomorphin-2 (Selective) (pKi 8.5) [2109] –
Rat, endomorphin-1 (Selective) (pKi 8.3)
[622, 2109]
nociceptin/orphanin FQ (PNOC,
Q13519) (Selective) (pKi 9.7–10.4)
[149, 1242, 1303, 1307, 1439]
Agonists – – levorphanol (pIC50 9.9) [692],
hydromorphone (pKi 9.6) [2007], fentanyl
(pKi 9.2) [1893], buprenorphine (Partial
agonist) (pKi 8.8) [1893], methadone (pIC50
8.4) [1523], codeine (pKi 6.9) [1893],
tapentadol (pKi 6.8) [1916], meperidine
(pIC50 6.5) [1523]
–
Selective agonists [D-Ala2]deltorphin I (pKd 9.4) [487,
1795], DPDPE (pKi 8.8) [1337, 1893],
[D-Ala2]deltorphin II (pKi 8.8) [488],
SNC80 (pKi 7.2) [258, 1549]
U50488 (pKi 7.8–9.7) [297, 1478,
1744, 1893, 1962, 2128, 2130],
enadoline (pKi 9.6) [808, 1383],
U69593 (pKi 9.5) [1034, 1893],
salvinorin A (pKi 7.8–8.7) [251,
1603]
sufentanil (pKi 9.9) [1960], DAMGO (pKi 9.3)
[691, 1893], loperamide (pKi 9.3) [308],
morphine (pKi 9) [620, 1893], PL017 (pKi
8.2) [290, 1893]
N/OFQ-(1-13)-NH2 (pKi
10.1–10.4) [149, 661, 1242, 1439],
Ro64-6198 (pKi 9.6) [855]
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(continued)
Nomenclature Æ receptor  receptor  receptor NOP receptor
Antagonists naltrexone (pKi 8) [1893], naloxone
(pKi 7.2) [1893]
buprenorphine (pKi 9.1–10.2) [1893,
2130], nalmefene (pKi 9.5) [1893],
naltrexone (pKi 8.4–9.4) [1478, 1744,
1893], naloxone (pKi 7.6–8.6) [1478,
1744, 1893, 2128, 2130]
naltrexone (pKi 9.7) [1893], nalmefene
(pKi 9.5) [1893], nalorphine (pKi 8.9)
[1893], methylnaltrexone (pKi 8.7)
[2007]
–
Selective antagonists naltriben (pKi 10) [1773, 1893],
naltrindole (pKi 9.7) [1521, 1893],
TIPP (Inverse agonist) (pKi 9) [1664,
1893]
nor-binaltorphimine (pKi 8.9–11)
[1478, 1520, 1744, 1893, 2128,
2130], 5’-guanidinonaltrindole (pKi
9.7–9.9) [882, 1478, 1797]
alvimopan (pKi 9.3) [1056],
levallorphan (pKi 8.8–9.3) [1187],
CTAP (pKi 8.6) [290, 1893]
UFP-101 (pKi 10.2) [259],
Banyu Compound-24 (pKi 9.6)
[523], SB 612111 (pKi 9.5)
[2112], J-113397 (pIC50 8.3)
[919]
Labelled ligands [3H]naltrindole (Antagonist) (pKd
10.4) [2072] – Rat, [3H]DPDPE
(Agonist) [26], [3H]deltorphin II
(Agonist) [252], [3H]naltriben
(Antagonist) [1088]
[3H]U69593 (Agonist) (pKd 8.7–8.8)
[1034, 1478, 1744], [3H]enadoline
(Agonist) [1746]
[3H]DAMGO (Agonist) (pKd 9.2)
[1567] – Rat, [3H]PL017 (Agonist)
[717] – Rat
[3H]N/OFQ (Agonist) (pKd 10.2)
[437, 1307]
Comments: Three naloxone-sensitive opioid receptor genes have
been identified in humans, and while the -receptor in particular
may be subject to extensive alternative splicing [1468], these puta-
tive isoforms have not been correlated with any of the subtypes of
receptor proposed in years past. Opioid receptors may heterodimer-
ize with each other or with other 7TM receptors [884], and give rise
to complexes with a unique pharmacology, however, evidence for
such heterodimers in native cells is equivocal and the consequences
this heterodimerization for signalling remains largely unknown. For
-opioid receptors at least, dimerization does not seem to be re-
quired for signalling [1026]. A distinct met-enkephalin receptor lack-
ing structural resemblance to the opioid receptors listed has been
identified (OGFR, 9NZT2) and termed an opioid growth factor
receptor [2110].
Endomorphin-1 and endomorphin-2 have been identified as highly
selective, putative endogenous agonists for the -opioid receptor.
At present, however, the mechanisms for endomorphin synthesis in
vivo have not been established, and there is no gene identified that
encodes for either. Thus, the status of these peptides as endogenous
ligands remains unproven.
Two areas of increasing importance in defining opioid receptor func-
tion are the presence of functionally relevant single nucleotide poly-
morphisms in human -receptors [1423] and the identification of bi-
ased signalling by opioid receptor ligands, in particular, compounds
previously characterized as antagonists [231]. Pathway bias for ag-
onists makes general rank orders of potency and efficacy somewhat
obsolete, so these do not appear in the table. As ever, the mecha-
nisms underlying the acute and long term regulation of opiod recep-
tor function are the subject of intense investigation and debate.
The richness of opioid receptor pharmacology has been enhanced
with the recent discovery of allostericmodulators of MOPr and DOPr,
notably the positive allosteric modulators and silent allosteric "an-
tagonists" outlined in [240, 241]. Negative allosteric modulation of
opioid receptors has been previously suggested [908], whether all
compounds are acting at a similar site remains to be established.
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Orexin receptors
G protein-coupled receptors! Orexin receptors
Overview: Orexin receptors (nomenclature as agreed by the NC-IUPHAR Subcommittee on Orexin receptors [627]) are activated by the endogenous polypeptides orexin-A (HCRT, O43612) and
orexin-B (HCRT, O43612) (also known as hypocretin-1 and -2; 33 and 28 aa) derived from a common precursor, preproorexin or orexin precursor, by proteolytic cleavage [1629]. Binding to both receptors may be
accomplished with [125I]orexin A (human, mouse, rat) [773].
Nomenclature OX1 receptor OX2 receptor
HGNC, UniProt HCRTR1, O43613 HCRTR2, O43614
Rank order of potency orexin-A (HCRT, O43612) > orexin-B (HCRT, O43612) orexin-A (HCRT, O43612) = orexin-B (HCRT, O43612)
Selective agonists – [Ala11, D-Leu15]orexin-B (pEC50 9.9) [62]
(Sub)family-selective
antagonists
suvorexant (pKi 9.3) [377], SB-649868 (pKi 9.1) [419], filorexant (pKi 8.6) [2035],
almorexant (pIC50 7.9) [216]
filorexant (pKi 9.5) [2035], suvorexant (pKi 9.5) [377], SB-649868 (pKi 8.9) [419],
almorexant (pIC50 8.1) [216]
Selective antagonists SB-408124 (pKi 7.2–7.6) [1042, 1190], SB-334867 (pKi 7.4–7.5) [1190, 1518] EMPA (pKi 9) [1189], JNJ 10397049 (pKi 7.9–8.6) [1238], TCS-OX2-29 (pKi 7.4)
[760]
Labelled ligands [3H]SB-674042 (Antagonist) (pKd 8.3–9.1) [1042, 1190, 1193] –
Comments: The primary coupling of orexin receptors to Gq/11 proteins is rather speculative and based on the strong activation of phospholipase C. Coupling of both receptors to Gi/o and Gs has also been
reported [1019, 1555]; for most cellular responses observed, the G protein pathway is unknown. The rank order of endogenous agonist potency may depend on the cellular signal transduction machinery. The
synthetic [Ala11, D-Leu15]orexin-B may show poor OX2 receptor selectivity [1540].
Loss-of-function mutations in the gene encoding the OX2 receptor underlie canine hereditary narcolepsy [1111].
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Oxoglutarate receptor
G protein-coupled receptors! Oxoglutarate receptor
Overview: Nomenclature as recommended by NC-IUPHAR [396].
Nomenclature oxoglutarate receptor
HGNC, UniProt OXGR1, Q96P68
Endogenous agonists α-ketoglutaric acid (pEC50 3.3–4.5) [728, 1785]
P2Y receptors
G protein-coupled receptors! P2Y receptors
Overview: P2Y receptors (nomenclature as agreedby the NC-IUPHARSubcommittee on P2YReceptors [1, 2]) are activated by the endogenous ligands ATP, adenosine diphosphate, uridine triphosphate,
uridine diphosphate and UDP-glucose. The relationship of many of the cloned receptors to endogenously expressed receptors is not yet established and so it might be appropriate to use wording such as
‘uridine triphosphate-preferring (or ATP-, etc.) P2Y receptor’ or ‘P2Y1-like’, etc., until further, as yet undefined, corroborative criteria can be applied [244, 486, 837, 2003, 2146].
Nomenclature P2Y1 receptor P2Y2 receptor P2Y4 receptor P2Y6 receptor
HGNC, UniProt P2RY1, P47900 P2RY2, P41231 P2RY4, P51582 P2RY6, Q15077
Rank order of
potency
adenosine diphosphate>ATP uridine triphosphate=ATP uridine triphosphate>ATP (at rat
recombinant receptors, UTP = ATP)
uridine diphosphate
uridine triphosphate>ATP
Endogenous
agonists
– – – uridine diphosphate (Selective) (pEC50
6.5) [359]
Agonists ADPβS (pEC50 7.3) [1848], 2MeSADP
(pIC50 5.4–7) [1658, 1970]
– – Rp-5-OMe-UDPαB (pEC50 8.1) [611,
666]
Selective agonists MRS2365 (pEC50 9.4) [314],
2-Cl-ADP(α-BH3) (pEC50 8.1) [73]
2-thioUTP (pEC50 7.3) [470], PSB1114
(EC50 value determined using an IP3
functional assay) (pEC50 6.9) [471],
Ap4A (pEC50 6.1) [270, 1471], UTPγS
(pEC50 5.8) [1054], MRS2768 (EC50
value determined using an IP3
functional assay) (pEC50 5.7) [973]
MRS4062 (pEC50 7.6) [1213], UTPγS
[1055] – Unknown
MRS2957 (pEC50 7.9) [1212],
MRS2693 (pEC50 7.8) [143],
3-phenacyl-UDP (pEC50 7.2) [470]
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(continued)
Nomenclature P2Y1 receptor P2Y2 receptor P2Y4 receptor P2Y6 receptor
Antagonists – – ATP (pKd 6.2) [925] –
Selective antagonists MRS2500 (pKi 8.8–9.1) [274, 942],
BMS compound 16 [PMID:23368907] (pKi
8.2) [295, 2115], MRS2279 (pKi 7.9) [1970],
MRS2179 (pKi 7–7.1) [197, 1970],
2,2’-pyridylisatogen tosylate (pKi 6.8) [570]
AR-C118925XX (pIC50 6) [924] – MRS2578 (pIC50 7.4) [1196]
Labelled ligands [3H]MRS2279 (Antagonist) (pKd 8.1) [1970],
[3H]2MeSADP (Agonist) (pKd 7.3) [1848],
[35S]ADPβS (Agonist) – Unknown
– – –
Nomenclature P2Y11 receptor P2Y12 receptor P2Y13 receptor P2Y14 receptor
HGNC, UniProt P2RY11, Q96G91 P2RY12, Q9H244 P2RY13, Q9BPV8 P2RY14, Q15391
Rank order of potency ATP>uridine triphosphate –
adenosine diphosphateATP
–
Rank order of potency
Human
– – – uridine diphosphate  UDP-glucose
Endogenous agonists – adenosine diphosphate (Selective) (pKi
5.9) [740]
– –
Agonists – 2MeSADP (pKi 9.2) [740] – MRS2690 (pEC50 6.6–7.3) [571, 974]
Selective agonists AR-C67085 (pEC50 8.5) [88, 360],
NF546 (pEC50 6.3) [1255], NAADP
[1322], NAD [1323]
– – –
Antagonists NF340 (pIC50 6.4–7.1) [1255] PSB-0739 (pKi 7.6) [91] – –
Selective antagonists NF157 (pKi 7.3) [1923] AZD1283 (pKi 8) [76, 2116], ARL66096
(pIC50 7.9) [806, 807], ticagrelor (pKi 7.8)
[2113]
MRS2211 (pIC50 6) [950] PPTN (pKi 10.1) [96]
Labelled ligands – [3H]2MeSADP (Agonist) (pIC50 7.5–9.6)
[1848], [3H]PSB-0413 (Antagonist) (pKd
8.3–8.5) [469, 1431]
– –
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Comments: cangrelor shows selectivity for P2Y12 and P2Y13
receptors compared with other P2Y receptors [1209, 1848].
NF157 also has antagonist activity at P2X1 receptors [1923].
Uridine diphosphate has been reported to be an antagonist at the
P2Y14 receptor [548]. [
35S]ATPαS has been used to label P2Y re-
ceptors in rat synaptosomal membranes [1682, 1683].
An orphan GPCR suggested to be a ‘P2Y15’ receptor [823] ap-
pears not to be a genuine nucleotide receptor [2], but rather re-
sponds to dicarboxylic acids [728]. Further P2Y-like receptors have
been cloned from non-mammalian sources; a clone from chick
brain, termed a p2y3 receptor (ENSGALG00000017327), couples
to the Gq/11 family of G proteins and shows the rank order
of potency adenosine diphosphate > uridine triphosphate > ATP
= uridine diphosphate [1998]. In addition, human sources have
yielded a clone with a preliminary identification of p2y5 (LPAR6,
P43657) and contradictory evidence of responses to ATP [954,
1999]. This protein is now classified as LPA6, a receptor for lysophos-
phatidic acid (LPA) [1467, 2079]. The clone termed p2y9 (LPAR4,
Q99677) is also a receptor for lysophosphatidic acid, LPA4 [1406].
The clone p2y7 (NOP9, Q86U38), originally suggested to be a
P2Y receptor [22], has been shown to encode a leukotriene re-
ceptor [2095]. A P2Y receptor that was initially termed a p2y8
receptor (P79928) has been cloned from Xenopus laevis; it shows
the rank order of potency ADPβS > ATP = uridine triphosphate =
guanosine-5’-triphosphate = CTP = TTP = ITP > ATPγS and elic-
its a Ca2+-dependent Cl- current in Xenopus oocytes [169]. The
p2y10 clone (P2RY10, O00398) lacks functional data. Diadenosine
polyphosphates also have effects on as yet uncloned P2Y-like recep-
tors with the rank order of potency of Ap4A>Ap5a> Ap3a, coupling
via Gq/11 [270]. P2Y-like receptors have recently been described
on mitochondria [126]. CysLT1 and CysLT2 leukotriene receptors
respond to nanomolar concentrations of uridine diphosphate, al-
though they are activated principally by leukotrienes LTC4 and LTD4
[1257, 1258]. Human GPR17 (13304) and rat GPR17, which are
structurally related to CysLT and P2Y receptors, are also activated by
leukotrienes [1542] as well as uridine diphosphate and UDP-glucose
[344, 540]. Activity at the rat GPR17 is inhibited by submicromolar
concentrations of MRS2179 and cangrelor [344].
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Parathyroid hormone receptors
G protein-coupled receptors! Parathyroid hormone receptors
Overview: The parathyroid hormone receptors (nomenclature as agreed by the NC-IUPHAR Subcommittee on Parathyroid Hormone Receptors [575]) are family B G protein-coupled receptors.
The parathyroid hormone (PTH)/parathyroid hormone-related peptide (PTHrP) receptor (PTH1 receptor) is activated by precursor-derived peptides: PTH (PTH, P01270) (84 amino acids), and PTHrP (PTHLH, P12272)
(141 amino-acids) and related peptides (PTH-(1-34), PTHrP-(1-36) (PTHLH, P12272)). The parathyroid hormone 2 receptor (PTH2 receptor) is activated by the precursor-derived peptide TIP39 (PTH2, Q96A98) (39
amino acids). [125I]PTH may be used to label both PTH1 and PTH2 receptors.
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Nomenclature PTH1 receptor PTH2 receptor
HGNC, UniProt PTH1R, Q03431 PTH2R, P49190
Rank order of potency PTH (PTH, P01270) = PTHrP (PTHLH, P12272) TIP39 (PTH2, Q96A98), PTH (PTH, P01270) PTHrP (PTHLH, P12272)
Endogenous agonists – TIP39 (PTH2, Q96A98) (pIC50 7.6–9.2) [626, 766]
Agonists teriparatide (pIC50 7.4) [573] –
Selective agonists PTHrP-(1-34) (human) (pIC50 7.8–8.1) [574] – Rat –
Comments: Although PTH (PTH, P01270) is an agonist at human PTH2 receptors, it fails to activate the rodent orthologues. TIP39 (PTH2, Q96A98) is a weak antagonist at PTH1 receptors [883].
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Endocrinol [PMID:21750510]
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Platelet-activating factor receptor
G protein-coupled receptors! Platelet-activating factor receptor
Overview: Platelet-activating factor (PAF, 1-O-alkyl-2-acetyl-sn-glycero-3-phosphocholine) is an ether phospholipid mediator associated with platelet coagulation, but also subserves inflammatory roles. The PAF re-
ceptor (provisional nomenclature recommended by NC-IUPHAR [530]) is activated by PAF and other suggested endogenous ligands are oxidized phosphatidylcholine [1204] and lysophosphatidylcholine
[1425]. It may also be activated by bacterial lipopolysaccharide [1358].
Nomenclature PAF receptor
HGNC, UniProt PTAFR, P25105
Selective agonists methylcarbamyl PAF – Unknown
Selective antagonists foropafant (pKi 10.3) [739], ABT-491 (pKi 9.2) [30], CV-6209 (pIC50 8.1–8.3) [619, 1357], L659989 (pKi 7.8) [811], apafant (pKi 5.2–7.5) [1460, 1831]
Labelled ligands [3H]PAF (Agonist) (pKd 8.8–8.9) [555, 1357]
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Comments: Note that a previously recommended radioligand ([3H]apafant; Kd 44.6 nM) is currently unavailable.
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Prokineticin receptors
G protein-coupled receptors! Prokineticin receptors
Overview: Prokineticin receptors, PKR1 and PKR2 (provisional
nomenclature as recommended by NC-IUPHAR [530]) re-
spond to the cysteine-rich 81-86 amino-acid peptides prokineticin-1
(PROK1, Q9HC23) (also known as endocrine gland-derived vascular
endothelial growth factor, mambakine) and prokineticin-2 (PROK2,
Q9HC23) (protein Bv8 homologue). An orthologue of PROK1 from
black mamba (Dendroaspis polylepis) venom, mamba intestinal toxin
1 (MIT1, [1678]) is a potent, non-selective agonist at prokineticin
receptors [1215], while Bv8, an orthologue of PROK2 from amphib-
ians (Bombina sp., [1304]), is equipotent at recombinant PKR1 and
PKR2 [1371], and has high potency in macrophage chemotaxis as-
says, which are lost in PKR1-null mice.
Nomenclature PKR1 PKR2
HGNC, UniProt PROKR1, Q8TCW9 PROKR2, Q8NFJ6
Rank order of potency prokineticin-2 (PROK2, Q9HC23) > prokineticin-1 (PROK1, Q9HC23) >
prokineticin-2β (PROK2) [1109, 1215, 1775]
prokineticin-2 (PROK2, Q9HC23) > prokineticin-1 (PROK1, Q9HC23) >
prokineticin-2β (PROK2) [1109, 1215, 1775]
Endogenous agonists prokineticin-2 (PROK2, Q9HC23) (pIC50 8.2–8.4) [300, 1215], prokineticin-1
(PROK1, Q9HC23) (pIC50 6.6–7.6) [300, 1215], prokineticin-2β (PROK2) (pIC50
7.5) [300]
prokineticin-2 (PROK2, Q9HC23) (pIC50 8.1–8.2) [300, 1215], prokineticin-1
(PROK1, Q9HC23) (pIC50 7.1–7.3) [300, 1215], prokineticin-2β (PROK2) (pIC50
<6) [300]
Agonists MIT1 (pIC50 8.4) [1215] MIT1 (pIC50 9.2) [1215]
Selective agonists IS20 (pEC50 7.4) [581], IS1 (pEC50 5.6) [581] –
Selective antagonists triazine compound PC1 (pKi 7.7) [87], triazine compound PC7 (pIC50 7.5)
[842, 1552], triazine compound PC10 (pIC50 7) [842]
PKR-A (pIC50 7.3–7.4) [312]
Labelled ligands [125I]BH-MIT1 (Agonist) (pIC50 8.4) [1215] [125I]BH-MIT1 (Agonist) (pIC50 9.2) [1215]
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Comments: Genetic mutations in PROKR1 are associated with Hirschsprung’s disease [1614], while genetic mutations in PROKR2 are associated with hypogonadotropic hypogonadism with anosmia [430],
hypopituitarism with pituitary stalk interruption [1575] and Hirschsprung’s disease [1614].
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Prolactin-releasing peptide receptor
G protein-coupled receptors! Prolactin-releasing peptide receptor
Overview: The precursor (PRLH, P81277) for PrRP generates 31 and 20-amino-acid versions. QRFP43 (QRFP, P83859) (named after a pyroglutamylated arginine-phenylalanine-amide peptide) is a 43 amino acid
peptide derived from QRFP (P83859) and is also known as P518 or 26RFa. RFRP is an RF amide-related peptide [756] derived from a FMRFamide-related peptide precursor (NPVF, Q9HCQ7), which is cleaved to
generate neuropeptide SF (NPFF, O15130), neuropeptide RFRP-1 (NPVF, Q9HCQ7), neuropeptide RFRP-2 (NPVF, Q9HCQ7) and neuropeptide RFRP-3 (NPVF, Q9HCQ7) (neuropeptide NPVF).
Nomenclature PrRP receptor
HGNC, UniProt PRLHR, P49683
Rank order of potency PrRP-20 (PRLH, P81277), PrRP-31 (PRLH, P81277) [1043]
Endogenous agonists PrRP-20 (PRLH, P81277) (Selective) (pKi 9–9.6) [481, 1043], PrRP-31 (PRLH, P81277) (Selective) (pKi 9–9.2) [481, 1043]
Endogenous antagonists neuropeptide Y (NPY, P01303) (Selective) (pKi 5.4) [1032]
Labelled ligands [125I]PrRP-20 (human) (Agonist) (pKd 9.2–10.6) [1043], [
125I]PrRP31 (Agonist) [473]
Comments: The orphan receptor GPR83 (Q9NYM4) shows sequence similarities with NPFF1, NPFF2, PrRP and QRFP receptors.
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Prostanoid receptors
G protein-coupled receptors! Prostanoid receptors
Overview: Prostanoid receptors (nomenclature as agreed by the NC-IUPHAR Subcommittee on Prostanoid Receptors [2043]) are activated by the endogenous ligands prostaglandins PGD2,
PGE2 , PGF2α, PGH2, prostacyclin [PGI2] and thromboxane A2. Measurement of the potency of PGI2 and thromboxane A2 is hampered by their instability in physiological salt solution; they are often replaced by
cicaprost and U46619, respectively, in receptor characterization studies.
Nomenclature DP1 receptor DP2 receptor IP receptor FP receptor TP receptor
HGNC, UniProt PTGDR, Q13258 PTGDR2, Q9Y5Y4 PTGIR, P43119 PTGFR, P43088 TBXA2R, P21731
Rank order of potency PGD2  PGE2 > PGF2α >
PGI2, thromboxane A2
– PGI2  PGD2, PGE2, PGF2α
> thromboxane A2
PGF2α > PGD2 > PGE2 >
PGI2, thromboxane A2
thromboxane A2 = PGH2 
PGD2, PGE2, PGF2α, PGI2
Rank order of potency – PGD2  PGF2α, PGE2 >
PGI2, thromboxane A2
Agonists – 13,14-dihydro-15-keto-PGD2
(pKi 7.4–8.5) [712, 1656,
1815]
iloprost (pKi 7.5–8) [7, 2030],
treprostinil (pKi 7.5) [2019]
bimatoprost (pIC50 5.3)
[2044]
–
Selective agonists BW 245C (pKi 8.4–9.4) [171,
2045, 2046], L-644,698 (pKi
9–9.3) [2045, 2046],
SQ-27986 (pKi 8) [1712],
RS 93520 (Partial agonist) (pKi
7.5) [1712], ZK118182 (pKi
7.3) [1712]
15(R)-15-methyl-PGD2 (pKi
8.9) [712, 1312, 1815]
AFP-07 (pIC50 8.5) [288],
BMY 45778 (pIC50 8) [881],
esuberaprost (pKd 7.9) [892],
cicaprost (pKi 7.8) [7]
fluprostenol (pKi 8.6) [7],
latanoprost (free acid form)
(pKi 8.6) [7], AL12180 (pEC50
7.7–7.9) [1714], tafluprost
[1843]
I-BOP (pKd 8.9–9.3) [1233],
U46619 (pKi 7.5) [7], STA2
(pIC50 6.4–7.1) [59]
Antagonists – ramatroban (pKi 7.4) [1815] – – ramatroban (pKi 8) [1869]
Selective antagonists laropiprant (pKi 10.1) [1808]
– Unknown, BWA868C (pKi
8.6–9.3) [171, 606, 2045],
S-5751 (pKi 8.8) [54],
ONO-AE3-237 (pKi 7.7) [758,
1895, 1897]
CAY 10471 (pIC50 8.9) [1610,
1927], AZD1981 (pIC50 8.4)
[1150]
RO1138452 (pKi 8.7) [158],
RO3244794 (pA2 8.5) [158]
AS604872 (pKi 7.5) [346] ifetroban (pKi 8.4–10) [1426],
vapiprost (pKi 8.3–9.4) [59,
1151], SQ-29548 (pKi
8.1–9.1) [7, 1834, 2030],
ONO-3708 (pKi 7.4–8.9)
[910]
Labelled ligands [3H]PGD2 (Agonist) (pKd
7.9–9.5) [2030, 2045]
[3H]PGD2 (Agonist) (pKd
7.8–8.2) [1216, 1723]
[3H]iloprost (Agonist) (pKd
7.7–9) [7, 170, 2030]
[3H]PGF2α (Agonist) (pKd
8.1–9) [7, 8, 2030],
[3H](+)-fluprostenol (Agonist)
(pKd 7.5) – Unknown
[125I]SAP (Antagonist) (pKd
7.7–9.3) [1356], [125I]BOP
(Agonist) (pKd 8.7) [1328],
[3H]SQ-29548 (Antagonist)
(pKd 7.4–8.2) [7, 2030]
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Nomenclature EP1 receptor EP2 receptor EP3 receptor EP4 receptor
HGNC, UniProt PTGER1, P34995 PTGER2, P43116 PTGER3, P43115 PTGER4, P35408
Rank order of potency PGE2 > PGF2α, PGI2 > PGD2,
thromboxane A2
PGE2 > PGF2α, PGI2 > PGD2,
thromboxane A2
PGE2 > PGF2α, PGI2 > PGD2,
thromboxane A2
PGE2 > PGF2α, PGI2 > PGD2,
thromboxane A2
Endogenous agonists PGE1 (pKi 6.8) [1713], PGI2 (pKi 4.8)
[1713]
PGE2 (pKi 7.5–8.3) [7, 1799, 2030] –
Agonists 17-phenyl-!-trinor-PGE2 (pKi 8.1)
[1713]
evatanepag (pIC50 7.3) [260] – Rat misoprostol (methyl ester) (EP3-III
isoform) (pKi 6.5) [7]
–
Selective agonists ONO-DI-004 (pKi 6.8) [1826] – Mouse ONO-AE1-259 (pKi 8.5) [1826] –
Mouse, butaprost (free acid form) (pKi
5.9–7) [7, 1799]
SC46275 (pEC50 10.4) [1655] – Guinea
pig, MB-28767 (EP3-III isoform) (pKi
9.9) [7], ONO-AE-248 (pEC50 5.6–6.7)
[534, 1140]
L902688 (pEC50 8.1–10.3) [535, 1064],
ONO-AE1-437 (pKi 9.1) [1294] –
Mouse, CP734432 (pIC50 8.7) [1529],
ONO-AE1-329 (pEC50 7.7–7.8) [534,
535]
Antagonists – – – evatanepag (pKi 8.6) [1345],
Selective antagonists ONO-8711 (pKi 9.2) [1992],
GW848687X (pIC50 8.6) [605],
SC-51322 (pKi 7.9) [7]
TG4-155 (TG4-155 also has affinity for
the human DP1 receptor (pKb = 7.8))
(pKB 8.6) [865], TG7-171 (pKB 8.6)
[567], PF-04852946 (pKB 8.4–8.5)
[920], PF-04418948 (PF-04418948 has
weaker affinity at the EP2-receptor in
guinea-pigs) (pKB 8.3) [153, 2136]
L-798,106 (EP3-III isoform) (pKi
7.8–9.7) [888, 890, 1810], L-826266
(EP3-III isoform (pKi=8.04 in the
presence of HSA)) (pKi 9.1) [890],
ONO-AE3-240 (pIC50 8.8) [38] –
Mouse, DG-041 (pKi 8.4) [888]
MK-2894 (pKi 9.2) [7, 161, 350],
ONO-AE3-208 (pKi 8.5), BGC201531
(pKi 7.9) [1230], ER819762 (pIC50 7.2)
[304], GW 627368 (pKi 7–7.1) [2030,
2031]
Labelled ligands [3H]PGE2 (Agonist) (pKd 7.6–7.9) [7,
1713, 2030]
[3H]PGE2 (Agonist) (pKd 7.7–7.9) [7,
2030]
[3H]PGE2 (Agonist) (pKd 8.2–9.5) [7,
2030]
[3H]PGE2 (Agonist) (pKd 7.6–9.5) [7,
401, 2019, 2030]
Comments: ramatroban is an antagonist at both DP2 and TP re-
ceptors. Whilst cicaprost is selective for IP receptors, it does exhibit
moderate agonist potency at EP4 receptors [7]. Apart from IP recep-
tors, iloprost also binds to other prostanoid receptors such as EP1
receptors. The TP receptor exists in α and β isoforms due to alterna-
tive splicing of the cytoplasmic tail [1566]. The IP receptor agonist
treprostinil binds also to human EP2 and DP1 receptors with high
affinity (pKi 8.44 and 8.36, respectively).
The EP1 agonist 17-phenyl-!-trinor-PGE2 also shows agonist ac-
tivity at EP3 receptors. Butaprost and SC46275 may require de-
esterification within tissues to attain full agonist potency. There is
evidence for subtypes of FP [1105], IP [1851, 2037] and TP [1005]
receptors. mRNA for the EP1 and EP3 receptors undergo alternative
splicing to produce two [1441] and at least six variants, respectively,
which can interfere with signalling [1441] or generate complex pat-
terns of G-protein (Gi/o, Gq/11, Gs and G12,13) coupling (e.g.
[997, 1370]). The number of EP3 receptor (protein) variants are vari-
able depending on species, with five in human, three in rat and three
in mouse. The possibility of additional receptors for the isoprostanes
has been suggested [1531]. Putative receptor(s) for prostamide F
(which as yet lack molecular correlates) and which preferentially rec-
ognize PGF2-1-ethanolamide and its analogues (e.g. Bimatoprost)
have been identified, together with moderate-potency antagonists
(e.g. AGN 211334) [2042].
The free acid form of AL-12182, AL12180, used in in vitro studies, has
a EC50 value of 15nM which is the concentration of the compound
giving half-maximal stimulation of inositol phosphate turnover in
HEK-293 cells expressing the human FP receptor [1714].
References given alongside the TP receptor agonists I-BOP [1233]
and STA2 [59] use human platelets as the source of TP receptors for
competition radio-ligand binding assays to determine the indicated
activity values.
Pharmacological evidence for a second IP receptor, denoted IP2,
in the central nervous system [1851, 1994] and in the BEAS-2B
human airway epithelial cell line [2033] is available. This recep-
tor is selectively activated by 15R-17,18,19,20-tetranor-16-m-tolyl-
isocarbacyclin (15R-TIC) and 15R-Deoxy 17,18,19,20-tetranor-16-
m-tolyl-isocarbacyclin (15-deoxy-TIC). However, molecular biolog-
ical evidence for the IP2 subtype is currently lacking.
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Proteinase-activated receptors
G protein-coupled receptors! Proteinase-activated receptors
Overview: Proteinase-activated receptors (PARs, nomencla-
ture as agreed by the NC-IUPHAR Subcommittee on
Proteinase-activated Receptors [770]) are unique members
of the GPCR superfamily activated by proteolytic cleavage of their
amino terminal exodomains. Agonist proteinase-induced hydrol-
ysis unmasks a tethered ligand (TL) at the exposed amino termi-
nus, which acts intramolecularly at the binding site in the body of
the receptor to effect transmembrane signalling. TL sequences at
human PAR1-4 are SFLLRN-NH2, SLIGKV-NH2, TFRGAP-NH2 and
GYPGQV-NH2, respectively. With the exception of PAR3, these syn-
thetic peptide sequences (as carboxyl terminal amides) are able to
act as agonists at their respective receptors. Several proteinases, in-
cluding neutrophil elastase, cathepsin G and chymotrypsin can have
inhibitory effects at PAR1 and PAR2 such that they cleave the ex-
odomain of the receptorwithout inducing activation of Gαq-coupled
calcium signalling, thereby preventing activation by activating pro-
teinases but not by agonist peptides. Neutrophil elastase cleavage
of PAR2 can however activate MAP kinase signaling by exposing a TL
that is different from the one revealed by trypsin [1553]. The role of
such an action in vivo is unclear.
Nomenclature PAR1 PAR2 PAR3 PAR4
HGNC, UniProt F2R, P25116 F2RL1, P55085 F2RL2, O00254 F2RL3, Q96RI0
Agonist proteases thrombin (F2, P00734), activated protein C
(PROC, P04070), matrix metalloproteinase 1
(MMP1, P45452), matrix metalloproteinase 13
(MMP13, P45452) [70]
Trypsin, tryptase, TF/VIIa, Xa thrombin (F2, P00734) thrombin (F2, P00734), trypsin,
cathepsin G (CTSG, P08311)
Selective agonists TFLLR-NH2 (pEC50 5.4) [340] GB110 (pEC50 6.5) [98],
2-furoyl-LIGRLO-amide (pKi 5.4) [1243],
SLIGKV-NH2 [1069], SLIGRL-NH2 [1069]
– AYPGKF-NH2, GYPGKF-NH2,
GYPGQV-NH2
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(continued)
Nomenclature PAR1 PAR2 PAR3 PAR4
Selective antagonists vorapaxar (pKi 8.1) [281], atopaxar (pIC50 7.7)
[978], RWJ-56110 (pIC50 6.4) [48]
GB88 (pIC50 5.7) [1813], P2pal18s [1705] – –
Labelled ligands [3H]haTRAP (Agonist) (pKd 7.8) [15] 2-furoyl-LIGRL[N-(Alexa Fluor 594)-O]-NH2
(Agonist) [771],
2-furoyl-LIGRL[N[3H]propionyl]-O-NH2 (Agonist)
[771], [3H]2-furoyl-LIGRL-NH2 (Selective Agonist)
[903],
trans-cinnamoyl-LIGRLO [N-[3H]propionyl]-NH2
(Agonist) [28]
– –
Comments TFLLR-NH2 is selective relative to the PAR2
receptor [155, 915].
2-Furoyl-LIGRLO-NH2 activity was measured via
calcium mobilisation in HEK 293 cells which
constitutively coexpress human PAR1 and PAR2.
– –
Comments: thrombin (F2, P00734) is inactive at the PAR2 receptor.
Endogenous serine proteases (EC 3.4.21.) active at the proteinase-activated receptors include: thrombin (F2, P00734), generated by the action of Factor X (F10, P00742) on liver-derived prothrombin (F2, P00734);
trypsin, generated by the action of enterokinase (TMPRSS15, P98073) on pancreatic-derived trypsinogen (PRSS1, P07477); tryptase, a family of enzymes (α/β1 TPSAB1, Q15661 ; γ1 TPSG1, Q9NRR2; Æ1 TPSD1,
Q9BZJ3) secreted from mast cells; cathepsin G (CTSG, P08311) generated from leukocytes; liver-derived protein C (PROC, P04070) generated in plasma by thrombin (F2, P00734) and matrix metalloproteinase 1
(MMP1, P45452).
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QRFP receptor
G protein-coupled receptors! QRFP receptor
Overview: The human gene encoding the QRFP receptor (QRFPR, also known as the peptide P518 receptor), previously designated as an orphan GPCR receptor was identified in 2001 by Lee et al. from a
hypothalamus cDNA library [1066]. However, the reported cDNA (AF411117) is a chimera with bases 1-127 derived from chromosome 1 and bases 155-1368 derived from chromosome 4. When corrected, QRFPR
(also referred to as SP9155 or AQ27) encodes a 431 amino acid protein that shares sequence similarities in the transmembrane spanning regions with other peptide receptors. These include neuropeptide FF2 (38%),
neuropeptide Y2 (37%) and galanin GalR1 (35%) receptors.
Nomenclature QRFP receptor
HGNC, UniProt QRFPR, Q96P65
Endogenous agonists QRFP43 (QRFP, P83859) (pIC50 7.8–9.3) [557, 1850] – Rat, QRFP26 (QRFP) (pEC50 8.2) [867]
Labelled ligands [125I]QRFP43 (human) (Agonist) (pKd 7.8–10.3) [557, 1017, 1850]
Comments: The orphan receptor GPR83 (9NYM4) shows sequence similarities with the QRFP receptor, as well as with the NPFF1, NPFF2, and PrRP receptors.
Further Reading
Fukusumi S et al. (2006) Recent advances in mammalian RFamide peptides: the discovery and functional analyses of PrRP, RFRPs and QRFP. Peptides 27: 1073-86 [PMID:16500002]
Relaxin family peptide receptors
G protein-coupled receptors! Relaxin family peptide receptors
Overview: Relaxin family peptide receptors (RXFP, nomencla-
ture as agreed by the NC-IUPHAR Subcommittee on Re-
laxin family peptide receptors [105, 677]) may be divided
into two pairs, RXFP1/2 and RXFP3/4. Endogenous agonists at these
receptors are a number of heterodimeric peptide hormones analo-
gous to insulin: relaxin-1 (RLN1, P04808), relaxin (RLN2, P04090),
relaxin-3 (RLN3, Q8WXF3) (also known as INSL7), insulin-like pep-
tide 3 (INSL3 (INSL3, P51460)) and INSL5 (INSL5, Q9Y5Q6).
Species homologues of relaxin have distinct pharmacology - relaxin
(RLN2, P04090) interacts with RXFP1, RXFP2 and RXFP3, whereas
mouse and rat relaxin selectively bind to and activate RXFP1 [1686]
and porcine relaxin may have a higher efficacy than human relaxin
(RLN2, P04090) [678]. Relaxin-3 (RLN3, Q8WXF3) has differential
affinity for RXFP2 receptors between species; mouse and rat RXFP2
have a higher affinity for relaxin-3 (RLN3, Q8WXF3) [1685]. At least
two binding sites have been identified on the RXFP1 and RXFP2 re-
ceptors: a high-affinity site in the leucine-rich repeat region of the
ectodomain and a somewhat lower-affinity site located in the sur-
face loops of the transmembrane domain [678, 1812]. The unique
N-terminal LDLa module of RXFP1 and RXFP2 is essential for receptor
signalling [1687].
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Nomenclature RXFP1 receptor RXFP2 receptor RXFP3 receptor RXFP4 receptor
HGNC, UniProt RXFP1, Q9HBX9 RXFP2, Q8WXD0 RXFP3, Q9NSD7 RXFP4, Q8TDU9
Rank order of potency relaxin (RLN2, P04090) = relaxin-1
(RLN1, P04808) > relaxin-3 (RLN3,
Q8WXF3) [1812]
INSL3 (INSL3, P51460) > relaxin
(RLN2, P04090) relaxin-3 (RLN3,
Q8WXF3) [1022, 1812]
relaxin-3 (RLN3, Q8WXF3) >
relaxin-3 (B chain) (RLN3, Q8WXF3)
> relaxin (RLN2, P04090) [1119]
INSL5 (INSL5, Q9Y5Q6) = relaxin-3
(RLN3, Q8WXF3) >
relaxin-3 (B chain) (RLN3, Q8WXF3)
[1117, 1118]
Endogenous antagonists – – INSL5 (INSL5, Q9Y5Q6) (pKi 7)
[2129]
–
Antagonists B-R13/17K H2 relaxin (pEC50
5.7–6.7) [788, 1382], LGR7-truncate
[1687]
– R3(B123-27)R/I5 chimeric peptide
(pIC50 9.2) [1018]
R3(B123-27)R/I5 chimeric peptide
(pIC50 8–8.6) [714, 1018]
Selective antagonists – A(9-26)INSL3 (pKi 9.1) [787],
A(10-24)INSL3 (pKi 8.7) [787],
A(C10/15S)INSL3 (pKi 8.6) [2118],
INSL3 B chain dimer analogue 8 (pKi
8.5) [1710], A(110/15C)INSL3 (pKi
8.3) [2118],
cyclic INSL3 B-chain analogue 6 (pKi
6.7) [1708], INSL3 B-chain analogue
(pKi 5.1) [411],
(des 1-8) A-chain INSL3 analogue
[253]
minimised relaxin-3 analogue 3 (pKi
7.6) [1706], R3-B1-22R (pIC50 7.4)
[714]
minimised relaxin-3 analogue 3
(pIC50 6.6) [1706]
Selective allosteric
modulators
ML290 (Agonist) (pEC50 7) [2057,
2060]
– – –
Labelled ligands [33P]relaxin (human) (Agonist) (pKd
9.3–9.7) [678, 1812],
[125I]relaxin (human) (Agonist)
[125I]INSL3 (human) (Agonist) (pKd
10) [1340], [33P]relaxin (human)
(Agonist) (pKd 9–9.2) [678, 1812]
[125I]relaxin-3 (human) (Agonist)
(pKd 9.5) [1119],
[125I]relaxin-3-B/INSL5 A chimera
(Agonist) (pKd 9.3) [1117]
[125I]relaxin-3 (human) (Agonist)
(pKd 8.7–9.7) [1118],
[125I]relaxin-3-B/INSL5 A chimera
(Agonist) (pKd 8.9) [1117],
europium-labelled INSL5 (pKd 8.3)
[714]
Comments europium-labelled relaxin is a
fluorescent ligand for this receptor
(Kd=0.5nM) [1707].
europium-labelled INSL3 is a
fluorescent ligand for this receptor
(Kd=1nM) [1709].
europium-labelled relaxin-3-B/INSL5
A chimera
and R3-B1-22R are fluorescent
ligands for this receptor (Kd=5nM
and 28nM) [714, 715].
europium-labelled relaxin-3-B/INSL5
A chimera
is a fluorescent probe at this receptor
(Kd=5nM) [714].
europium-labelled mouse INSL5 is a
fluorescent ligand at this receptor
(Kd=5nM) [120].
Comments: Relaxin has recently successfully completed a Phase III
clinical trial for the treatment of acute heart failure. 48 hr infusion
of relaxin reduced dyspnoea and 180 day mortality [1262]. Small
molecule agonists active at RXFP1 receptors have been developed
[1718, 2060], and one of these (ML290) is an allosteric agonist at
RXFP1 [2060]. The antifibrotic actions of relaxin are dependent on
the angiotensin receptor AT2, are absent in AT2 knockout mice, and
are associated with heterodimer formation between RXFP1 and AT2
[330]. Mutations in INSL3 and LGR8 (RXFP2) have been reported in
populations of patients with cryptorchidism [512]. Numerous splice
variants of the human RXFP1 and RXFP2 receptors have been identi-
fied, most of which do not bind relaxin family peptides [1340]. Splice
variants of RXFP1 encoding the N-terminal LDLa module act as an-
tagonists of RXFP1 signalling [1685, 1687]. cAMP elevation appears
to be a major signalling pathway for RXFP1 and RXFP2 [795, 796],
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but RXFP1 also activates MAP kinases, nitric oxide signalling, tyrosine
kinase phosphorylation and relaxin can interact with glucocorticoid
receptors [681]. RXFP1 signalling involves lipid rafts, residues in the
C-terminus of the receptor and activation of phosphatidylinositol-3-
kinase [682]. More recent studies provide evidence that RXFP1 is
pre-assembled in signalosomes with other signalling proteins includ-
ing Gαs, Gβγ and adenylyl cyclase 2 that display constitutive activity
and are exquisitely sensitive to sub-picomolar concentrations of re-
laxin [679]. The cyclic AMP signalling pattern is highly dependent
on the cell type in which RXFP1 is expressed [680].
The receptor expression profiles suggested that RXFP3 was a neu-
ropeptide receptor and RXFP4 a gut hormone receptor. Studies in
rats and mice (including wildtype, and relaxin-3 and RXFP3 gene-
deletion strains [671, 782, 1759, 1971] have revealed putative roles
for the relaxin-3/RXFP3 system in the modulation of feeding [564,
566, 714, 1706, 1760], anxiety [1618, 2114], and reward and mo-
tivated, goal-directed behaviours [782, 1619, 1971], particularly in
relation to the integration of stress and corticotrophin-releasing fac-
tor signalling [1162], with implications for the therapeutic treatment
of clinical anxiety, depression, eating disorders and addiction (see
[565, 1761] for review). Relaxin-3 (RLN3, Q8WXF3) acts as an ag-
onist at both RXFP3 and RXFP4 whereas INSL5 (INSL5, Q9Y5Q6)
is an agonist at RXFP4 and a weak antagonist at RXFP3. Unlike
RXFP1 and RXFP2 both RXFP3 and RXFP4 are encoded by a single
exon and therefore no splice variants exist. The rat RXFP3 sequence
has two potential start codons that encode RXFP3L and RXFP3S
with the longer variant having an additional 7 amino-acids at the
N-terminus. It is not known which variant is expressed. Rat and
dog RXFP4 sequences are pseudogenes [2027]. Recent studies sug-
gest that INSL5 is an incretin secreted from enteroendocrine L cells
and that the INSL5/RXFP4 system has roles in controlling food in-
take and glucose homeostasis [652]. RXFP3 couples to Gi/o and
inhibits adenylyl cyclase [1119, 2144], and also causes Erk1/2 phos-
phorylation [2144]. Relatively little is known about RXFP4 signalling
but like RXFP3 it couples to inhibitory Gi/o G-proteins [1120]. Re-
cent studies suggest that relaxin (RLN2, P04090) also interacts with
RXFP3 to cause a pattern of activation of signalling pathways that
are a subset of those activated by relaxin-3 (RLN3, Q8WXF3). The
two patterns of signaling observed in several cell types expressing
RXFP3 are strong inhibition of forskolin-stimulated cyclic AMP ac-
cumulation, ERK1/2 activation and nuclear factor NF-B reporter
gene activation with relaxin-3 (RLN3, Q8WXF3), and weaker activ-
ity with relaxin (RLN2, P04090), porcine relaxin, or insulin-like pep-
tide 3 (INSL3 (INSL3, P51460)) and a strong stimulation of activa-
tor protein (AP)-1 reporter genes with relaxin (RLN2, P04090), and
weaker activation with relaxin-3 (RLN3, Q8WXF3) or porcine relaxin
[2144]. Thus at RXFP3, relaxin (RLN2, P04090) is a biased ligand
compared to the cognate ligand relaxin-3 (RLN3, Q8WXF3). Two
pharmacologically distinct ligand binding sites were also identified
on RXFP3-expressing cells using [125I]relaxin-3-B/INSL5 A chimera
which binds with high affinity and displays competition by relaxin-3
(RLN3, Q8WXF3) or a relaxin-3 (B chain) (RLN3, Q8WXF3) peptide,
and [125I]relaxin (human) which displays competition by relaxin
(RLN2, P04090), relaxin-3 (RLN3, Q8WXF3), or INSL3 (INSL3,
P51460) and weakly by porcine relaxin.
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Somatostatin receptors
G protein-coupled receptors! Somatostatin receptors
Overview: Somatostatin (somatotropin release inhibiting factor)
is an abundant neuropeptide, which acts on five subtypes of so-
matostatin receptor (sst1-sst5; nomenclature as agreed by
the NC-IUPHAR Subcommittee on Somatostatin Recep-
tors [790]). Activation of these receptors produces a wide range
of physiological effects throughout the body including the inhibi-
tion of secretion of many hormones. The relationship of the cloned
receptors to endogenously expressed receptors is not yet well es-
tablished in some cases. Endogenous ligands for these receptors
are somatostatin-14 (SRIF-14 (SST, P61278)) and somatostatin-28
(SRIF-28 (SST, P61278)). Cortistatin-14 {Mouse, Rat} has also been
suggested to be an endogenous ligand for somatostatin receptors
[404].
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Nomenclature sst1 receptor sst2 receptor sst3 receptor sst4 receptor sst5 receptor
HGNC, UniProt SSTR1, P30872 SSTR2, P30874 SSTR3, P32745 SSTR4, P31391 SSTR5, P35346
Agonists pasireotide (pIC50 8) [1669] vapreotide (pKi 8.3–10.1) [233,
1474], pasireotide (pIC50 9)
[1669]
pasireotide (pIC50 8.8) [1669],
vapreotide (pKi 7.4–7.9) [233,
1474, 1738]
NNC269100 (pKi 8.2) [1132] pasireotide (pIC50 9.8) [1669],
vapreotide (pKi 7.3–9.2) [233,
1265, 1474, 1736, 1737, 1738]
Selective agonists L-797,591 (pKi 8.8) [1595],
Des-Ala1,2,5-[D-Trp8,
IAmp9]SRIF
(pIC50 7.5) [484]
L-054,522 (pKi 11) [2084],
BIM 23027 (pIC50 10.9) [271],
seglitide (pKi 8.8–10.3) [233,
1474, 1736, 1737, 1738, 2084],
octreotide (pKi 8.7–9.9) [233,
1474, 1736, 1737, 1738, 2084]
L-796,778 (pKi 7.6) [1595] L-803,087 (pKi 9.2) [1595] BIM 23052 (pKi 7.4–9.6) [1265,
1736, 1737, 1738], L-817,818
(pKi 9.4) [1595], BIM 23268 (pKi
8.7) [1265]
Selective
antagonists
SRA880 (pKd 8–8.1) [792] [D-Tyr
8]CYN 154806 (pKd
8.1–8.9) [1412]
NVP ACQ090 (pKi 7.9) [793] – –
Labelled ligands – [125I]Tyr3 SMS 201-995
(Agonist) (pKd 9.9) [1736, 1737],
[125I]BIM23027 (Agonist) (pIC50
9.7) [772] – Rat
– – [125I]Tyr3 SMS 201-995
(Agonist) (pKd 9.6) [1736, 1737]
Comments – – Troxler et al. (2010) describe the
identification of non-peptidic,
subtype-selective sst3 receptor
antagonists [1907].
– –
Comments: [125I]Tyr11-SRIF-14, [125I]LTT-SRIF-28, [125I]CGP 23996 and [125I]Tyr10-CST14 may be used to label somatostatin receptors nonselectively. A number of nonpeptide subtype-selective agonists
have been synthesised [1595]. A novel peptide somatostatin analogue, somatoprim, has affinity for sst2, sst4 and sst5 receptors and is a potent inhibitor of GH secretion [1514, 1726].
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Ben-Shlomo A et al. (2010) Pituitary somatostatin receptor signaling. Trends Endocrinol. Metab. 21:
123-33 [PMID:20149677]
Colao A et al. (2011) Resistance to somatostatin analogs in acromegaly. Endocr. Rev. 32: 247-71
[PMID:21123741]
Csaba Z et al. (2012) Molecular mechanisms of somatostatin receptor trafficking. J. Mol. Endocrinol. 48:
R1-12 [PMID:22159161]
Hoyer D et al. (2000) Somatostatin receptors. In The IUPHAR Compendium of Receptor Characterization
and Classification, 2nd edn. Edited by Watson SP, Girdlestone D: IUPHAR Media: 354-364
Schulz S et al. (2014) Fine-tuning somatostatin receptor signalling by agonist-selective phosphorylation
and dephosphorylation: IUPHAR Review 5. Br. J. Pharmacol. 171: 1591-9 [PMID:24328848]
Zatelli MC et al. (2009) The significance of new somatostatin analogs as therapeutic agents. Curr Opin
Investig Drugs 10: 1025-31 [PMID:19777390]
Searchable database: http://www.guidetopharmacology.org/index.jsp Somatostatin receptors 5849
Full Contents of ConciseGuide: http://onlinelibrary.wiley.com/doi/10.1111/bph.13348/full
S.P.H. Alexander et al. The Concise Guide to PHARMACOLOGY 2015/16: G protein-coupled receptors. British Journal of Pharmacology (2015) 172, 5744–5869
Succinate receptor
G protein-coupled receptors! Succinate receptor
Overview: Nomenclature as recommended by NC-IUPHAR [396].
Nomenclature succinate receptor
HGNC, UniProt SUCNR1, Q9BXA5
Endogenous agonists succinic acid (pEC50 3.1–4.7) [728, 1785]
Tachykinin receptors
G protein-coupled receptors! Tachykinin receptors
Overview: Tachykinin receptors (provisional nomenclature
as recommended by NC-IUPHAR [530]) are activated by the
endogenous peptides substance P (TAC1, P20366) (SP), neurokinin A
(TAC1, P20366) (NKA; previously known as substance K, neurokinin
α, neuromedin L), neurokinin B (TAC3, Q9UHF0) (NKB; previously
known as neurokinin β, neuromedin K), neuropeptide K (TAC1,
P20366) and neuropeptide γ (TAC1, P20366) (N-terminally extended
forms of neurokinin A). The neurokinins (A and B) are mammalian
members of the tachykinin family, which includes peptides of mam-
malian and nonmammalian origin containing the consensus se-
quence: Phe-x-Gly-Leu-Met. Marked species differences in in vitro
pharmacology exist for all three receptors, in the context of nonpep-
tide ligands.
Nomenclature NK1 receptor NK2 receptor NK3 receptor
HGNC, UniProt TACR1, P25103 TACR2, P21452 TACR3, P29371
Rank order of potency substance P (TAC1, P20366) > neurokinin A (TAC1,
P20366) > neurokinin B (TAC3, Q9UHF0)
neurokinin A (TAC1, P20366) > neurokinin B
(TAC3, Q9UHF0) substance P (TAC1, P20366)
neurokinin B (TAC3, Q9UHF0) > neurokinin A
(TAC1, P20366) > substance P (TAC1, P20366)
Agonists substance P-OMe (pIC50 7.4–7.5) [1882] – –
Selective agonists [Sar9,Met(O2)
11]SP (pIC50 9.7–9.9) [1882],
septide (pKi 7–9.3) [125, 711], [Pro
9]SP (pIC50
8.6) [1896] – Rat
[Lys5,Me-Leu9,Nle10]NKA-(4-10) (pIC50 8.8–9.4)
[1229] – Rat, GR64349 (pEC50 8.4) [407] – Rat,
[βAla8]neurokinin A-(4-10) (pKd 6) [477]
[Phe(Me)7]neurokinin B (pKi 8.7–9.6) [1644,
1645], senktide (pKi 7.1–8.6) [1644, 1645, 1882]
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(continued)
Nomenclature NK1 receptor NK2 receptor NK3 receptor
Selective antagonists aprepitant (pKi 10.1) [673, 674], lanepitant (pKi
9.8–10) [613], lanepitant (pIC50 9.8) [798],
CP 99994 (pKi 9.3–9.7) [50, 1645], casopitant
(pKi 9.4) [798, 1905], vestipitant (pKi 9.4) [221,
418], nolpitantium (pIC50 8.9–9) [1882], RP67580
(pIC50 7.7) [528]
GR94800 (pKi 9.8) [200], saredutant (pKi 9.4–9.7)
[50, 477, 1645], GR 159897 (pKd 7.8–9.5) [133,
477, 1770], MEN10627 (pKi 9.2) [603],
nepadutant (pKi 8.5–8.7) [272, 343]
osanetant (pKi 8.4–9.7) [50, 110, 342, 476, 898,
1450, 1644, 1645, 1882], talnetant (pKi 7.4–9)
[129, 604, 1644, 1645], PD157672 (pIC50
7.8–7.9) [165, 1882]
Labelled ligands [125I]L703,606 (Antagonist) (pKd 9.5) [537],
[125I]BH-[Sar9,Met(O2)
11]SP (Agonist) (pKd 9)
[1901] – Rat, [3H]BH-[Sar9,Met(O2)
11]SP
(Agonist) (pKd 8.7) [1902] – Rat,
[3H]SP (human, mouse, rat) (Agonist) (pKd 8.6)
[80], [125I]SP (human, mouse, rat) (Agonist),
[18F]SPA-RQ (Antagonist) [317]
[3H]saredutant (Antagonist) (pKd 9.7) [649] – Rat,
[125I]NKA (human, mouse, rat) (Agonist) (pKd
9.3) [1990], [3H]GR100679 (Antagonist) (pKd 9.2)
[669]
[3H]osanetant (Antagonist) (pKd 9.9),
[3H]senktide (Agonist) (pKd 8.1–8.7) [660] –
Guinea pig, [125I][MePhe7]NKB (Agonist)
Comments: The NK1 receptor has also been described to couple to other G proteins [1606]. The hexapeptide agonist septide appears to bind to an overlapping but non-identical site to substance P (TAC1,
P20366) on the NK1 receptor. There are suggestions for additional subtypes of tachykinin receptor; an orphan receptor (SwissProt P30098) with structural similarities to the NK3 receptor was found to respond to
NKB when expressed in Xenopus oocytes or Chinese hamster ovary cells [433, 1004].
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Thyrotropin-releasing hormone receptors
G protein-coupled receptors! Thyrotropin-releasing hormone receptors
Overview: Thyrotropin-releasing hormone (TRH) receptors (provisional nomenclature as recommended by NC-IUPHAR [530]) are activated by the endogenous tripeptide TRH (TRH, P20396) (pGlu-
His-ProNH2). TRH (TRH, P20396) and TRH analogues fail to distinguish TRH1 and TRH2 receptors [1822]. [
3H]TRH (human, mouse, rat) is able to label both TRH1 and TRH2 receptors with Kd values of 13 and 9
nM respectively.
Nomenclature TRH1 receptor TRH2 receptor
HGNC, UniProt TRHR, P34981 –
Antagonists diazepam (pKi 5.2) [444] – Rat –
Selective antagonists midazolam (pKi 5.5) [444] – Rat, chlordiazepoxide (pKi 4.8) [444] – Rat,
chlordiazepoxide (pKi 4.7) [1804] – Mouse
–
Comments – A class A G protein-coupled receptor: not present in man
Further Reading
Bílek R et al. (2011) TRH-like peptides. Physiol Res 60: 207-15 [PMID:21114375]
Foord SM et al. (2005) International Union of Pharmacology. XLVI. G protein-coupled receptor list. Phar-
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Trace amine receptor
G protein-coupled receptors! Trace amine receptor
Overview: Trace amine-associated receptors were initially discov-
ered as a result of a search for novel 5-HT receptors [185], where
15 mammalian orthologues were identified and divided into two
families. The TA1 receptor (nomenclature as agreed by the
NC-IUPHAR Subcommittee for the Trace amine recep-
tor [1181]) has been shown to have affinity for the endogenous
trace amines tyramine, β-phenylethylamine and octopamine in ad-
dition to the classical amine dopamine [185]. Emerging evidence
suggests that TA1 is a modulator of monoaminergic activity in the
brain [2062] with TA1 and dopamine D2 receptors shown to form
constitutive heterodimers when co-expressed [492]. In addition to
trace amines, receptors can be activated by amphetamine-like psy-
chostimulants, and endogenous thyronamines such as thyronamine
and 3-iodothyronamine.
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Nomenclature TA1 receptor
HGNC, UniProt TAAR1, Q96RJ0
Rank order of potency tyramine > β-phenylethylamine > octopamine = dopamine [185]
Agonists RO5166017 (pEC50 7.3) [1574]
Antagonists EPPTB (Inverse agonist) (pIC50 5.1) [199]
Labelled ligands [3H]tyramine (Agonist) (pKd 7.7) [185]
Comments: In addition to TA1, analysis has shown that in man
there are up to 5 functional TAAR genes (TAAR2,5,6,8,9). See [185]
for detailed discussion. The product of the gene TAAR2 (also known
as GPR58) appears to respond to β-phenylethylamine > tyramine
and to couple through Gs [185].
TAAR3, in some individuals, and TAAR4 are pseudogenes in man, al-
though functional in rodents. The signalling characteristics and phar-
macology of TAA5 (PNR, PutativeNeurotransmitterReceptor: TAAR5,
O14804), TAA6 (Trace amine receptor 4, TaR-4: TAAR6, 96RI8), TAA8
(Trace amine receptor 5, GPR102: TAAR8, Q969N4 ) and TAA9 (trace
amine associated receptor 9: TAAR9, 96RI9) are lacking. The thy-
ronamines, endogenous derivatives of thyroid hormone, have been
shown to have affinity for rodent cloned trace amine receptors, in-
cluding TA1 [1657]. An antagonist EPPTB has recently been de-
scribed that has a pKi of 9.1 at the mouse TA1 but less than 5.3
for human TA1 [1792].
Further Reading
Jing L et al. (2015) Trace amine-associated receptor 1: A promising target for the treatment of psychos-
timulant addiction. Eur. J. Pharmacol. [PMID:26092759]
Liberles SD. (2015) Trace amine-associated receptors: ligands, neural circuits, and behaviors. Curr. Opin.
Neurobiol. 34C: 1-7 [PMID:25616211]
Maguire JJ et al. (2009) International Union of Pharmacology. LXXII. Recommendations for trace amine
receptor nomenclature. Pharmacol. Rev. 61: 1-8 [PMID:19325074]
Miller GM. (2011) The emerging role of trace amine-associated receptor 1 in the functional regulation of
monoamine transporters and dopaminergic activity. J. Neurochem. 116: 164-76 [PMID:21073468]
Sotnikova TD et al. (2009) Trace amine-associated receptors as emerging therapeutic targets. Mol. Phar-
macol. 76: 229-35 [PMID:19389919]
Zucchi R et al. (2006) Trace amine-associated receptors and their ligands. Br J Pharmacol 149: 967-978
[PMID:17088868]
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Urotensin receptor
G protein-coupled receptors! Urotensin receptor
Overview: The urotensin-II (U-II) receptor (UT, nomenclature
as agreed by the NC-IUPHAR Subcommittee on the
Urotensin receptor [439, 530, 1952]) is activated by the en-
dogenous dodecapeptide urotensin-II (UTS2, O95399), originally
isolated from the urophysis, the endocrine organ of the caudal neu-
rosecretory system of teleost fish [134]. Several structural forms of
U-II exist in fish and amphibians. The Goby orthologue was used to
identify U-II as the cognate ligand for the predicted receptor encoded
by the rat gene gpr14 [375, 1130, 1327, 1410]. Human urotensin-II
(UTS2, O95399), an 11-amino-acid peptide [375], retains the cyclo-
hexapeptide sequence of goby U-II that is thought to be important
in ligand binding [219, 957]. This sequence is also conserved in the
deduced amino-acid sequence of rat urotensin-II {Rat} (14 amino-
acids) and mouse urotensin-II {Mouse} (14 amino-acids), although
the N-terminal is more divergent from the human sequence [374]. A
second endogenous ligand for UT has been discovered in rat [1816].
This is the urotensin II-related peptide (UTS2B, Q765I0), an octapep-
tide that is derived from a different gene, but shares the C-terminal
sequence (CFWKYCV) common to U-II from other species. Identi-
cal sequences to rat urotensin II-related peptide (UTS2B, Q765I0) are
predicted for the mature mouse and human peptides.
Nomenclature UT receptor
HGNC, UniProt UTS2R, Q9UKP6
Endogenous agonists urotensin II-related peptide (UTS2B, Q765I0) (pKd 9.6) [1179], urotensin-II (UTS2, O95399) (pKi 8.6) [440, 475, 647]
Selective agonists [Pen5]-U (4-11) (human) (pKi 9.7) [647], U-II-(4-11) (human) (pKi 9.6) [647], FL104 (pEC50 5.8–7.5) [1075, 1077], AC-7954 (pKi 6.6) [382, 1076]
Selective antagonists urantide (pKi 8.3) [1469], SB-706375 (pKi 8) [440], palosuran (pIC50 7.1) [353], SB-611812 (pKi 6.6) [1550]
Labelled ligands [125I]U-II (human) (Agonist) (pKd 9.4–9.6) [42, 1179]
Comments: In human vasculature, human urotensin-II (UTS2, O95399) elicits both vasoconstrictor (pD2 9.3-10.1, [1179]) and vasodilator (pIC50 10.3-10.4, [1800]) responses.
Further Reading
Douglas SA Ohlstein EH. (2000) Urotensin receptors. In The IUPHAR Receptor Compendium of Receptor
Characterization and Classification. Edited by Girdlestone D: IUPHAR Media Ltd: 365-372
Foord SM et al. (2005) International Union of Pharmacology. XLVI. G protein-coupled receptor list. Phar-
macol Rev 57: 279-288 [PMID:15914470]
Guidolin D et al. (2010) Urotensin-II as an angiogenic factor. Peptides 31: 1219-24 [PMID:20346384]
Hunt BD et al. (2010) A rat brain atlas of urotensin-II receptor expression and a review of central urotensin-
II effects. Naunyn Schmiedebergs Arch. Pharmacol. 382: 1-31 [PMID:20422157]
Maryanoff BE et al. (2010) Urotensin-II receptor modulators as potential drugs. J. Med. Chem. 53:
2695-708 [PMID:20043680]
Ross B et al. (2010) Role of urotensin II in health and disease. Am. J. Physiol. Regul. Integr. Comp. Physiol.
298: R1156-72 [PMID:20421634]
Vasopressin and oxytocin receptors
G protein-coupled receptors! Vasopressin and oxytocin receptors
Overview: Vasopressin (AVP) and oxytocin (OT) receptors (nomenclature as recommended by NC-IUPHAR [530]) are activated by the endogenous cyclic nonapeptides vasopressin (AVP, P01185) and
oxytocin (OXT, P01178). These peptides are derived from precursors which also produce neurophysins (neurophysin I for oxytocin; neurophysin II for vasopressin).
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Nomenclature V1A receptor V1B receptor V2 receptor OT receptor
HGNC, UniProt AVPR1A, P37288 AVPR1B, P47901 AVPR2, P30518 OXTR, P30559
Rank order of
potency
vasopressin (AVP, P01185) > oxytocin
(OXT, P01178)
vasopressin (AVP, P01185) > oxytocin
(OXT, P01178)
vasopressin (AVP, P01185) > oxytocin
(OXT, P01178)
oxytocin (OXT, P01178) > vasopressin
(AVP, P01185)
Endogenous
agonists
vasopressin (AVP, P01185) (pKi 8.5–9.3)
[24, 311, 369, 415, 1359, 1501, 1627,
1839, 1840, 1870, 1871, 2073]
vasopressin (AVP, P01185) (pKi 9–9.5)
[24, 311, 415, 648, 1359, 1627, 1839,
1840, 1871, 2073]
vasopressin (AVP, P01185) (pKi 7.9–9.1)
[24, 311, 319, 415, 1359, 1627, 1700,
1839, 1840, 1871, 2073]
oxytocin (OXT, P01178) (pKi 8.2–9.6)
[24, 319, 320, 345, 648, 853]
Selective agonists F180 (pKd 7.9–8.3) [49, 369] d[Leu
4]LVP (pKi 9.8) [1485],
d[Cha4]AVP (pKi 9–9.7) [415, 648]
VNA932 (pIC50 7.1) [501], OPC-51803
(pKi 7) [1359], d[Val
4,DArg8]VP
[Thr4,Gly7]OT (pKi 8.2–8.4) [320,
472, 853]
Antagonists conivaptan (pKi 8.2–8.4) [1839, 1840] nelivaptan (pKi 8.4–9.3) [644, 648,
1702]
– L-371,257 (pKi 8.8) [648]
Selective
antagonists
relcovaptan (pKi 8.1–9.3) [24, 369, 648,
1501, 1700, 1839, 1870, 1871, 1910],
d(CH2)5[Tyr(Me)
2,Arg8]VP (pKi 9)
– conivaptan (pKi 9.4) [381], tolvaptan
(pKi 9.4) [2073], satavaptan (pKi
8.4–9.3) [24, 369, 370, 1699, 1700,
1839, 1910], lixivaptan (Inverse agonist)
(pKi 8.9–9.2) [33, 1700],
d(CH2)5[D-Ile
2,Ile4]AVP (pKi 6.9–8.4)
[1700], mozavaptan (Inverse agonist)
(pKi 7.4–8.1) [370, 1700, 1839, 1871,
2073, 2074]
SSR126768A (pKi 8.8–9.1) [1701],
desGlyNH2-d(CH2)5[Tyr(Me)
2,Thr4,
Orn8]OT
(pKi 8.5), L-372662 (pKi 8.4) [121]
Labelled ligands [125I]OH-LVA (Antagonist) (pKd
10.3–10.4) [319, 369, 1501],
[3H]AVP (human, mouse, rat) (Agonist)
(pKd 8.6–10.2) [208, 319, 369, 370,
1359, 1501, 1627, 1839, 1840, 1870,
1871, 1910, 2073],
[3H]d(CH2)5[Tyr(Me)
2]AVP
(Antagonist) (pKd 9)
[3H]AVP (human, mouse, rat) (Agonist)
(pKd 8.6–9.6) [208, 319, 369, 370,
1359, 1501, 1627, 1839, 1840, 1870,
1871, 1910, 2073]
[3H]AVP (human, mouse, rat) (Agonist)
(pKd 8.4–9.4) [319, 369, 370, 1359,
1627, 1839, 1840, 1871, 1910, 2073],
[3H]dDAVP (Agonist) (pKd 7.2–9.1)
[319, 370, 1871],
[3H]desGly-NH2[D-Ile
2,Ile4]VP (pKd
8.6)
[125I]d(CH2)5[Tyr(Me)
2,Thr4,Orn8,
Tyr-NH2
9]OVT
(Antagonist) (pKd 10),
[3H]OT (human, mouse, rat) (Agonist)
(pKd 8.2–9.5) [319, 553, 853, 952],
[111In]DOTA-dLVT (pKd 8.3) [318]
Comments: The V2 receptor exhibits marked species differences, such that many ligands (d(CH2)5[D-Ile
2,Ile4]AVP and [3H]desGly-NH2[D-Ile
2,Ile4]VP) exhibit low affinity at human V2 receptors [29]. Similarly,
[3H]d[D-Arg8]VP is V2 selective in the rat, not in the human [1627]. The gene encoding the V2 receptor is polymorphic in man, underlying nephrogenic diabetes insipidus [148]. D[Cha
4]AVP is selective only for
the human and bovine V1b receptors [415], while d[Leu
4]LVP has high affinity for the rat V1b receptor [1485].
Further Reading
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Knepper MA. (2012) Systems biology in physiology: the vasopressin signaling network in kidney. Am. J.
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Meyer-Lindenberg A et al. (2011) Oxytocin and vasopressin in the human brain: social neuropeptides for
translational medicine. Nat. Rev. Neurosci. 12: 524-38 [PMID:21852800]
Neumann ID et al. (2012) Balance of brain oxytocin and vasopressin: implications for anxiety, depression,
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VIP and PACAP receptors
G protein-coupled receptors! VIP and PACAP receptors
Overview: Vasoactive intestinal peptide (VIP) and pituitary adeny-
late cyclase-activating peptide (PACAP) receptors (nomenclature
as agreed by the NC-IUPHAR Subcommittee on Vasoac-
tive Intestinal Peptide Receptors [704, 705]) are acti-
vated by the endogenous peptides VIP (VIP, P01282), PACAP-38
(ADCYAP1, P18509), PACAP-27 (ADCYAP1, P18509), peptide his-
tidine isoleucineamide (PHI {Mouse, Rat}), peptide histidine me-
thionineamide (PHM (VIP, P01282)) and peptide histidine valine
(PHV (VIP, P01282)). VPAC1 and VPAC2 receptors display compa-
rable affinity for the PACAP peptides, PACAP-27 (ADCYAP1, P18509)
and PACAP-38 (ADCYAP1, P18509), and VIP (VIP, P01282), whereas
PACAP-27 (ADCYAP1, P18509) and PACAP-38 (ADCYAP1, P18509)
are >100 fold more potent than VIP (VIP, P01282) as agonists of
most isoforms of the PAC1 receptor. However, one splice variant of
the human PAC1 receptor has been reported to respond to PACAP-38
(ADCYAP1, P18509), PACAP-27 (ADCYAP1, P18509) and VIP (VIP,
P01282) with comparable affinity [393]. PG 99-465 [1320] has been
used as a selective VPAC2 receptor antagonist in a number of phys-
iological studies, but has been reported to have significant activity
at VPAC1 and PAC1 receptors [422]. The selective PAC1 receptor
agonist maxadilan, was extracted from the salivary glands of sand
flies (Lutzomyia longipalpis) and has no sequence homology to VIP
(VIP, P01282) or the PACAP peptides [1330]. Two deletion variants
of maxadilan, M65 [1918] and Max.d.4 [1331] have been reported
to be PAC1 receptor antagonists, but these peptides have not been
extensively characterised.
Nomenclature PAC1 receptor VPAC1 receptor VPAC2 receptor
HGNC, UniProt ADCYAP1R1, P41586 VIPR1, P32241 VIPR2, P41587
Rank order of potency PACAP-27 (ADCYAP1, P18509), PACAP-38
(ADCYAP1, P18509) VIP (VIP, P01282)
VIP (VIP, P01282), PACAP-27 (ADCYAP1, P18509),
PACAP-38 (ADCYAP1, P18509) GHRH (GHRH,
P01286), PHI {Pig}, secretin (SCT, P09683)
VIP (VIP, P01282), PACAP-38 (ADCYAP1, P18509),
PACAP-27 (ADCYAP1, P18509) > PHI {Pig}
GHRH (GHRH, P01286), secretin (SCT, P09683)
Selective agonists maxadilan (pEC50 10.3) [422], maxadilan (pEC50
6.2) [422]
[Lys15,Arg16,Leu27]VIP-(1-7)/GRF-(8-27)-NH2
(pEC50 8.3) [1315], [Ala11,22,28]VIP (pKi 8.1)
[1393]
Ro 25-1553 (pIC50 7.8–9.5) [634, 887, 1315],
Ro 25-1392 (pKi 8) [2056]
Selective antagonists – PG 97-269 (pIC50 8.7) [633, 887] –
Labelled ligands [125I]PACAP-27 (Agonist) (pKd 9.1) [1509] [
125I]VIP (human, mouse, rat) (Agonist) (pKd 9.4)
[1393], [125I]PACAP-27 (Agonist)
[125I]VIP (human, mouse, rat) (Agonist) (pKd 9.2)
[1393], [125I]PACAP-27 (Agonist)
Comments: Subtypes of PAC1 receptors have been proposed based on tissue differences in the potencies of PACAP-27 (ADCYAP1, P18509) and PACAP-38 (ADCYAP1, P18509); these might result from differences
in G protein coupling and second messenger mechanisms [1939], or from alternative splicing of PAC1 receptor mRNA [1788].
Further Reading
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soactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide. Pharmacol Rev 50:
265-270 [PMID:9647867]
Harmar AJ et al. (2012) Pharmacology and functions of receptors for vasoactive intestinal peptide and
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